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Abstract 
 
In common with other hollow organs, the gastric mucosa consists of exocrine and 
endocrine epithelial cells and sub-epithelial stromal cells, all of which secrete 
mediators into the tissue microenvironment that define mucosal architecture and 
maintain organ function. Gastric myofibroblasts are an important stromal cell 
population involved in maintaining mucosal integrity, and are implicated in 
pathophysiological processes including chronic inflammation, fibrosis and cancer. 
Urokinase plasminogen activator (uPA) and its inhibitor plasminogen activator 
inhibitor (PAI)-1 are secreted by gastric epithelial and stromal cells and, together 
with the uPA receptor (uPAR), are believed to be involved in epithelial-
mesenchymal signalling. However, the role of the uPA system in regulating gastric 
mucosal morphological homeostasis and responses to acute and chronic challenges 
is not yet fully understood.  
 
In this thesis, it was shown that transgenic PAI-1-H/Kβ mice, which have increased 
expression of PAI-1 in gastric parietal cells, have elevated concentrations of 
circulating PAI-1 and develop age-dependent increases in corpus mucosal 
thickness, independent of changes in parietal cell and myofibroblast abundance. 
PAI-1 did not have a direct trophic effect on gastric epithelial cells, indicating that 
PAI-1 might act via an indirect mechanism to modulate gastric epithelial cell 
turnover.  
 
In order to determine whether PAI-1 influences the gastric tissue microenvironment 
via myofibroblast gene expression, global transcript expression profiles of gastric 
myofibroblasts from wild-type and PAI-1 null (PAI-1-/-) mice were compared. 
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Whole genome microarrays and subsequent validation by immunofluorescence 
indicated that mouse antral myofibroblasts are highly heterogeneous, including both 
desmin positive and desmin negative cells with distinct global transcript expression 
profiles. Furthermore, there was evidence that antral myofibroblasts displayed 
phenotypic plasticity in vitro, developing a neuroendocrine-like phenotype marked 
by expression of secretogranin-2. Plasticity may be functionally significant in vivo, 
supporting the role of myofibroblasts in wound healing. 
 
The role of PAI-1 in gastric mucosal responses to chronic Helicobacter infection 
was investigated using the H. felis model in wild-type, PAI-1-/- and PAI-1-H/Kβ 
mice. Both absence of PAI-1 and increased expression of gastric PAI-1 were 
protective against Helicobacter-induced preneoplastic gastric histopathology. 
Responses to acute gastric mucosal injury were investigated using intragastric 
indomethacin administration. Gastric PAI-1 protected against the development of 
lesions, whilst exogenous PAI-1 exacerbated the development of indomethacin-
induced gastric mucosal injury. Gastric uPA expression did not effect the 
development of lesions, whilst absence of uPAR tended to exacerbate lesion 
development.  
 
Taken together, the data presented in this thesis suggest a broadly protective role of 
PAI-1 in the gastric mucosa. A common therapeutic strategy for the prevention of 
NSAID-induced gastric injury, ulcer complications and progression of 
Helicobacter-induced gastric preneoplasia might be emerging, aimed at specifically 
increasing PAI-1 bioavailability in the gastric mucosa. 
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1.1 Overview 
 
The epithelial lining of hollow organs consists of both exocrine and endocrine cells, 
which secrete mediators facilitating responses to the luminal environment that 
support mucosal homeostasis and organ function. In the glandular stomach, 
epithelial cells secrete mediators involved in luminal nutrient sensing and mucosal 
defence. The best-characterised gastric endocrine mediator is gastrin, which was 
identified as a gastric acid secretagogue by Edkins in the early 20th century, 
following the work of Bayliss and Starling on establishing the endocrine concept 
(Bayliss & Starling, 1902; Edkins, 1905; Edkins, 1906).  
 
In order to detect and appropriately respond to nutrients and noxious stimuli, a 
sophisticated luminal sensing system exists in the gastric mucosa. Given that the 
gastric lumen is a potentially hostile low pH and proteolytic environment, the 
gastric mucosa possesses robust intrinsic defence mechanisms, at least partly 
mediated by prostaglandins and gaseous messengers, to maintain tissue integrity 
(Wallace, 2008). This defensive network is up-regulated in response to ingested 
noxious agents in the lumen. Both nutrient sensing and mucosal defence is 
mediated by an array of autocrine, paracrine, endocrine and neuronal interactions, 
between epithelial cells and the various stromal cell types found within the mucosa, 
including fibroblast-like cells, immune cells and neurons (Dockray, 2003; Wallace, 
2008).  
 
The myofibroblast is a key mediator of communication between epithelial cells and 
underlying stromal cells throughout the gastrointestinal tract. Residing within the 
lamina propria, myofibroblasts are in close proximity to both epithelial cells and 
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subepithelial stromal cell populations, relaying local signals between these 
compartments (Valentich & Powell, 1994; Powell et al., 1999). Consequently, 
myofibroblasts have a critical role in epithelial-mesenchymal cross talk maintaining 
gastric mucosal integrity, and also in pathophysiological states, such as chronic 
inflammation, fibrosis and cancer. 
 
The urokinase plasminogen activator (uPA) system is comprised of an extracellular 
protease (uPA), its receptor (uPAR) and its inhibitors plasminogen activator 
inhibitor type-1 and type-2 (PAI-1 and PAI-2). These proteins have important 
regulatory roles in tissue remodelling, via a plasmin-activated proteolytic cascade 
and via non-proteolytic mechanisms. Consequently, the uPA system is involved in 
tissue homeostasis, wound healing, chronic inflammation, fibrosis and cancer 
(Andreasen et al., 2000; Smith & Marshall, 2010). Both parenchymal and 
mesenchymal cells express members of the uPA system in many tissues, including 
the stomach (Kaneko et al., 2003; Kenny et al., 2008). Therefore, these proteins 
directly influence epithelial-mesenchymal signalling in mucosal tissues. 
 
The aim of this thesis was to examine the role of the uPA system in regulating 
epithelial-mesenchymal signalling in the stomach, with a particular focus on 
responses to non-steroidal anti-inflammatory drug (NSAID)-induced gastric 
mucosal injury and chronic Helicobacter infection. 
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1.2 Gastric mucosal morphology & physiology 
 
1.2.1 Gastric epithelial morphology  
 
Although there are similarities in the gross morphology of different parts of the 
gastrointestinal tract, there are nevertheless marked differences in mucosal structure 
in different regions. The mammalian stomach consists of two distinct glandular 
regions (the corpus and antrum) comprised of different types of gland, containing 
exocrine and enteroendocrine cells. The corpus consists of oxyntic glands, 
containing hydrochloric acid-secreting parietal cells and pepsinogen-secreting chief 
cells, as well as mucous-secreting cells, enteroendocrine cells and rare caveolated 
cells (Karam & Leblond, 1992; Figure 1.1). Enteroendocrine cells of the adult 
corpus mucosa include histamine-secreting enterochromaffin-like (ECL) cells, 
somatostatin-secreting D cells, ghrelin-secreting cells, termed X/A-like cells in 
rodents and P/D1 cells in humans, and serotonin-secreting enterochromaffin (EC) 
cells (Simonsson et al., 1988; Date et al., 2000; Rindi et al., 2002; Rindi et al., 
2004). The antrum consists of pyloric glands, populated by mucous-secreting cells 
and enteroendocrine cells (Figure 1.1). Antral enteroendocrine cells include gastrin-
secreting G cells, D cells, EC cells and a few ghrelin-secreting cells (Tzaneva, 
2003; Rindi et al., 2004). The gastric epithelium exits as a continually renewing 
monolayer, arranged into invaginated tubular units that form the gastric pits and 
glands (Lee, 1985a; Karam & Leblond, 1992). 
 
Corpus glands consist of four regions: pit, isthmus, neck and base. Gastric pits are 
populated mainly by mucous-secreting pit cells. Within the isthmus is located the         
a 
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As the prevalence of HP infection has declined, because
of improved sanitation and efforts to eradicate the or-
ganism, the prevalence of nonsteroidal anti-inflamma-
tory drug (NSAID)-induced ulcers and HP-negative/
NSAID-negative ulcers has risen and is taking on greater
clinical importance. Schwarz’s dictum “no acid, no ulcer”
remains valid, even today.15 Acid control remains the
mainstay for the treatment and prevention of ulcers
caused by NSAIDs, gastrinoma (Zollinger–Ellison syn-
drome [ZES]), and stress as well as HP-negative/NSAID-
negative idiopathic ulcers.16,17
The era of effective management of ulcers has ushered
in a new acid-related challenge, gastroesophageal reflux
disease (GERD). Until recently, the clinical importance of
reflux had been largely underappreciated because peptic
ulcers were so prominent. As with ulcers, the duration
and degree of acid inhibition were shown to correlate
with healing of erosive esophagitis and control of reflux
symptoms.18 However, a greater degree and duration of
24-hour acid inhibition were required to effectively man-
age GERD than H2RAs could provide. Although H2RAs
could improve the condition, they could not predictably
heal esophagitis (especially severe grades) or eliminate
symptoms. It was this clinical niche for which the PPIs
were ideally suited. PPIs can predictably heal esophagitis,
no matter how severe, and prevent recurrence.19,20 Al-
though currently available PPIs can eliminate most reflux
symptoms, better therapies are needed to eliminate
nighttime reflux, symptoms in patients with endoscopic-
negative reflux disease, and alleged extraesophageal man-
ifestations of GERD such as cough and asthma.21–23
The purpose of this review is to reemphasize the im-
portance and relevance of gastric acid secretion and its
regulation. We will review the physiology and pathophys-
iology of acid secretion as well as evidence regarding its
inhibition in the management of acid-related clinical
conditions. As we reexamine and update this area, we
hope to rekindle the excitement surrounding acid that
was at the roots of gastroenterology and provide infor-
mation relevant to the future care of patients with acid-
peptic disorders.
Functional Anatomy of the Stomach
Mucosal Anatomy
The stomach consists of 3 topographic (fundus,
corpus, and antrum) and 2 functional (oxyntic and py-
loric gland) areas. The oxyntic gland area, the hallmark of
which is the oxyntic (oxys, Greek for acid) or parietal cell,
comprises 80% of the organ (fundus and corpus). The
pyloric gland area, the hallmark of which is the gastrin or
G cell, comprises 20% of the organ (antrum). It is esti-
mated that the human stomach contains 1! 109 parietal
and 9 ! 106 gastrin cells.24 There is debate as to whether
the cardia, a transition zone of 0–9 mm between the
squamous mucosa of the esophagus and the oxyntic
mucosa of the stomach, exists as a normal anatomic
structure or develops as a result of abnormal reflux.
Autopsy and endoscopic studies suggest that cardiac mu-
cosa is absent in over 50% of the general population.25
The oxyntic gland area is organized in vertical tubular
units that consist of an apical pit region, an isthmus, and
the actual gland region that forms the lower part of the
unit (Figure 1). The gland consists of a neck and a base.
The progenitor cell of the gastric unit, located in the
isthmus, gives rise to all gastric epithelial cells. The mu-
Figure 1. Functional mucosal
anatomy. Somatostatin-contain-
ing D cells contain cytoplasmic
processes that terminate in the vi-
cinity of acid-secreting parietal
and histamine-secreting entero-
chromaffin-like cells in the oxyntic
gland area (fundus and corpus)
and gastrin-secreting G cells in
the pyloric gland area (antrum).
The functional correlate of this
anatomic coupling is a tonic
paracrine restraint exerted by
somatostatin on acid secretion
that is exerted directly on the pa-
rietal cell as well as indirectly by
inhibiting histamine and gastrin
secretion.
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Figure 1.1. Major mature cell populations of the oxyntic and pyloric glands. 
The mature cell populations of the oxyntic gastric unit include surface mucous (pit) 
cells, parietal cells, mucous neck cells, chief cells and various enteroendocrine 
cells, including ECL cells, EC cells and D cells. Many mucous-secreting cells 
populate pyloric units, as well as enteroendocrine cells, including G cells, D cells 
and EC cells. Image reproduced with permission from Schubert & Peura, 2008. 
 
 
 
granule-free stem cell and proliferating progenitor cells, from which all mature cell 
populations of the gastric unit are derived (Karam & Leblond, 1992). The neck 
region contains many mucous-secreting cells, whilst chief cells are restricted to the 
gland base. Parietal cells, enteroendocrine cells and caveolated cells are distributed 
along the length of corpus units (Karam & Leblond, 1992). Enteroendocrine cells 
are infrequent in gastric pits and increase in frequency from the isthmus and neck to 
the gland base (Karam & Leblond, 1993a). The morphology of the human corpus 
gastric unit is largely consistent with that of the mouse, except that mucous pit cells 
exclusively populate the pit and the stem cell contains mini-granules (Karam et al., 
2003). 
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Mucous-secreting cells are the principal cell population in antral units, exclusively 
populating the pit region and constituting much of the gland. Enteroendocrine cells 
are dispersed amongst the gland and isthmus regions, located within the basal third 
of the unit (Lee, 1985b; Lee & Leblond, 1985a; Lee & Leblond, 1985b). However, 
the isthmus is predominantly populated by the granule-free stem cell and 
proliferating progenitors.  
 
1.2.2 Gastric epithelial stem cells 
 
Experiments utilizing chimaeric mice or mutagenesis to trace cell lineage illustrate 
the monoclonal nature of adult mouse gastric units, whereby all differentiated cell 
types within the gastric unit can be traced to a single multipotential stem cell 
(Thompson et al., 1990; Bjerknes & Cheng, 2002). It had been believed that all 
cells of the mouse antral unit were derived from the undifferentiated stem cell 
within the isthmus (Lee & Leblond, 1985a). However, an Lgr5-expressing stem cell 
has recently been identified within the basal region of some glands of the antrum, 
corpus-antrum transition zone and gastroesophageal junction in the adult mouse, 
and also within corpus glands of the developing mouse stomach (Barker et al., 
2010). Lineage tracing confirms that these stem cells are self-renewing and 
multipotential, generating epithelial cells for renewal of the gastric unit under basal 
conditions. 
 
Identification of specific epithelial stem cell markers in the gastric mucosa is 
necessary for elucidating gastric stem cell biology. As well as the Lgr5-expressing 
population of stem cells at the gland base, a rare population of quiescent βgal-
marked-villin expressing multipotential cells is located within or below the isthmus 
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of some mouse antral glands (Qiao et al., 2007). This particular population of stem 
cells is stimulated by pro-inflammatory signals, and may be important for epithelial 
restitution following mucosal injury. Phosphorylation of the specific linker Thr 
residues of Smad2/3 has been identified as a putative marker of quiescent stem cells 
in the mouse corpus and antral isthmus, representing stem cells in a pre-
proliferative state under regulation by CDK4 and D-type cyclins (Fukui et al., 
2011). Recently, CD44 has been identified as a putative marker of the stem cell 
within the corpus unit, transducing proliferative signals responsible for basal stem 
cell turnover (Khurana et al., 2013). However, much still remains to be elucidated 
about the molecular characteristics of gastric stem cells. 
 
Various cell-types are believed to regulate the gastric epithelial stem cell niche. 
Parietal cells appear to be an important source of paracrine factors regulating stem 
cell and proliferating progenitor cell activity in corpus units, since their ablation 
leads to expansion of the granule-free stem cell, pit cell progenitor and mucous 
neck cell progenitor populations in mice (Li et al., 1996). Subepithelial stromal 
cells are also believed to contribute to the maintenance of the epithelial stem cell 
niche. Myofibroblasts are secretory and contractile fibroblast-like stromal cells that 
also have characteristics of smooth muscle cells (Gabbiani et al., 1971; Majno et 
al., 1971; Powell et al., 1999; Tomasek et al., 2002). A more detailed description of 
the characteristics of myofibroblasts and a discussion on their definition can be 
found in section 1.3. Myofibroblasts are found within the lamina propria of gastric 
glands, and so are in close proximity to epithelial stem cells (Wu et al., 1999). Their 
role in the regulation of the non-pathological gastric stem cell niche has not been 
elucidated but the role of stromal cells in maintaining the intestinal stem cell niche 
is better characterised. Proliferation of the intestinal stem cell is regulated by bone 
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morphogenetic protein (BMP)-4 derived from subepithelial stromal cells, which 
suppresses Wnt signalling activity (He et al., 2004). The colon cancer stem cell 
phenotype is maintained by myofibroblast-derived hepatocyte growth factor (HGF), 
activating Wnt signalling (Vermeulen et al., 2010). Similar mechanisms may 
maintain the non-pathological gastric stem cell niche.  
 
1.2.3 Gastric epithelial cell turnover and differentiation  
 
In mouse corpus glands, undifferentiated stem cells undergo asymmetric division to 
generate three types of immature progenitor cells (pre-pit, pre-neck and pre-parietal 
cells), enteroendocrine cells and to renew themselves. Proliferating progenitors in 
the isthmus undergo bi-directional migration, depending upon the ultimate fate of 
the cell. Mutagenesis experiments have confirmed the existence of long-lived 
progenitors within the corpus isthmus (Bjerknes & Cheng, 2002). The proliferating 
pre-pit cell precursor gives rise to both pre-pit cells and pre-parietal cells with 
dense mucous granules. The proliferating pre-neck cell precursor yields pre-neck 
cells and pre-parietal cells with cored granules. A granule-free pre-parietal cell is 
also derived directly from the undifferentiated stem cell, as are enteroendocrine and 
caveolated cells (Karam & Leblond, 1993a; Karam & Leblond, 1993b). 
 
Pre-pit cells have a turnover of less than 2.6 days and migrate upwards, towards the 
lumen (Karam & Leblond, 1993b; Karam & Leblond, 1993c). As they migrate 
upwards along the pit-axis, pre-pit cells mature into pit cells, developing larger and 
more numerous dense mucous secretory granules. Migration of pit cells along the 
pit axis takes approximately 3.1 days. Pre-neck cells have a turnover of 
approximately 3 days and migrate downwards, along the neck region, eventually 
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becoming pre-zymogenic cells upon transitioning from the neck to the base region 
(Karam & Leblond, 1993b; Karam & Leblond, 1993d). Downwards migration of 
mucous neck cells along the neck axis takes approximately 1-2 weeks and is 
associated with maturation of the cored mucous secretory granules. Pre-zymogenic 
cells are marked by a replacement of mucous with pepsinogenic material in 
secretory granules, and maturation of zymogenic chief cells is associated with 
progressive replacement of mucous secretory granules with pepsinogenic granules. 
The turnover of the chief cell lineage is approximately 194 days.  
 
Pre-parietal cells have a turnover of approximately 3 days and mature into parietal 
cells within the isthmus. Parietal cells migrate bi-directionally in the mouse corpus 
unit, to populate all sections of the gland and the pit (Karam, 1993; Karam & 
Leblond, 1993b).  The turnover of parietal cells in these studies was reported as 
approximately 54 days, but a more recent study concluded that parietal cell 
turnover is in the region of 30-40 days (Kirton et al., 2002). Upon reaching the pit 
surface or gland base, degenerated pit cells, chief cells and parietal cells either 
undergo apoptosis followed by phagocytosis by a neighbouring epithelial cell or 
macrophage or they undergo necrosis and are extruded (Karam, 1993; Karam & 
Leblond, 1993c; Karam & Leblond, 1993d).  
 
Both granule-free and bi-directionally migrating immature granule-containing cells 
are found within the isthmus of the mouse antral gland (Lee & Leblond, 1985a). 
Antral mucous pit cells increase in maturity along the pit-axis from partially 
differentiated dense-granule cells at the pit-base, adjacent to the isthmus, becoming 
mature cells at the mid-pit region and senescing towards the luminal opening, 
where they are extruded or phagocytosed by adjacent cells (Lee, 1985b). Similarly, 
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mucous gland cells increase in maturity during their downward migration from the 
isthmus-neck border, where they exist as immature core-granule cells, to the gland 
base, with extrusion or phagocytosis of cells occurring along the entire gland-axis 
(Lee & Leblond, 1985b).  
 
Gastric enteroendocrine cells arise in the isthmus, differentiating directly from the 
granule-free stem cell (Lee & Leblond, 1985a; Karam & Leblond, 1993a). In the 
corpus, enteroendocrine cells migrate bi-directionally, but the majority migrate 
downwards, to populate the neck and the base of the gland with increasing 
frequency (Karam & Leblond, 1993a). All antral enteroendocrine cells migrate 
downwards (Lee & Leblond, 1985b).  
 
1.2.4 Signalling pathways maintaining normal gastric epithelial cell turnover 
and differentiation in the adult stomach 
 
Gastric mucosal morphology is maintained by autocrine, paracrine, endocrine and 
neuronal inputs, involving multiple epithelial and stromal cell-derived growth 
factors and signalling molecules. Parietal cells are key regulators of epithelial cell 
differentiation in the corpus unit. Deletion of parietal cells is associated with 
expansion of the pit-cell lineage and inhibition of the neck and chief cell 
differentiation sequence (Li et al., 1996, Li et al., 1998). Furthermore, targeted 
expression of simian virus 40 T antigen by pre-parietal cells results in loss of both 
the mature parietal cell and mature chief cell populations, owing to suppression of 
differentiation of pre-parietal and pre-zymogenic cells, and an expansion of the pre-
parietal and pit cell populations (Li et al., 1995). In another model of parietal cell 
ablation, tamoxifen-induced parietal cell loss is associated with the emergence of a 
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spasmolytic polypeptide expressing metaplasia (SPEM)-like phenotype, 
characterised by a marked increase in proliferating stem and precursor cells, 
mucosal hypertrophy and expansion of cells expressing mucous neck cell markers 
into the gland base, indicating altered differentiation of chief cells (Huh et al., 
2012).  
 
1.2.4.1 Epidermal growth factor receptor signalling  
 
The epidermal growth factor receptor (EGFR) is expressed on mucous-secreting 
cells of the pit and gland regions of corpus and antral units, including the 
proliferative zone, on parietal cells and on G cells (Orsini et al., 1993; Murayama et 
al., 1995). Transforming growth factor (TGF)-α, an EGFR ligand, is expressed by 
differentiated epithelial cells of corpus and antral units, particularly by parietal cells 
and most robustly by pit cells (Thomas et al., 1992; Abe et al., 1997). 
Overexpression of TGF-α alters the differentiation sequence of corpus units. 
Phenotypically this is associated with mucosal hyperplasia and antralisation of the 
corpus unit, marked by expansion of the mucous pit cell population, loss of mature 
parietal and chief cells and migration of the proliferative zone towards the base of 
the gland (Sharp et al., 1995; Goldenring et al., 1996).  
 
Other EGFR ligands expressed by gastric epithelial cells include heparin-binding 
epidermal growth factor (HB-EGF), which is expressed predominantly by parietal 
cells in the corpus unit and G cells in the antral unit, and amphiregulin, expressed 
by parietal cells (Murayama et al., 1995; Abe et al., 1997). Amphiregulin-deficient 
mice develop SPEM and mice expressing a mutant and defective EGFR develop 
SPEM more rapidly following parietal cell ablation (Ogawa et al., 2006; Nam et 
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al., 2009). This further highlights the requirement of intact EGFR signalling and the 
role of the parietal cell population in the maintenance of normal turnover and 
differentiation of gastric epithelial cells. 
 
1.2.4.2 Transforming growth factor-β signalling 
 
BMPs are members of the TGF-β family of signalling proteins, and are expressed 
by both epithelial cells and myofibroblasts in the gastric mucosa (van den Brink et 
al., 2001). BMP-4, expressed by myofibroblasts, is a downstream target of Sonic 
hedgehog (Shh). Noggin is an inhibitor of BMP signalling and its overexpression 
and subsequent suppression of gastric epithelial cell BMP signalling is associated 
with parietal cell loss and expansion of mucous neck cells, zymogenic cells, cells 
expressing markers of both of these cell types and the proliferating cell populations 
i.e. a SPEM-like phenotype (Shinohara et al., 2010). This hyperproliferative state is 
associated with elevated expressions of amphiregulin and TGF-α. Conversely, BMP 
signalling negatively regulates proliferation of intestinal stem cells to maintain the 
quiescent stem cell niche, and may have a similar role in the stomach (He et al., 
2004). 
 
Activins are signalling molecules of the TGF-β family known to have an important 
role in gastric epithelial cell differentiation. Activin receptor type II is expressed by 
parietal, pit and zymogenic cells within the gastric corpus and activation of 
signalling via this receptor by elevated concentrations of circulating activins results 
in loss of mature parietal cells, inhibition of zymogenic lineage differentiation and 
expansion of the granule-free, pit, pre-pit, caveolated and pre-caveolated cell 
populations, recapitulating some of the effects of parietal cell ablation (Li et al., 
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1998). This is not associated with altered rates of proliferation or apoptosis 
however.  
 
1.2.4.3 Insulin-Like Growth Factor signalling 
 
Insulin-like growth factor (IGF)-I and IGF-II are secreted by myofibroblasts in the 
gastrointestinal mucosa, mediating mesenchymal-epithelial signalling via receptors 
on epithelial cells and stromal cells; IGF-I and IGF-II stimulate proliferation and 
migration of gastric myofibroblasts and gastric epithelial cells (Steenfos et al., 
1992; Powell et al., 1999; Watanabe et al., 2000; Hemers et al., 2005; McCaig et 
al., 2006). Expression of IGF-I, IGF-I receptor and IGF signalling molecules is 
enriched in the gastric epithelial progenitor cell population compared to adjacent pit 
cells, and it has been proposed that IGF signalling is a critical mediator of gastric 
epithelial progenitor cell biology, under regulation by pit-cell derived factors (Mills 
et al., 2002).  
 
1.2.4.4 Hedgehog Signalling 
 
Shh is expressed by epithelial cells of the corpus gland and activates signalling in 
both epithelial and myofibroblast-like cells of the gland, but not pit cells (van den 
Brink et al., 2001; Fukaya et al., 2006). Hedgehog signalling-dependent 
differentiation of the pit cell lineage is mediated by expression of Indian hedgehog 
(Fukaya et al., 2006). The gastric mucosa of mice lacking Shh is replaced by an 
intestinal mucosal phenotype, highlighting the importance of this morphogen in 
normal gastric epithelial differentiation (Ramalho-Santos et al., 2000). 
Furthermore, inhibition of Shh signalling results in a marked increase in epithelial 
cell proliferation, expansion of the pit cell population, diminished neck and chief 
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cell populations and inhibition of zymogenic lineage differentiation, mirroring the 
effects of parietal cell ablation (van den Brink et al., 2001; Xiao et al., 2010). This 
suggests a pivotal role for this signalling pathway in mediating parietal cell 
organizing activity in the corpus unit.  
 
1.2.4.5 Wnt signalling 
 
It is postulated that Wnt signalling mediates the maintenance of the gastric stem 
cell phenotype. Lgr5-expressing stem cells respond to Wnt-signals, as determined 
by Axin2 expression and stimulation by intraperitoneal R-spondin1 administration 
(Barker et al., 2010). Furthermore, activation of Wnt signalling in gastric epithelial 
cells is associated with de-differentiation in the corpus and hyperproliferation in 
both corpus and antral mucosa (Radulescu et al., 2013).  
 
1.2.4.6 Notch signalling 
 
There is evidence that the proliferating stem and progenitor cell phenotypes are also 
maintained by Notch signalling. Hes1 expressing proliferative cells are found 
within the isthmus of corpus and antral glands and inhibition of Notch signalling is 
associated with almost complete suppression of gastric epithelial cell proliferation 
in vivo (Kim & Shivdasani, 2011). Additionally activation of Notch signalling in 
parietal cells results in de-differentiation into multipotential stem or progenitor cells 
capable of regenerating entire gastric units.  
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1.2.5 The effects of gastrin on gastric mucosal morphology  
 
G cells in the gastric antral mucosa secrete the hormone gastrin, which modulates 
the activity of parietal cells and ECL cells via activation of the cholecystokinin 
(CCK)-2 receptor (Schmitz et al., 2001). Exogenous and endogenous gastrins have 
a trophic effect upon corpus mucosa, which is associated with expanded parietal 
and ECL cell populations (Crean et al., 1969; Willems et al., 1972; Hansen et al., 
1976; Johnson, 1977; Dembinski & Johnson, 1979; Ryberg et al., 1990a; Ryberg et 
al., 1990b; Wang et al., 1996; Tsutsui et al., 1997; Kidd et al., 2000; Jain & 
Samuelson, 2006). However, prolonged hypergastrinaemia is associated with 
parietal cell and ECL cell loss and progression to gastric adenocarcinoma (Wang et 
al., 2000).  
 
In a number of studies, hypergastrinaemia has been associated with CCK2 receptor-
dependent increases in basal gastric epithelial cell apoptosis and increased 
susceptibility to γ-radiation- and Helicobacter-induced apoptosis of gastric 
epithelial cells, partially reversible by expression of glycine-extended gastrin (Kidd 
et al., 2000; Cui et al., 2004; Cui et al., 2006; Przemeck et al., 2008). Conversely, 
other studies have indicated that both amidated gastrin and glycine-extended gastrin 
exert anti-apoptotic effects on isolated gastric epithelial cells and gastric cancer 
cells, and also that expression of anti-apoptotic proteins is increased in 
hypergastrinaemia-associated ECL cell carcinoid tumours (Konturek et al., 2003; 
Pritchard et al., 2008; He et al., 2008). This highlights the role of the 
microenvironment and cell phenotype in determining the effects of gastrin upon 
gastric epithelial cell apoptosis.  
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Whilst gastrin has been shown to directly stimulate proliferation of ECL cells, a 
direct mitogenic effect on parietal cells has not been demonstrated (Jain & 
Samuelson, 2006). Gastrin induces the expression of growth factors by gastric 
epithelial cells, which may mediate some of its trophic activity. Exogenous gastrin 
increases the expression of HB-EGF and amphiregulin by parietal cells, whilst 
prolonged hypergastrinaemia induces expression of TGF-α and HB-EGF (Tsutsui et 
al., 1997; Miyazaki et al., 1999; Wang et al., 2000; Dickson et al., 2006). 
Additionally, gastrin induces expression of the growth factor regenerating islet-
derived 1 (Reg-1), expressed by ECL cells in the gastric mucosa (Fukui et al., 1998; 
Higham et al., 1999; Ashcroft et al., 2004; Steele et al., 2007). Increased secretion 
of these growth factors into the gastric mucosal microenvironment is thought to 
stimulate proliferation of epithelial progenitor cell populations via paracrine 
interactions (Jain & Samuelson, 2006). Furthermore, the presence of CCK-2 
receptors on some gastric epithelial progenitors suggests that gastrin may act 
directly to stimulate proliferation of these cells (Kazumori et al., 2001). 
 
1.2.6 Gastric mucosal luminal sensing 
     
In order that gastrointestinal morphology and function are maintained, a complex 
mucosal sensory system exists, facilitating appropriate responses to the highly 
variable luminal environment. These responses are mediated via paracrine, 
endocrine, neural and immune interactions, disruption of which results in 
gastrointestinal pathophysiology. An important function of the gastrointestinal 
mucosa is to integrate luminal nutrient content with appropriate gut and systemic 
responses. In the intestine, various enteroendocrine and caveolated cells express G 
protein-coupled receptors (GPCRs), transporters and ion channels on the apical 
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surface, which act as taste receptors and luminal nutrient chemoreceptors. 
Activation of these nutrient receptors elicits the basolateral secretion of an array of 
paracrine mediators, acting upon local cells and afferent nerve terminals, and gut 
hormones, which together target the gut, brain and peripheral tissues to facilitate 
digestion, nutrient absorption, satiety, glucose homeostasis and peripheral nutrient 
processing (Tolhurst et al., 2012; Reimann et al., 2012).  
 
In the stomach, antral G cells sense luminal nutrients via GPCRs, such as the 
extracellular calcium-sensing receptor, which acts as an amino acid sensor as well 
as sensing increases in luminal calcium and pH (Conigrave et al., 2000; Quinn et 
al., 2004; Haid et al., 2011). Activation of these chemoreceptors stimulates 
endocrine secretion of gastrin (Feng et al., 2010). Gastrin primarily acts via CCK-2 
receptors on ECL cells, promoting histamine secretion, to stimulate secretion of 
gastric acid by parietal cells (Tari et al., 1997; Watson et al., 2006; Schubert & 
Peura, 2008). An increase in luminal gastric acid stimulates secretion of 
somatostatin by D cells, which acts upon G cells, ECL cells and parietal cells to 
inhibit secretion of gastrin, histamine and gastric acid respectively, forming a self-
regulating system via negative feedback (Watson et al., 2006; Schubert & Peura, 
2008; Figure 1.2).  
 
Secretion by enteroendocrine cells is modulated by basolateral inputs such as 
growth factors, cytokines and neurotransmitters (Dockray, 2003). Gastrin releasing 
peptide (GRP) positively regulates gastrin and somatostatin secretion (Watson et 
al., 2006). Proinflammatory cytokines stimulate gastrin secretion but inhibit 
somatostatin release, increasing gastric acid secretion as part of the host response to 
gastric bacterial infection (Dockray, 2003). Sensing of the luminal environment also 
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takes place at the subepithelial level of the mucosa and within the submucosa and 
muscular layers. Intramural mechanoreceptive vagal afferent fibres sense gastric 
distension following a meal; CCK potentiates firing of these afferents, inhibiting 
food intake (Berthoud & Powley, 1992; Schwartz et al., 1993). Mucosal and 
submucosal mechanisms responsible for the detection of and responses to 
potentially injurious agents in the gastric lumen are discussed in section 1.4. 
 
 
 
Figure 1.2 Physiological control of gastric acid secretion. Following ingestion of 
a meal, nutrients, particularly amino acids, are sensed by antral G cells, stimulating 
endocrine secretion of gastrin. Gastrin acts via CCK2 receptors on ECL cells, 
potentiating histamine release, which subsequently stimulates exocrine secretion of 
gastric acid by parietal cells. Increases in luminal gastric acid stimulate 
somatostatin release from D cells, which acts to inhibit the secretion of gastrin, 
histamine and gastric acid, creating a self-regulating system. Image reproduced 
with permission from Watson et al., 2006. 
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1.3 Myofibroblasts 
 
1.3.1 Physiological and pathophysiological roles of myofibroblasts 
 
Myofibroblasts are a key stromal cell population involved in physiological and 
pathophysiological tissue remodelling. During wound healing, myofibroblasts           
respond to tissue insult by migrating into the damaged tissue, where they produce 
paracrine factors involved in regulating epithelial responses, acute inflammatory 
responses, angiogenesis, neurogenic responses and extracellular matrix (ECM) 
remodelling (Powell et al., 1999). The secretory and contractile myofibroblast 
produces ECM components, including fibronectin, laminins and particularly 
collagens, and transfers contractile force to granulation tissue to bring about wound 
contraction, before undergoing apoptosis (Mahida et al., 1997; Tomasek et al., 
2002). Persistent activation of myofibroblasts in the contracted wound marks 
deregulation of ECM remodelling activity and tensional homeostasis, forming the 
basis of fibrosis in many tissues, including skin, lung, liver, kidney and heart (van 
den Borne et al., 2010; Hinz et al., 2012).  
 
Myofibroblasts are also important mediators of immune responses, chronic 
inflammation and tumour progression. Myofibroblasts, fibroblasts and fibroblast-
like cell populations act as antigen presenting cells and express Toll-like receptors, 
activation of which elicits secretion of cytokines, chemokines and other 
inflammatory mediators (Powell et al., 2011; Pinchuk et al., 2010). This contributes 
to persistent activation and recruitment of immune cells in chronically inflamed 
tissues (Andoh et al., 2007; Pinchuk et al., 2010; Pinchuk et al., 2013). 
Myofibroblasts, fibroblasts and fibroblast-like cells can also function in an 
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immunosuppressive role, in high interferon (IFN)-γ microenvironments (Powell et 
al., 2011).  Interactions between myofibroblasts in the tumour microenvironment 
and cancer cells drive invasive cancer cell growth, via direct cell-cell connections 
and paracrine interactions (De Wever et al., 2008). 
 
1.3.2 Morphological and molecular characterisation of myofibroblasts  
 
Myofibroblasts are differentiated cells with characteristics of both fibroblasts and 
smooth muscle cells. Their discovery in granulation tissue led to the theory that the 
force required to elicit contraction during wound healing may be produced by these 
cells via the same mechanisms as smooth muscle contraction (Gabbiani et al., 1971; 
Majno et al., 1971). The myofibroblast is characterised by the presence of many 
mitochondria and cisternae of rough endoplasmic reticulum, as seen in the 
fibroblast, and obvious bundles of fibrils arranged in parallel with the cell axis, in 
keeping with smooth muscle like morphology. A basement membrane like material 
is observed on these cells, deposited in parallel to the cell surface at attachment 
sites, that can transfer contractile force generated within the cell to the ECM 
(Gabbiani et al., 1971).  
 
Vimentin and α-smooth muscle actin (SMA) are widely used as markers for 
differentiated myofibroblasts. Other markers of the differentiated myofibroblast 
may also include desmin, endosialin, podoplanin, osteopontin, periostin, fibroblast 
activation protein, palladin 4Ig, prolyl-4 hydroxylase, γ-SMA, P311, integrin 
α11β1, cadherin-11 and stromelysin-3, as well as absence of epithelial cytokeratins, 
smoothelin, CD14, CD31 and CD34  (Park et al., 1999; De Wever et al., 2008; 
Hinz et al., 2012). Expression of these markers is variable and depends upon the 
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tissue and cellular origin of the myofibroblast, which may derive from a number of 
cell types. Consequently, De Wever et al. have proposed that expression of α-SMA 
and at least three other markers is required to identify myofibroblasts as distinct 
from other myofibroblast-like cell populations, such as cancer-associated 
fibroblasts (CAFs) and activated fibroblasts (De Wever et al., 2008). Similarly, 
Eyden has put forward more stringent criteria to define the myofibroblast, based on 
morphology, expression of protein markers and ultrastructural features (Eyden, 
2008).  
 
1.3.3 Myofibroblast lineages and differentiation  
 
Transdifferentiation of fibroblasts is considered the primary source of 
myofibroblasts during epithelial wound healing, but myofibroblasts have also been 
suggested to arise from various undifferentiated and differentiated cell types, 
including mesenchymal stem cells, epithelial cells, endothelial cells, pericytes, 
myoepithelial cells, smooth muscle cells, fibrocytes, adipocytes, hepatic stellate 
cells, pancreatic stellate cells and mesothelial cells (De Wever et al., 2008; Hinz et 
al., 2012; Lv et al., 2013). The various origins of a myofibroblast population 
depend upon the tissue and physiological or pathophysiological microenvironment 
they inhabit. It follows that myofibroblasts, which exist as phenotypically 
heterogeneous populations, can show characteristics of the parent cell type and it 
has been argued that there is some ambiguity in defining the myofibroblast in terms 
of its differentiation from other cells (Eyden, 2008). Phenotypically heterogeneous 
myofibroblasts, derived from different progenitors, may be functionally distinct 
from each other and may contribute different elements of the mechanisms required 
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for their tissue remodelling activity in wound healing, fibrosis, chronic 
inflammation and tumourigenesis. 
 
Fibroblast transdifferentiation occurs in response to paracrine factors, notably  
TGF-β, but possibly also platelet derived growth factor (PDGF), connective tissue 
growth factor, Wnt, Jagged, Shh, Fizz1, endothelin-1, lysophosphatidic acid and 
chemokines, produced by local inflammatory and parenchymal cells of the injured 
tissue (Werner & Grose, 2003; De Wever et al., 2008; Liu et al., 2009; Horn et al., 
2012; Hinz et al., 2012). Treatment of cultured subcutaneous and lung fibroblasts 
with TGF-β induces expression of α-SMA, primarily through Smad2 
phosphorylation (Desmouliere et al., 1993; Evans et al., 2003; Wipff et al., 2007). 
Furthermore, administration of TGF-β to granulation tissue produces a distinct 
phenotype when compared to administration of other growth factors and cytokines: 
an abundance of myofibroblasts, which express α-SMA by definition, and 
collagenous deposits (Desmouliere et al., 1993). TGF-β signalling via Smad 
synergises with hyaluronic acid-dependent co-localisation of EGFR and CD44 in 
lipid rafts, also stimulated by TGF-β signalling, to elicit fibroblast 
transdifferentiation (Midgley et al., 2013). Stimulation of Wnt signalling in cultured 
mouse embryonic fibroblasts activates TGF-β signalling to induce α-SMA, via 
Smad2 phosphorylation, transforming the cells into contractile and migratory 
myofibroblasts (Carthy et al., 2011). Conversely, TGF-β-induced transformation of 
skin fibroblasts into myofibroblasts is associated with activation of Wnt signalling 
and subsequent negative regulation of α-SMA expression (Liu et al., 2012).  
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Fibroblast transdifferentiation is also stimulated by mechanical stimuli within the 
connective tissues, of which the fibroblast is a resident cell. When tissue is 
damaged, the ECM undergoes remodelling and loses its ability to shield resident 
cells from external forces and normal tissue tension. In response to exposure to 
these forces, fibroblasts express contractile stress fibres composed of cytoplasmic 
actins, the first step towards transformation into myofibroblasts (Tomasek et al., 
2002). Development of α-SMA-negative stress fibres is initiated only beyond a 
threshold ECM stiffness of ~3000-18000Pa in culture and in vivo, and the threshold 
for fully differentiated α-SMA-expressing myofibroblasts is further elevated to 
~20000Pa in culture, translating to an ECM stiffness ~25000-50000Pa in 
contracting granulation tissue and fibrotic tissue (Hinz, 2010). ECM contraction 
activates latent TGF-β, via integrin-mediated mechanisms, thus myofibroblasts are 
able to stimulate further myofibroblast differentiation in granulation tissue and, 
significantly, during fibrosis (Wipff et al., 2007). TGF-β signalling in fibroblasts is 
associated with disruption of microtubule polymerization and localization mDia2 to 
actin stress fibres, via Rho/SRF activation, facilitating stress fibre formation and 
myofibroblast differentiation (Sandbo et al., 2013).  
 
Bone marrow-derived myofibroblasts are myofibroblasts originating from 
circulating precursors, namely mesenchymal stem cells and CD34+ fibrocytes 
derived from CD34+ monocytes (De Wever et al., 2008). Bone marrow derived 
myofibroblast precursors infiltrate tissues in response to chemokine signals, such as 
CXCL12 and SDF-1, which is particularly significant in myofibroblast recruitment 
to the tumour microenvironment (De Wever et al., 2008; Quante et al., 2011). Bone 
	  	   24	  
marrow-derived myofibroblasts are also found in injured and fibrotic tissue stroma 
(Fujimiya et al., 2009; Akita et al., 2012; Binai et al., 2012).  
  
Epithelial cells are another potential source of myofibroblasts-like cells, via 
epithelial-to-mesenchymal transition (EMT). Resident epithelial cells lose epithelial 
markers and develop mesenchymal markers, including α-SMA. Activation of 
various signalling pathways induces EMT in vitro and in vivo, including Notch, 
hedgehog and Wnt, via integration with TGF-β signalling, (Zavadil et al., 2004; 
Syn et al., 2009; Aoyagi-Ikeda et al., 2011; Chen et al., 2012). Recently, bi-
phenotypic cells, expressing markers of both epithelial cells and myofibroblasts, 
have been identified within the surface mucosa of human gastrointestinal biopsy 
tissues (Nemeth & Tiszlavicz, 2012). The origin of these cells remains to be 
elucidated, but their identification highlights the interchangeability of epithelial cell 
and myofibroblast phenotypes. In a manner similar to EMT, endothelial cells may 
undergo transition to a myofibroblast-like phenotype, and this can also contribute to 
the pathogenesis of fibrotic diseases and cancer (Piera-Velazquez et al., 2011; Lin 
et al., 2012). 
 
1.3.4 Myofibroblasts in gastric physiology and pathophysiology 
 
Myofibroblasts are located within the lamina propria of gastrointestinal mucosa 
(Wu et al., 1999; Powell et al., 2011). Myofibroblasts cultured from colonies 
arising from denuded gastric mucosa have been phenotypically confirmed using 
antibodies to α-SMA and vimentin at passages 1 and 8, showing preservation of the 
phenotype in prolonged culture (Wu et al., 1999). Characterisation of cultured 
gastric myofibroblasts by electron microscopy also identifies groups of 
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microfilaments running lengthwise below the cell membrane (Wu et al., 1999). 
Myofibroblasts interact with epithelial cells and other stromal cells by direct cell-
cell communication and via secretion of an array of mediators, including proteases, 
growth factors, cytokines, chemokines and lipid products (Valentich & Powell, 
1994; Powell et al., 1999). Thus myofibroblasts are critical regulators of 
gastrointestinal epithelial cell function, both in normal physiology and in 
pathophysiological processes, including gastroduodenal ulcer, Helicobacter 
infection and gastric cancer. 
 
Myofibroblasts migrate from the gastric lamina propria through pores in the 
basement membrane of human gastric mucosa denuded of surface epithelial cells, 
in a model of gastric mucosal injury (Wu et al, 1999). The role of myofibroblasts in 
responses to gastric mucosal injury is described in section 1.4.6. As a source of 
growth factors, cytokines, chemokines and other paracrine mediators, 
myofibroblasts mediate epithelial and immune responses during Helicobacter 
infection (Fu et al., 1999; Nakamura et al., 2002; Kim et al., 2004a; McCaig et al., 
2006; Pinchuk et al., 2013). Myofibroblasts also play an important role in the 
microenvironment of gastric adenocarcinoma, as described in section 1.5.3.  
 
1.4 Gastric mucosal defence and injury  
 
1.4.1 Local gastric mucosal defence mechanisms 
 
The gastric mucosa is constantly exposed to a variety of cytotoxic agents and 
noxious stimuli, including gastric acid, pepsin, ingested toxins, bacteria, bacterial 
products, extremes of osmolality as well as mechanical stress; in humans there may 
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also be exposure to ethanol and damaging drugs such as NSAIDs. A complex 
system of luminal sensing and defensive mechanisms protects the integrity of the 
mucosa. One of the primary functions of this cytoprotective system is to maintain a 
near-neutral pH at the luminal surface of the epithelium. This is achieved via 
secretion of bicarbonate and mucus by surface epithelial cells, creating an adherent 
gel that acts as a neutralising and physical barrier against back-diffusion of acid and 
pepsin (Allen & Flemstrom, 2005). A more loosely adherent mucus layer is also 
present, which acts as a lubricant and protects the mucosa from the shear stresses 
generated by ingested particles (Atuma et al., 2001). Furthermore, a hydrophobic 
surfactant layer of active phospholipids is present within the adherent mucus on the 
surface epithelium, forming an additional barrier against acid back-diffusion 
(Goddard et al., 1990).  
 
The intrinsic properties of the surface epithelial cells impart further protection on 
the gastric mucosa, providing a second line of defence when the bicarbonate-
mucus-phospholipid barrier is breached. Gastric epithelial cells are highly resistant 
to proton diffusion across their apical membrane, making them resistant to acid-
induced damage (Wallace, 2008). Superoxide dismutase scavenges superoxide 
produced during normal epithelial cell metabolism, protecting mucosal cells from 
oxidative stress-induced injury (Al-Jiboury & Kaunitz, 2012). When exposed to 
noxious stimuli or cytotoxic agents, gastric epithelial cells produce protective heat 
shock proteins and superoxide scavenging enzymes (Laine et al., 2008; Al-Jiboury 
& Kaunitz, 2012).  The resilience of surface epithelial cells is further enhanced by 
their rapid turnover rate of approximately 3 days and extrusion of degenerated cells 
(Karam & Leblond, 1993c; Wallace, 2008). Together, these mechanisms ensure that 
a robust continuous barrier is maintained. Furthermore, the surface epithelial cells 
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are connected by tight junctions that enable modulation of paracellular 
permeability, forming a physical barrier against acid and pepsin back diffusion 
(Takezono et al., 2004; Laine et al., 2008).  
 
Exposure of the surface epithelium to acid and other irritants stimulates a 
hyperaemic response, representing a third line of mucosal defence. Spinal afferent 
neurons innervating the mucosa detect acid entry into the mucosa via acid sensing 
channels within their terminals, located just beneath the surface epithelial cells, and 
also sense the luminal environment (Laine et al., 2008). Activation of these neurons 
in response to noxious stimuli results in the release of calcitonin gene-related 
peptide (CGRP) from nerve terminals in close proximity to submucosal arterioles, 
resulting in generation of the vasodilator nitric oxide (NO) and consequently 
increased mucosal blood flow (Guth, 1992; Wallace, 2008; Laine et al., 2008). This 
facilitates rapid dilution and removal of the noxious agent. Endothelial cells of the 
mucosal microvasculature also produce NO and other vasodilators, such as 
prostacyclin and hydrogen sulphide (Fiorucci et al., 2006; Laine et al., 2008). As 
well as maintaining microcirculatory blood flow, these agents attenuate 
inflammatory cytokine production and prevent leukocyte and platelet adherence to 
endothelial cells, thus protecting the microvasculature and preventing inflammatory 
cell extravasation into the mucosa (Guth, 1992; Wallace & Miller, 2000; Fiorucci et 
al., 2006; Laine et al., 2008).  
 
1.4.2 Systemic gastric mucosal defence mechanisms 
 
In addition to locally mediated mechanisms, central nervous system- and hormone-
mediated mechanisms contribute to gastric mucosal defence. Direct and adaptive 
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gastric cytoprotection is impaired in acutely vagotomised animals, rendering them 
more sensitive to mucosal injury in response to cytotoxic agents (Henagan et al., 
1984; Mozsik et al., 1991; Evangelista & Maggi, 1991; Karadi et al., 1999). 
Endogenous and exogenous CCK and leptin, administered centrally or peripherally, 
induce NO-mediated hyperaemia via a vago-vagal reflex involving activation of 
capsaicin-sensitive afferent fibres, independently of prostaglandin production 
(Evangelista & Maggi, 1991; Konturek et al., 1995; Heinemann et al., 1996, 
Brzozowski et al., 2001). Central activation of the vagus nerve also increases 
surface epithelial cell pH and mucus viscosity. 
 
Central administration of various other peptides protects against ethanol-induced 
gastric mucosal injury via vagal stimulation and subsequent release of CGRP, NO 
and, to varying degrees, prostaglandins. Centrally acting gastroprotective peptides 
include thyrotropin releasing hormone, corticotrophin releasing factor (CRF), 
peptide YY, ghrelin, orexin, glucagon-like peptide-1, enkephalins, β-endorphin, 
nociceptin, nocistatin, CGRP, calcitonin, adrenomedullin, amylin and cannabinoids 
(Brzozowski et al., 2005; Shujaa et al., 2009; Tache, 2012). Similarly, peripheral 
administration of ghrelin and orexin induces gastric cytoprotection, via stimulation 
of vagal-CGRP-NO-mediated hyperaemia and prostaglandin-mediated mechanisms 
(Konturek et al., 2004; Brzozowski et al., 2005; Brzozowski et al., 2008). 
 
Gastric cytoprotection is also elicited by peripheral administration of CRF, possibly 
through stimulation of gastroprotective glucocorticoids and also via activation of 
CRF receptor type 2 on gastric epithelial cells, inhibiting apoptosis (Chatzaki et al., 
2006; Filaretova et al., 2012). Gastrin is gastroprotective via activation of CCK-2 
receptors on afferent neurons, stimulating CGRP release and NO-mediated 
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hyperaemia (Stroff et al., 1995; Mercer et al., 1997) Melatonin, produced by the 
pineal gland and enteroendocrine cells, stimulates a number of gastroprotective 
mechanisms, in part via an increase in plasma gastrin (Brzozowska et al., 2009; 
Konturek et al., 2010). Peripheral administration of peptide YY to plasma 
concentrations mimicking postprandial levels induces gastric cytoprotection via 
mechanisms independent of vagal stimulation (Kawakubo et al., 2002). 
 
1.4.3 Gastric mucosal defence against bacteria and bacterial products 
 
Gastric cytoprotection extends to antibacterial mechanisms, to protect the mucosa 
against noxious interactions with ingested bacteria and bacterial products and 
prevent entry of bacteria and toxins into the circulation. Gastric secretions form the 
first line of defence. Gastric acid creates a hostile luminal environment for many 
bacteria, such that bactericidal activity of gastric juice is critically dependent upon a 
pH below 4 (Giannella et al., 1972). Gastric juice contains antibacterial lysozyme, 
lactoferrin and immunoglobulins (Valnes et al., 1984; Wallace, 2008). The mucus 
layer acts as a bacterial trap, aiding clearance of bacteria from the gastric lumen 
(Wallace, 2008). Together these mechanisms prevent bacterial colonisation of the 
gastric mucosa and subsequent damaging inflammatory responses.  
 
The second line of defence against bacterial colonisation involves activation of 
innate immune responses. Toll-like receptors on gastric epithelial cells detect 
luminal bacteria, via recognition of pathogen-associated molecular patterns 
(Aderem & Ulevitch, 2000; Schmausser et al., 2004). This activates signalling 
cascades that stimulate secretion of antibacterial peptides by epithelial cells, 
including cathelicidin and β-defensins (Cunliffe & Mahida, 2004; Laine et al., 
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2008). Despite the robust antibacterial defence mechanisms that exist in the 
stomach, a number of species of bacteria have evolved mechanisms to evade 
destruction and clearance, notably some Helicobacter species.  
 
1.4.4 Prostaglandins in gastric mucosal defence 
 
Prostaglandins are products of arachidonic acid metabolism, catalysed by 
cyclooxygenase (COX) enzymes (Vane, 1971; Whittle, 1981). Constitutive 
production of prostaglandins is mediated via the COX-1 isoform, expressed in most 
tissues, whereas the COX-2 isoform is inducible and produces prostaglandins in 
response to inflammation (Kargman et al., 1996; Peskar et al., 2001). In the 
stomach, COX-1 and COX-2 are predominantly expressed by myofibroblasts, 
fibroblasts and macrophages (Wu et al., 1999; Tatsuguchi et al., 2000; Fu et al., 
1999; van Rees et al., 2002, Kim et al., 2004a). Epithelial cells express COX-2 in 
gastric adenocarcinoma (van Rees et al., 2002). Both COX-1 and COX-2 activity 
contributes to prostaglandin-mediated gastric cytoprotection (Wallace et al., 2000; 
Peskar et al., 2001; Laine et al., 2008). Simultaneous inhibition of COX-1 and 
COX-2 produces gastric mucosal injury, associated with a significant decrease in 
gastric mucosal prostaglandin E2 (PGE2) expression. Injury can be significantly 
attenuated by intravenous administration of PGE2 4 hours after administration of 
combined COX-1 and COX-2 inhibitors (Tanaka et al., 2002).  
 
Prostaglandins mediate many of the cytoprotective mechanisms in the 
gastrointestinal tract and are an essential component of the gastric mucosal defence 
system. Prostaglandins inhibit the secretion of gastric acid, accounting in part for 
their protective activity. However, gastric cytoprotection induced by exogenous 
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prostaglandins is seen at concentrations below anti-secretory doses (Robert et al., 
1979). Secretion of bicarbonate, mucus and surfactant phospholipids is enhanced by 
prostaglandins, in favour of gastric mucosal defence (Wallace, 2008). 
Prostaglandins produced by the COX-1 isoform maintain normal mucosal blood 
flow and gastric motility, to protect the integrity of the microvasculature and 
prevent mucosal hypoxia (Wallace et al., 2000; Laine et al., 2008). Furthermore, 
prostaglandins attenuate deleterious inflammatory responses, such as mast cell, 
macrophage and neutrophil activation and adherence of leukocytes to the 
microvascular endothelium (Wallace et al., 2000; Wallace, 2008). Prevention of 
leukocyte adherence is mediated by prostaglandins produced via the COX-2 
isoform (Wallace et al., 2000).  Prostaglandins also act directly on epithelial cells to 
enhance their resilience to cytotoxic agents (Wallace, 2008). Furthermore, 
modulation of paracellular permeability in response to exposure of surface 
epithelial cells to acid is mediated by PGE2 (Takezono et al., 2004).  
 
1.4.5 NSAID-induced gastric mucosal injury 
 
NSAIDs produce anti-inflammatory effects via systemic inhibition of COX-1 and 
COX-2 enzymes, preventing the production of prostaglandins (Vane, 1971; Whittle, 
1981; Higgs et al., 1987). Aspirin has a distinct mechanism of action compared to 
other NSAIDs, irreversibly inhibiting COX-1 via acetylation of the hydroxyl group 
of Ser 530, preventing access for arachidonic acid to the active site (Roth et al., 
1975). Consequently, prostaglandin-mediated gastric cytoprotective mechanisms 
are attenuated by NSAID administration, rendering the gastric mucosa more 
susceptible to injury by cytotoxic agents that the stomach is routinely exposed to 
(Wallace, 2008). NSAIDs also have direct topical cytotoxic effects on gastric 
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epithelial cells and are also likely to produce gastric mucosal damage indirectly via 
some prostaglandin-independent mechanisms (Wallace, 2008; Laine et al., 2008, 
Takeuchi, 2012). Upper gastrointestinal bleeding and ulceration is a common 
clinical consequence of NSAID treatment for this reason (Levy, 1974; Somerville et 
al., 1986; Carson et al., 1987; Hernandez-Diaz & Rodriguez, 2000). 
 
1.4.6 Responses to gastric mucosal injury 
 
Despite the robust mucosal defence system in the stomach, cytoprotective 
mechanisms are often breached, resulting in some level of gastric mucosal injury. 
The first level of mucosal injury involves loss of surface epithelial cells. In order to 
maintain the integrity of the epithelial barrier function and prevent deep mucosal 
injury, epithelial restitution occurs rapidly in response to denudation of the mucosa. 
Restitution is driven by migration of epithelial cells over periods of minutes to           
hours, followed over hours to days by proliferation in the isthmus (Lacy & Ito, 
1984). These processes are differentially mediated by prostaglandins and a number 
of growth factors, including epidermal growth factor (EGF), TGF-α, HGF, 
keratinocyte growth factor, IGF-I, IGF-II, insulin and PDGF (Tarnawski et al., 
1985; Takahashi et al., 1996; Tarnawski & Jones, 1998; Watanabe et al., 2000; 
Tetreault et al., 2005). EGFR is an important component of epithelial restitution 
mechanisms, transducing mitotic signals in response to direct activation by EGF or 
transactivation by prostaglandins (Tarnawski & Jones, 1998; Pai et al., 2002). One 
mechanism by which NSAIDs induce gastric mucosal damage is by inhibiting 
EGFR signalling, impairing epithelial restitution (Pai et al., 2001). 
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Epithelial restitution is also critically dependent upon the formation and 
maintenance of a protective mucoid cap over the exposed basement membrane,        
consisting of mucus, fibrin, plasma and cellular debris (Wallace & Whittle, 1986a; 
Wallace & Whittle, 1986b; Wallace & McKnight, 1990). The relatively high pH of  
 
 
 
 
Figure 1.3. Gastric mucosal defence mechanisms can be triggered at multiple 
levels of the mucosa and submucosa, and are mediated via local and systemic 
signals. Image reproduced with permission from Laine et al., 2008. 
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the mucoid cap is sustained by continuous mucosal blood flow; both NSAIDs and 
vasoconstricting agents, such as endothelin-1, disrupt the mucoid cap, facilitating 
deeper haemorrhagic mucosal injury (Wallace & McKnight, 1990). Trefoil factor 
family (TFF) peptides, secreted by gastric epithelial cells as a constituent of mucus, 
also enhance epithelial restitution, via modulation of epithelial cell migration and 
prevention of apoptosis of migrating cells (Hoffmann, 2005). 
 
The next level of mucosal injury involves a breach of the basement membrane by 
cytotoxic agents, resulting in access to and necrosis of deeper mucosal layers, 
including endothelial cells of the microvasculature and epithelial cells of the gastric 
gland. This type of injury is characterised by gross haemorrhagic lesions and 
mucosal erosions. Gastric ulceration occurs when aggressive factors overcome 
defensive factors sufficiently to permit necrotic injury to penetrate the muscularis 
mucosae. Inflammatory responses to necrotic mucosal injury are characterised by 
activation of mast cells, macrophage and neutrophil recruitment and activation, 
adherence of leukocytes to the microvascular endothelium and extravasation of 
leukocytes and plasma into the mucosa, contributing to gastric mucosal injury 
(Martin & Wallace, 2006; Wallace, 2008). Ischaemia develops due to destruction of 
the microvasculature, release of vasoconstricting agents in response to 
inflammatory signals and thrombosis, augmenting mucosal necrosis (Tarnawski & 
Ahluwalia, 2012; Tarnawski et al., 2012; Tarnawski et al., 2013). Oxidative stress 
contributes to mucosal necrosis and gastric ulceration; consequently antioxidants 
are protective against gastric mucosal injury (Matsui et al., 2011; Bindu et al., 
2011; Uc et al., 2012).  
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Healing of necrotic mucosal lesions is a multi-step process, involving re-
epithelialisation of surface and glandular mucosa, angiogenesis, to restore the 
disrupted microvasculature, and ECM remodelling, to rebuild the lamina propria 
(Tarnawski et al., 2013). Healing of ulcers is more complex, involving extensive re-
epithelialisation, angiogenesis and ECM remodelling, characterised by the 
formation of granulation tissue and eventual replacement with scar tissue (Wallace, 
2008; Tarnawski & Ahluwalia, 2012; Tarnawski et al., 2013). These regenerative 
processes are stimulated and mediated by various growth factors and signalling 
molecules, derived from epithelial cells, myofibroblasts, endothelial cells, platelets, 
inflammatory cells and bone marrow-derived mesenchymal stem cells (Wallace, 
2008; Hayashi et al., 2008; Tarnawski & Ahluwalia, 2012; Tarnawski et al., 2012).  
 
Re-epithelialisation occurs at the ulcer margin, to repopulate the necrotic area with 
mucosal glands and surface epithelial cells. Epithelial cell proliferation, migration 
and differentiation are stimulated by an array of signalling molecules, including 
EGF, Reg-1, IGF-I, HGF, PDGF, basic fibroblast growth factor (bFGF), TFF 
peptides, hedgehog signalling molecules, COX-2 derived prostaglandins and 
cytokines (Kang et al., 2009; Fukuhara et al., 2010; Tarnawski & Ahluwalia, 2012; 
Tarnawski et al., 2013). As in restitution, EGFR is a critical mediator of gastric 
ulcer healing (Tarnawski & Jones, 1998; Tarnawski & Ahluwalia, 2012). Gastric 
glands develop from EGF secreting cells of the specialised ulcer-associated cell 
lineage, which invade granulation tissue, proliferate and migrate upwards from the 
ulcer base, forming tubular structures (Wright et al., 1990). Additionally, bone 
marrow-derived mesenchymal stem cells are able to contribute to the regenerated 
epithelium (Okamoto et al., 2002). 
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Angiogenesis arises within the granulation tissue, where endothelial cells 
proliferate and migrate from the intact microvessels surrounding the ulcer to form 
new capillaries and restore a microvascular network within the ulcer site 
(Tarnawski et al., 2013). Microvascular tubulogenesis is stimulated by angiogenic 
growth factors, such as vascular endothelial growth factor (VEGF), bFGF, PDGF 
and angiopoietins (Tarnawski & Ahluwalia, 2012; Tarnawski et al., 2013). 
Hypoxia-inducible factor-1, an inducer of VEGF expression, is produced in 
response to tissue ischaemia and consequently stimulates angiogenesis via VEGF 
(Ferrara, 2004). Similarly, VEGF expression is induced by various growth factors, 
melatonin, NO, cytokines and prostaglandins, produced in response to necrotic 
mucosal injury (Ferrara, 2004; Ganguly et al., 2010; Tarnawski & Ahluwalia, 
2012). TFF peptides also enhance angiogenesis, via COX-2 and EGFR signalling 
(Rodrigues et al., 2003). 
 
ECM remodelling takes place within ulcer granulation tissue, to provide a 
supportive matrix for the developing gastric glands and microvessels, and results in 
the formation of scar tissue. Myofibroblasts drive wound contraction and ECM 
deposition. Various growth factors, cytokines and signalling molecules drive 
migration and proliferation of fibroblasts and myofibroblasts, and myofibroblast 
differentiation, including TGF-β, PDGF, EGF, bFGF, IGF-I, tumour necrosis factor 
(TNF)-α, interleukin (IL)-1 and endothelin-1, derived from inflammatory cells and 
activated endothelial cells in granulation tissue (Watanabe et al., 2000; Nishida et 
al., 2006; Tarnawski & Ahluwalia, 2012). Extracellular proteases, such as matrix 
metalloproteinases (MMPs), are crucial in remodelling the ECM. Their expression 
and that of their inhibitors is tightly regulated during gastric ulcer healing, to 
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facilitate appropriate degradation of ECM components for the healing process 
(Tarnawski, 2005).  
 
1.5 Helicobacter infection and gastric adenocarcinoma 
 
1.5.1 Epidemiology of Helicobacter pylori 
 
H. pylori is a prevalent gastric bacterial pathogen, infecting up to 40% of the adult 
human population in developed countries, increasing to approximately 80-90% in 
developing countries (Rothenbacher & Brenner, 2003; Frenck & Clemens, 2003). 
Infection with H. pylori often goes undetected for a lifetime, as in the majority of cases 
infection causes mild, asymptomatic chronic pangastritis (McNamara & El-Omar, 
2008). However, in some individuals, infection elicits pathogenic immune 
responses. Without treatment, approximately 10% of infected individuals develop 
peptic ulcer disease, associated with antral-predominant colonisation by the bacteria 
and acid hypersecretion (McColl et al., 1997). Gastric adenocarcinoma develops in   
1-3% of infected individuals and is associated with a corpus-predominant pattern of 
colonisation and acid hyposecretion, whilst <0.1% of infected individuals develop 
mucosa associated lymphoid tissue lymphoma (Uemura et al., 2001; Peek & Blaser, 
2002). A combination of host genetic background, expression of bacterial virulence 
factors and environmental stimuli determine the nature of interactions between the 
pathogen and host and thus the outcome of infection (Cover & Blaser, 2009). 
 
H. pylori was first identified in 1982 as a pathogenic agent in peptic ulcer disease 
(Marshall & Warren, 1984). The Nobel Prize in Medicine was awarded to Robin 
Warren and Barry Marshall in 2005 for their discovery. A role in gastric carcinogenesis 
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was subsequently recognised and given prominence when H. pylori was classified as a 
Group I human carcinogen in 1994 by the International Agency for Research on 
Cancer (IARC, 1994). As a consequence, H. pylori eradication has proven to be an 
effective strategy for reducing the incidence of gastric adenocarcinoma, in both humans 
and animal models (Leung et al., 2004; Mera et al., 2005; Peek & Crabtree, 2006; 
Fuccio et al., 2007; Romero-Gallo et al., 2008).  
 
 
1.5.2 Characteristics of Helicobacter pylori 
 
 
H. pylori is a gram-negative, microaerophilic, spiral-shaped and flagellate 
bacterium that colonises the gastric mucosa and is capable of interacting directly 
with host epithelial cells, by inhabiting the adherent mucus layer (Marshall & 
Warren, 1984; Schreiber et al., 2004). Approximately 20% of the bacteria adhere to 
gastric epithelial cells (Peek & Crabtree, 2006). The bacteria are also able to 
penetrate into the mucosa, occupying both intracellular spaces within the gastric 
epithelial cells and interstitial spaces, including the lamina propria (Oh et al., 2005; 
Necchi et al., 2007; Ito et al., 2008). Following ingestion, H. pylori rapidly migrates 
from the highly acidic stomach lumen to the relatively high pH niche of the adherent 
mucus layer. The bacteria utilise cytoplasmic urease to convert urea to ammonia in the 
acidic gastric environment. This facilitates colonisation by buffering the periplasm and 
altering the mechanical properties of the mucus, to make it more permissive to the 
flagellar and corkscrew motility of the bacteria (Weeks et al., 2000; Salama et al., 
2013). Subsequently, H. pylori establish as the predominant bacterial species within the 
infected stomach (Cover & Blaser, 2009).  
 
	  	   39	  
The presence of various virulence factor loci within the genome determines the 
pathogenic potential of different strains of H. pylori. Expression of virulence factors 
facilitates interactions with host cells, allowing manipulation of gene expression, cell 
signalling and the cytoskeletal machinery. H. pylori virulence factors include surface 
adhesins, vacuolating cytotoxin (VacA), γ-glutamyl transpeptidase, cytotoxin-
associated gene A (CagA) and other gene products of the cag pathogenicity island 
(cag PAI) (Salama et al., 2013). All known strains of H. pylori carry the vacA gene; 
expression of different isoforms determines the pathogenic potential of the protein in 
each strain (Atherton et al., 1997; Basso et al., 1998; Rhead et al., 2007).  VacA is a 
vacuolating and channel forming toxin that disrupts epithelial cell barrier function and 
polarity, induces apoptosis via mitochondrial targeting and attenuates host T-cell 
responses (Cover & Blanke, 2005; Palframan et al., 2012). 
 
H. pylori strains possessing the cag PAI interact with host epithelial cells via a type 
IV secretion system (TFSS), enabling direct translocation of CagA and other 
bacterial proteins into host cells (Odenbreit et al., 2000; Backert et al., 2000). 
Phosphorylation of translocated CagA induces epithelial cell proliferation, scattering 
and elongation, via binding and activation of SHP2 tyrosine phosphatase (Segal et 
al., 1999; Higashi et al., 2004; Rieder et al., 2005; Tsutsumi et al., 2006). CagA also 
acts via phosphorylation-independent mechanisms to increase epithelial cell 
proliferation and motility, as well as eliciting a number of cytoskeletal disturbances, 
disrupting epithelial cell polarity, increasing IL-8 secretion and inducing oxidative 
DNA damage and apoptosis (Crabtree et al., 1995; Rieder et al., 2005; Murata-
Kamiya, 2011; Chaturvedi et al., 2011). Consequently, CagA-expressing strains 
are associated with more severe host inflammatory responses, increased incidence 
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of peptic ulcer disease and increased gastric cancer risk (Blaser et al., 1995; 
Kuipers et al., 1995; Parsonnet et al., 1997; Matos et al., 2013). 
 
1.5.3 Gastric adenocarcinoma 
 
 
Gastric cancer is the fourth most prevalent cancer and the second leading cause of 
cancer mortality worldwide (Parkin et al., 2005). H. pylori infection is known to be 
a risk factor for both intestinal and diffuse types of gastric adenocarcinoma (Peek 
& Blaser, 2002). Intestinal-type adenocarcinoma develops through a multi-step 
process, arising on a background of corpus-predominant chronic gastritis, followed 
by multifocal glandular atrophy associated with hypochlorhydria, metaplasia, 
dysplasia and carcinoma (Correa, 1992; El-Omar et al., 1997).  
 
It has been suggested that parietal cell loss is induced by an autoimmune response to 
Helicobacter infection  (Negrini et al., 1997; Veijola et al., 2010). Loss of parietal 
cells leads to SPEM and / or intestinal metaplasia (IM). In SPEM, loss of parietal 
cell-derived differentiation signals results in transdifferentiation of chief cells, so 
that they express markers of both chief and mucous cells (Weis & Goldenring, 
2009). In mouse models of Helicobacter infection, dysplasia arises directly from 
the SPEM phenotype, driven by a T helper cell (Th)1-predominant immune 
response (Roth et al., 1999; Nomura et al., 2004). In humans, IM may arise from 
atrophic gastritis or the SPEM phenotype. IM is marked by replacement of the 
gastric epithelium with intestinal epithelial cell populations, such as absorptive 
cells, goblet cells and Paneth cells, owing to altered differentiation signals in the 
gastric mucosa (Leung & Sung, 2002). Progressive alterations in foveolar mucins 
also develop; acid sialomucins characteristic of the small intestine and finally 
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colonic sulphated mucins are expressed (Silva et al., 2002). Differential 
expression of mucins is seen in different IM sub-types (Reis et al., 1999). Chronic 
Helicobacter-induced gastritis induces an accumulation of genetic mutations and 
epigenetic modifications, driving progression of metaplastic lesions through 
expansion of even a single clone of mutated glands (Jenks et al., 2003; Kim et al., 
2004b; Gutierrez-Gonzalez et al., 2011).  
 
Stromal cell populations are important drivers of gastric carcinogenesis. Bone 
marrow derived stem cells can engraft into gastric tumour tissue, contributing to 
both myofibroblast and cancer cell populations (Houghton et al., 2004; Worthley 
et al., 2009). Myofibroblasts are able to drive invasive cancer growth by 
modulating the microenvironment (De Wever et al., 2008). Gastric cancer-
associated myofibroblasts (CAMs) undergo phenotypic changes compared to 
normal tissue myofibroblasts (NTMs) and adjacent tissue myofibroblasts (ATMs). 
These include increased migration and proliferation and a significantly altered 
secretome, stimulating increased proliferation, migration and invasion of cancer 
cells, in part via increases in secretion of proteases and increased IGF-II activity 
(Holmberg et al., 2012; Fuyuhiro et al., 2012; Holmberg et al., 2013). 
Furthermore, CAMs from patients with poor survival lose the regulated secretory 
phenotype typical of gastric myofibroblasts (Balabanova, 2012). These alterations 
support the role of myofibroblasts as drivers of tumourigenesis, invasion and 
metastasis in gastric cancer. 
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1.5.4 Helicobacter pylori in the pathogenesis of gastric adenocarcinoma  
 
Host inflammatory responses to H. pylori infection contribute strongly to the aetiology 
of gastric adenocarcinoma. Inflammatory responses stimulate an array of cancer-
promoting activities including cell proliferation, transformation, migration, 
angiogenesis and inhibition of apoptosis (McNamara & El-Omar, 2008).  H. pylori 
infection produces both lymphocytic and neutrophilic gastritis, which is determined 
by local inflammatory responses and activation of both innate and adaptive immune 
systems (Ernst & Gold, 2000; Robinson et al., 2007).  
 
Local release of pro-inflammatory cytokines and chemokines is stimulated via 
recognition of translocated bacterial peptidoglycan, by the Nod1 intracellular pattern 
recognition receptor, inducing nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signalling in epithelial cells (Viala et al., 2004). Secretion 
of cytokines and chemokines stimulates recruitment of neutrophils, monocytes and 
lymphocytes to the gastric mucosa (Ernst & Gold, 2000; Robinson et al., 2007). 
Neutrophils induce oxidative DNA damage, contributing to the mutagenic effects of 
Helicobacter infection (Jenks et al., 2003; Touati et al., 2003). Another downstream 
effect of these local inflammatory signals relevant to carcinogenesis is the induction 
of proteases, such as uPA, MMP-7 and MMP-9, and their inhibitors, including PAI-1 
and PAI-2 (Wroblewski et al., 2003; Kitadai et al., 2003; Varro et al., 2004; Kenny et 
al., 2008; Keates et al., 2008). H. pylori also stimulates expression of a number of 
other genes implicated in promoting preneoplasia, metaplasia and carcinogenesis, 
including VEGF, HB-EGF, angiogenin and uPAR (Wallasch et al., 2002; Kitadai et 
al., 2003; Kenny et al., 2008). In terms of adaptive immune responses, H. pylori 
induces a Th1-predominant response in humans, characterised by IFN-γ secretion and 
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expression of pro-inflammatory cytokines such as TNF-α, IL-12, IL-2 and IL-18 
(Robinson et al., 2007; Wroblewski et al, 2010). This induces an aggressive 
inflammatory response, providing a background from which adenocarcinoma may 
arise (Sayi et al., 2009).  
 
Host genetic factors are important determinants of the pathological responses to 
H. pylori infection. Many polymorphisms exist within the array of pro- and anti-
inflammatory cytokines that mediate gastritis in response to infection, so that 
there is a great deal of variation in the nature and magnitude of these responses 
amongst individuals. For instance, a number of studies have shown that 
polymorphisms in the pro-inflammatory IL-1 and TNF-α and anti-inflammatory 
IL-10 gene clusters increase the risk of cancerous and pre-cancerous lesions 
developing in response to H. pylori infection (McNamara & El-Omar, 2008).   
 
Cancer-promoting epithelial cell and inflammatory responses are, in part, determined 
by the virulence of the infecting strain of bacteria. Many of the host inflammatory 
responses associated with H. pylori-induced pathologies are mediated by the 
TFSS, contributing to the increase in disease incidence associated with cag PAI-
positive strains of the bacterium. Activation of NF-κB and subsequent induction 
of epithelial pro-inflammatory cytokines, such as IL-8, is dependent upon an 
intact TFSS, encoded by genetic loci on the cag PAI (Crabtree, 1998;         
Glocker et al., 1998; Li et al., 1999; Guillemin et al., 2002). IL-8 is also induced 
by an active outer inflammatory protein A gene (Yamaoka et al., 2000; Yamaoka 
et al., 2002). Transcriptional responses of epithelial cells to infection with cag 
PAI-negative isogenic mutants resemble that of mock-infected cells, highlighting 
the importance of the TFSS for host cell responses to H. pylori (Guillemin et al., 
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2002). Furthermore, epithelial cells infected with cag PAI-negative mutants 
differentially express an array of genes determining cell proliferation, apoptosis 
and transcriptional activity, as well as inflammatory cytokine and protease 
production, compared to cag PAI-positive wild-type bacteria (Cox et al., 2001). 
CagA-stimulated modifications to the epithelial cell cytoskeleton and signalling 
pathways promote proliferation, migration and chromosome instability, enhancing 
preneoplastic remodelling and carcinogenesis (Segal et al., 1999; Higashi et al., 
2004; Ohnishi et al., 2008; Umeda et al., 2009; Murata-Kamiya, 2011). 
Furthermore, evolution of H. pylori during progression from chronic atrophic 
gastritis to gastric adenocarcinoma results in a more invasive phenotype. Cancer-
associated intracellular bacteria influence gastric epithelial stem cell activity in 
favour of carcinogenesis (Giannakis et al., 2008).  
 
1.5.5 Mouse models of Helicobacter-induced gastric carcinogenesis 
 
A number of animal models of Helicobacter infection have been developed, to 
elucidate the mechanisms underlying host-bacterial interactions in gastric 
carcinogenesis. These utilise either adapted strains of H. pylori or alternative 
Helicobacter species, infected into mice or Mongolian gerbils for the most part, to 
recapitulate human pathology (Pritchard & Przemeck, 2004). The mouse is a 
particularly attractive animal model to use due its availability, relative low-cost to 
maintain compared to larger mammalian models and ease of genetic manipulation.  
 
The genetic background of the host is an important determinant of the pathological 
outcome of infection, as illustrated by studies reporting varied responses of 
different mouse strains to infection with equivalent strains of Helicobacter 
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(Sakagami et al., 1996; Mohammadi et al., 1996; Lee et al., 1997; Wang et al., 
1998; Kim et al., 2001; Mahler et al., 2002; Thompson et al., 2004). Host gender 
also influences responses to Helicobacter infection; female C57BL/6 mice develop 
more severe inflammatory and histopathological responses to Helicobacter felis 
infection (Court et al., 2003). Conversely, male INS-GAS mice respond to H. pylori 
infection with an augmented histopathological response and accelerated progression 
to adenocarcinoma (Fox et al., 2003). These opposing results also highlight the role 
played by Helicobacter species in shaping pathogenesis.  
 
Cytotoxin producing strains of H. pylori elicit inflammatory and histological 
responses in mice with some features of those seen in humans (Marchetti et al., 
1995; Lee et al., 1997). Adapted strains of H. pylori are developed by in vivo 
passage of clinical isolates with the highest colonisation efficiency, via serial 
gavage (Marchetti et al., 1995; Lee et al., 1997; Thompson et al., 2004). One such 
strain is Sydney strain 1, used widely in mouse models owing to successful 
colonisation of the mouse gastric mucosa and persistent infection (Lee et al., 1997). 
However, adaptation of H. pylori strains for effective colonisation of the mouse 
gastric mucosa results in diminished functionality of virulence genes, such as those 
of the cag PAI, eliciting an attenuated host response thus limiting true recapitulation 
of human pathogenesis (Philpott et al., 2002; Court et al., 2002; Crabtree et al., 
2002). Consequently, wild-type mice fail to develop gastric adenocarcinoma in 
response to H. pylori infection, in the absence of other carcinogenic agents (Lee et 
al., 1997; Kim et al., 2003; Pritchard & Przemeck, 2004). 
 
H. felis is an alternative species of Helicobacter used in mouse models. Despite 
lacking the cag PAI, H. felis closely models human preneoplastic responses to H. 
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pylori in the stomach, when infected into the C57BL/6 mouse strain, including 
mucosal hyperplasia, oxyntic gland atrophy, glandular dilation, invasion of glands 
through the muscularis mucosae, lymphocytic infiltration, mucous cell metaplasia 
and SPEM, progressing to carcinoma in longer term infections (Fox et al., 1996; 
Sakagami et al., 1996; Fox et al., 1997; Wang et al., 1998; Lichtenberger et al., 
1999; Dial et al., 2000; Fox et al., 2002; Court et al., 2003; Nomura et al., 2004; 
Cai et al., 2005; Takaishi et al., 2009; Schmitz et al., 2011). Progression of H. felis-
stimulated carcinogenesis is accelerated in the hypergastrinaemic INS-GAS 
transgenic mouse model. INS-GAS mice develop spontaneous adenocarcinoma by 
20 months of age; when infected with H. felis mice develop adenocarcinoma as 
early as 8 months of age (Wang et al., 2000). This provides a convenient model to 
investigate host-bacterial interactions in Helicobacter pathogenesis over a shorter 
time frame.  
 
1.6 The urokinase plasminogen activator system 
 
1.6.1 Physiological and pathophysiological roles of the uPA system  
 
The uPA system is an important regulator of tissue remodelling in both physiological 
and pathophysiological processes. The system, consisting of uPA, uPAR and the 
inhibitors, PAI-1 and PAI-2, regulates extracellular proteolysis via plasmin activation 
and affects cell adhesion and signalling to influence wound healing, chronic 
inflammation, fibrosis and cancer (Blasi & Carmeliet, 2002; Castellino & Ploplis, 
2005; Smith & Marshall, 2010; Deryugina & Quigley, 2012). In the stomach, 
expression of uPA and PAI-1 is elevated at ulcer sites, and, in addition to uPAR, is 
stimulated by Helicobacter infection (Wodziński et al., 1993; Herszenyi et al., 1997; 
Kitadai et al., 2003; Kenny et al., 2008; Keates et al., 2008). Increased expression of 
	  	   47	  
uPA, uPAR and PAI-1 is associated with increased invasiveness of gastric cancer cells 
and enhanced angiogenesis, correlating with adverse outcomes in gastric cancer 
(Nekarda et al., 1994; Heiss et al., 1995; Ganesh et al., 1996; Lee et al., 2003; 
Kaneko et al., 2003; Kim et al., 2005; Zhang et al., 2006; Beyer et al., 2006; Kim et 
al., 2007; Kim et al., 2008; Baek et al., 2008; Kita et al., 2009; Park et al., 2011; Ding 
et al., 2013). 
 
1.6.2 The uPA system and extracellular proteolysis  
 
uPA is a serine protease with a fundamental role in the plasmin-stimulated 
extracellular proteolysis, cleaving plasminogen at the single Arg561-Val562 scissile bond 
to generate plasmin, a two-chain polypeptide complex linked by a single disulphide 
bond (Robbins et al., 1967). The proteolytic activity of plasmin drives fibrinolysis 
during wound healing and also elicits ECM degradation via direct plasmin activity and 
activation of proteolytic MMPs such as MMP-2, MMP-3, MMP-9, MMP-12 and 
MMP-13 (Nagase et al., 1990; Wong et al., 1992; Carmeliet et al., 1997; Monea et al., 
2002; Deryugina & Quigley, 2012). Extracellular proteolysis also liberates ECM-
bound growth factors and activates latent growth factors and cytokines (Lyons et al., 
1990; Houck et al., 1992; Campbell et al., 1992; Whitelock et al., 1996; Deryugina & 
Quigley, 2012). Plasmin-driven ECM degradation and growth factor activation 
facilitate cell migration and signalling, crucial for physiological and 
pathophysiological tissue remodelling processes including wound healing, 
angiogenesis, cancer cell proliferation, invasion and metastasis, as well as 
inflammatory cell recruitment (Castellino & Ploplis, 2005; Deryugina & Quigley, 
2012). PAI-1, a member of the serine protease inhibitor family of proteins, has a 
regulatory role with regard to these processes, specifically inhibiting the plasminogen 
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activators uPA and tissue plasminogen activator (tPA). PAI-1 binds covalently to uPA 
at its active site, and is itself inactivated by cleavage of the Arg-Met bond at its 
reactive centre (Andreasen et al., 1986; Egelund et al., 1998).  
 
uPA is secreted as a single chain glycosylated pro-enzyme and is converted to the 
active enzyme, consisting of two polypeptide chains linked by a disulphide bond, by 
limited proteolysis (Skriver et al., 1982; Neilsen et al., 1982). Both uPA and pro-uPA 
bind with high affinity to uPAR, which is associated with the extracellular surface of 
the cell by a carboxyl-terminal glycosylphosphatidylinositol (GPI) anchor (Ploug et 
al., 1991; Huai et al., 2006). Binding of uPA and pro-uPA to uPAR localises 
proteolytic activity to the cell surface. Pro-uPA is reciprocally activated by plasmin 
generated by active uPA, amplifying proteolytic activity at the cell surface (Skriver et 
al., 1982; Neilsen et al., 1982). Directional migration of cells through the ECM is 
facilitated by localised expression of uPAR at the leading edge of migrating cells, 
concentrating proteolytic activity and ECM remodelling in the direction of migration 
(Estreicher et al., 1990).  
 
1.6.3 Cell adhesion, migration and signalling via uPAR 
 
The uPA system mediates cell-ECM associations, via interactions between uPAR, 
integrins and the ECM component vitronectin (Wei et al., 1994; Wei et al., 1996). 
These interactions modulate cell adhesion, migration and intracellular signalling. 
Vitronectin is an ECM glycoprotein involved in cellular adhesion via interactions with 
integrins and is also an important element of cell migration, forming a matrix which 
the cell co-ordinately attaches to and detaches from as it migrates (Felding-
Habermann & Cheresh, 1993; Waltz et al., 1997). Integrins are transmembrane 
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receptors that interact with various ECM and cell surface components to mediate cell 
adhesion and transduce signals arising from cell-ECM and cell-cell associations (Wei 
et al., 1996). uPAR is also a high affinity receptor for vitronectin and forms stable 
complexes with integrins and caveolin (Wei et al., 1994; Wei et al., 1996; Wei et al., 
1999).  
 
The stable complexes formed by the interactions between uPAR, α3β1-integrin and 
caveolin alter the overall adhesive properties of β1-integrins, promoting adhesion via 
vitronectin (Wei et al., 1996; Wei et al., 1999; Wei et al., 2001). Furthermore, 
interactions between uPAR and α5β1-integrin enhance binding between this integrin 
isoform and the ECM component fibronectin (Wei et al., 2005). uPAR can bind uPA 
and vitronectin simultaneously such that uPA binding uPAR enhances adhesion via 
vitronectin, promoting interactions between uPAR and integrins and increasing the 
affinity of uPAR-vitronectin binding (Wei et al., 1994; Chapman & Wei, 2001; 
Sidenius et al., 2002; Kjoller, 2002; Huai et al., 2008).  
 
uPAR-mediated cell adhesion and migration via vitronectin is inhibited by PAI-1, 
through both uPA dependent and independent pathways. Binding of PAI-1 to uPAR 
bound uPA results in inactivation of cell surface αv-integrins and internalisation of the 
entire complex, along with integrins in complex with uPAR (Czekay et al., 2003). The 
low-density lipoprotein receptor-related protein (LRP) mediates endocytic 
internalisation of this multi-protein complex; rapid clearance of uPAR and αV-integrins 
in this way prevents reattachment of cells via vitronectin (Czekay et al., 2003). PAI-1 
also binds to vitronectin, stabilising PAI-1 in its active conformation in plasma and in 
the ECM (Wiman et al., 1988; Seiffert et al., 1991).  The binding sites for PAI-1 and 
uPAR overlap in the amino terminal somatomedin B domain of vitronectin. Therefore 
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PAI-1 competitively inhibits uPAR binding (Deng et al., 2001). Furthermore, PAI-1 in 
complex with vitronectin sterically hinders interactions via the RGD domain of 
vitronectin, inhibiting interactions between vitronectin and integrins (Stefansson et al., 
1996). PAI-1 can detach cells from the ECM by disrupting interactions between uPAR 
and integrins with vitronectin. 
 
Signalling via GPI-anchored uPAR relies upon direct interactions of uPAR and/or 
vitronectin with transmembrane or internalisation receptors, to transduce the signal 
across the membrane into the intracellular compartment. These include integrins, 
GPCRs, receptor tyrosine kinases, such as EGFR, cytokine receptors, caveolin and 
endocytic receptor 180 (Blasi & Carmeliet, 2002; Smith & Marshall, 2010). Various 
intracellular signalling molecules and pathways can be activated via uPAR, including 
tyrosine kinases such as focal adhesion kinase (FAK) and Src, the mitogen-activated 
protein kinase (MAPK) pathway, the janus kinase/signal transducers and activators 
of transcription pathway, the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and 
the Rho family GTPase Rac (Koshelnick et al., 1997; Tang et al., 1998; Nguyen et al., 
1998; Nguyen et al., 2000; Kjoller & Hall, 2001; Blasi & Carmeliet, 2002; Liu et al., 
2002; Aguirre Ghiso, 2002; Vial et al., 2003; Degryse et al., 2005; Alfano et al., 2006; 
Lester et al., 2007; Smith & Marshall, 2010). The complex array of signalling 
pathways stimulated via uPAR modulates a variety of cellular functions, including 
survival, proliferation, differentiation, cytoskeletal properties, migration, adhesion 
and protease expression.  
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1.6.4 The uPA system in wound healing and fibrosis 
 
The uPA system, together with tPA, critically regulates wound healing. Endothelial 
cell-derived tPA primarily drives plasminogen activation in the vasculature, 
stimulating fibrinolysis to prevent thrombosis (Andreasen et al., 2000; Zorio et al., 
2008; Del Rosso et al., 2011). Platelet-derived PAI-1 regulates fibrinolysis, binding 
to platelet-associated fibrin to stabilise the clot and prevent haemorrhage (Braaten 
et al., 1993). A variety of parenchymal and stromal cell types express uPA, uPAR 
and PAI-1 during wound healing, to regulate the complex array of activities 
involved in tissue remodelling and acute inflammatory responses, via modulation of 
extracellular proteolysis, cell adhesion, migration and signalling (Blasi & Carmeliet, 
2002; Smith & Marshall, 2010; Del Rosso et al., 2011). Consequently, aberrant 
expression of the tPA/uPA system is implicated in pathological responses to tissue 
injury, including haemorrhage, thrombotic events, fibrosis and chronic 
inflammation.  
 
The uPA system influences fibrosis, with tissue-specific effects (Zhang & Eddy, 
2008). Fibrosis is a pathological tissue state characterised by excessive and 
disorganised deposition of ECM, often in response to tissue injury, which has 
deleterious effects on tissue structure and function (Knapp et al., 1977; Hinz et al., 
2012). As described in section 1.2.1, persistent activation of myofibroblasts in the 
contracted wound results in deregulated ECM remodelling activity, leading to 
fibrosis (van den Borne et al., 2010; Hinz et al., 2012). Absence or deficiency of 
uPAR is associated with increased myofibroblast abundance and a fibrotic 
phenotype in kidney and skin (Zhang et al., 2003a; Zhang et al., 2003b; Kanno et 
al., 2008). uPA attenuates lung and liver fibrosis, exacerbates cardiac fibrosis and 
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has no effect upon kidney fibrosis (Salgado et al., 2000; Hattori et al., 2004; 
Moriwaki et al., 2004; Heymans et al., 2006; Yamaguchi et al., 2007). PAI-1 is 
associated with an increase in myofibroblast abundance and is pro-fibrotic in 
various tissues (Oda et al., 2001; Matsuo et al., 2005; Tuan et al., 2008; Hu et al., 
2009; Senoo et al., 2010; Bauman et al., 2010; Ghosh & Vaughan, 2012). A notable 
exception is cardiac tissue, where PAI-1 deficiency results in the development of 
spontaneous cardiac fibrosis in aged mice, although elevated PAI-1 is associated 
with injury-induced cardiac fibrosis (Moriwaki et al., 2004; Ghosh et al., 2010; 
Ghosh & Vaughan, 2012). Evidence from the above literature suggests that the uPA 
system can influence ECM turnover via effects on the recruitment, activation or 
persistence of myofibroblasts at the site of injury or by modulating plasmin/MMP-
directed ECM degradation.  
 
1.6.5 The uPA system in inflammation  
 
The uPA system plays a significant role in inflammatory responses, mediating 
inflammatory cell activation and facilitating migration of leukocytes into the 
compromised tissue. uPAR is expressed by myeloid cells and activated T lymphocytes 
and is stimulated in response to various pro-inflammatory cytokines and bacterial 
products (Plesner et al., 1994; Nykjaer et al., 1994; Bianchi et al., 1996; Del Rosso et 
al., 2011). Similarly, uPA expression by various cell types, including epithelial, 
endothelial, monocytes, neutrophils and natural killer cells, is stimulated by pro-
inflammatory cytokines, such as TNF-α, IL-1β, IL-2, IL-3 and bacterial products, such 
as lipopolysaccharide (LPS) (Mondino & Blasi, 2004; Del Rosso et al., 2011). Injury, 
inflammation and infection elicit significant local and systemic elevations of PAI-1 
(Quax et al., 1990;  Wang et al., 2005; Samad et al., 1996; Rijneveld et al., 2003; 
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Renckens et al., 2005; Renckens et al., 2007; Kowal et al., 2007; Kowal et al., 
2010; Budinger et al., 2011; Lim et al., 2011; Goolaerts et al., 2011).  
 
uPA and uPAR mediate various processes during inflammatory responses. uPA 
promotes neutrophil activation whilst uPAR facilitates neutrophil extravasation and 
migration (Abraham et al., 2003; Gyetko et al., 1995; May et al., 1998). uPA 
stimulates the release of pro-inflammatory cytokines from monocytes and activates 
latent pro-inflammatory cytokines via plasminogen activation (Vaday & Lider, 
2000; Del Rosso et al., 2011). Furthermore, the extracellular proteolytic activity of 
uPA and uPAR facilitates migration of leukocytes into the site of inflammation, as 
illustrated by impaired macrophage migration in plasminogen deficient mice 
(Mondino & Blasi, 2004; Gong et al., 2008).  
 
Interactions between uPA and uPAR, in association with transmembrane co-receptors, 
are chemotactic to various inflammatory cells via proteolytic-independent 
mechanisms (Del Rosso et al., 2011). For instance, uPAR-bound uPA is chemotactic 
to monocytes and basophils, predominantly via binding of a specific uPAR epitope 
to the GPCR FPRL1 and to FPRL2, respectively (Resnati et al., 2002; de Paulis et 
al., 2004). The chemotactic role of uPA-uPAR interactions during inflammation is 
highlighted by the fact that leukocyte recruitment is impaired in uPA-/- and uPAR-/- 
mice, leading to impaired host responses to bacterial infection and, ultimately, death 
(Gyetko et al., 1996; Gyetko et al., 2000; Gyetko et al., 2001; Gyetko et al., 2002; 
Rijneveld et al., 2002). 
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1.6.6 The uPA system in cancer 
 
Expression of uPA, uPAR and PAI-1 is elevated in various cancers, correlating with 
adverse outcomes and a poor prognosis (Kaneko et al., 2003; Beyer et al., 2006; He 
et al., 2007; Dass et al., 2008). Expression of uPA, uPAR and PAI-1 by cancer cells 
and stromal cells varies across different cancers. Expression of uPA, uPAR and 
PAI-1 is increased at the leading edge of invasive primary and secondary tumours 
of colorectal origin, primarily in the stromal compartment, where myofibroblasts 
express uPA and PAI-1; similarly myofibroblasts, and other stromal cells, express 
uPA, uPAR and PAI-1 in human mammary duct carcinoma microinvasive foci 
(Offersen et al., 2003; Neilsen et al., 2007; Illemann et al., 2009). In oral squamous 
cell carcinoma, uPAR-expressing cells are predominantly stromal whilst the 
predominant PAI-1 expressing cell population is the neoplastic cells (Lindberg et 
al., 2006). Strong expression of uPA by adenocarcinoma cells and expression of 
uPA, as well as strong expression of uPAR, by stromal myofibroblasts correlates 
with metastatic potential of pancreatic tumours (He et al., 2007). In gastric cancer, 
cancer cells primarily express uPA and uPAR, with less expression by stromal cells 
including endothelial cells, whilst cancer cells and stromal cells express PAI-1 
(Kaneko et al., 2003).  
 
Elevated expression of uPA and uPAR is associated with increased invasion and 
metastasis, via diverse pathways. The proteolytic activity of uPA-uPAR facilitates 
invasion of cancer cells through the basement membrane and ECM at the primary 
tumour site, intravasation, extravasation and invasion at metastatic foci (Mignati & 
Rifkin, 1993; Andreasen et al., 2000; Dass et al., 2008). Furthermore, non-
proteolytic functions of the uPA system drive cancer cell migration, invasion and 
	  	   55	  
metastasis. uPAR promotes cell adhesion and migration on vitronectin, associated 
with morphological changes characteristic of a more motile phenotype. This is 
stimulated by direct interactions between uPAR and vitronectin and activation of 
Rac-1 (Kjoller & Hall, 2001; Masden et al., 2007; Jo et al., 2009; Pirazzoli et al., 
2013). Consequently, uPAR-expressing cells have increased metastatic potential in 
a mouse xenograft model (Jo et al., 2009). Similarly, hypoxia stimulates uPAR 
expression in various cancer cell lines, inducing EMT. This is mediated by Rac-1 
and PI3K/Akt activation and is associated with increased migration and invasion in 
a breast cancer cell line (Lester et al., 2007). Breast cancer cell migration is also 
induced by uPAR binding uPA, stimulating FAK, cSrc and Shc phosphorylation and 
activation of the MAPK signalling pathway (Nguyen et al., 1998; Nguyen et al., 
2000). Additionally, increased expression of the uPA system is implicated in 
endothelial cell migration and ECM remodelling required for tumour angiogenesis 
(Rakic et al., 2003; Binder et al., 2007).   
 
uPA and uPAR influence cell proliferation, survival and differentiation via various 
pathways. uPA-uPAR acts through a complex of fibronectin, α5β1-integrin, EGFR and 
FAK to stimulate MAPK mediated proliferation of carcinoma cells, such that 
disruption of the interactions in this molecular complex or uPAR knockdown results in 
tumour cell dormancy in vivo (Yu et al. , 1997; Aguirre Ghiso, 1999; Aguirre Ghiso, 
2002; Liu et al., 2002). uPAR promotes survival via MAPK and PI3K/Akt mediated 
activation of Bcl-xL (Alfano et al., 2006). uPA-uPAR stimulated MAPK activation 
promotes proliferation and suppresses apoptosis in several cancer cell lines 
(Hildenbrand et al., 2008). Furthermore, uPAR induces cancer stem cell-like 
properties in breast cancer lines, increasing tumourigenicity of xenografted cells in 
vivo (Jo et al., 2010). 
	  	   56	  
The role of PAI-1 in cancer is somewhat complex and paradoxical. As an inhibitor of 
uPA-uPAR mediated proteolysis and signalling, one might reason that PAI-1 would 
protect against cancer progression. The results of some studies are in agreement with 
this hypothesis; PAI-1 transfected human prostate carcinoma cell xenografts display 
reduced tumourigenic, angiogenic and metastatic potential, whilst hyperthermia 
attenuates tumourigenesis and angiogenesis in murine mammary adenocarcinoma via 
an increase in PAI-1 expression (Soff et al., 1995; Roca et al., 2003). However, much 
evidence exists indicating that PAI-1 promotes tumourigenesis, angiogenesis, invasion 
and metastasis and is a poor prognostic indicator in a number of cancers, including 
gastric cancer (Nakamura et al., 1992; Nekarda et al., 1994; Heiss et al., 1995; 
Herszenyi et al., 1995; Ganesh et al., 1996; Tsuchiya et al., 1997; Plebani et al., 
1997; Bajou et al., 1998; Swiercz et al., 1998; Kawasaki et al., 1998; Harbeck et al., 
2004; Leissner et al., 2006; Leik et al., 2006; Beyer et al., 2006; Lin et al., 2008; 
Nishioka et al., 2012; Ding et al., 2013). Evidence has emerged to suggest that PAI-1 
elicits an inverted U-shaped dose-response curve in terms of angiogenesis, which could 
account for some of the conflicting observations reported on the role of PAI-1 in cancer 
progression (McMahon et al., 2001; Devy et al., 2002; Bajou et al., 2004). uPA-
independent pathways, involving interactions between PAI-1 and vitronectin that 
disrupt adhesion and signalling via uPAR, have the potential to modulate cell 
migration, proliferation, differentiation and apoptosis, and could account for the 
deleterious tissue remodelling activities of PAI-1. The role of PAI-1 in 
carcinogenesis is likely to be both tissue-dependent and dependent on the level of 
expression of PAI-1. 
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1.6.7 The uPA system in Helicobacter infection and gastric cancer  
 
uPA, uPAR and PAI-1 are up-regulated in response to H. pylori infection in humans 
and in gastric cancer cell lines (Herszenyi et al, 1997; Iwamoto et al., 2005; Kim et 
al., 2005; Kim et al., 2007; Iwamoto et al., 2008; Keates et al., 2008; Kenny et al., 
2008; Ikeda et al., 2009). In gastric cancer cells, various mediators are implicated in 
the mechanisms increasing expression of uPA and uPAR, including the COX-2 / 
PGE2 pathway, and in the case of uPAR, reactive oxygen species-induced NF-κB 
signalling, MAPK, c-Jun N-terminal kinases (JNK) and activator protein 1 (AP-1) 
signalling pathways, increasing their invasiveness (Kim et al., 2005; Kim et al., 
2007; Iwamoto et al., 2008). Increased expression of uPA by H. pylori stimulates 
proliferation of gastric epithelial cells, via proteolytic release of HB-EGF (Kenny et 
al., 2008). H. pylori increases PAI-1 expression in gastric cancer cells via the 
MAPK pathway (Keates et al., 2008). Similarly, PAI-2 expression is increased in 
gastric cancer cells, via RhoA-dependent activation of NF-κB signalling and via 
paracrine interactions mediated by COX-2 products and IL-8, inhibiting apoptosis 
and invasion (Varro et al., 2004).  
 
As well as H. pylori, other agents stimulate uPA and uPAR expression in gastric 
cancer. uPA and uPAR expression is stimulated by macrophage inhibitory cytokine-
1, via MAPK, and uPAR is additionally induced by EGF and macrophage-
stimulating protein via MAPK, AP-1 and NF-κB signalling pathways, increasing 
gastric cancer cell invasiveness (Lee et al., 2003; Baek et al., 2008; Park et al., 
2011). Similarly, lysophosphatidic acid stimulates uPAR expression and gastric 
cancer cell invasiveness via Rho family GTPases, JNK, AP-1 and NF-κB signalling 
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pathways (Kim et al., 2008). In vivo, xenografted gastric cancer cells over-
expressing uPA are highly tumourigenic and metastatic (Choi et al., 2002). 
 
1.7 Aims and Objectives  
 
The primary objective of this thesis was to elucidate the role of the uPA system, 
particularly PAI-1, in regulating epithelial-mesenchymal interactions involved in 
maintaining gastric mucosal morphology, mucosal responses to chronic 
Helicobacter infection and responses to NSAID-induced gastric mucosal injury.  
The specific aims were to: 
1. determine the role of PAI-1 in shaping gastric mucosal morphology, using 
both genetically modified mouse models and in vitro approaches; 
2. determine the role of PAI-1 in influencing gastric myofibroblast gene 
expression and secretion of myofibroblast-derived proteins into the gastric 
mucosal microenvironment, and also examine the functional significance of 
these findings; 
3. investigate the role of PAI-1 in determining gastric mucosal responses to 
chronic Helicobacter infection, using the H. felis mouse model; 
4. investigate the role of PAI-1, uPA and uPAR in determining responses to 
NSAID administration, using an indomethacin-based model of gastric 
mucosal injury. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 Materials 
 
2.1.1 Chemicals and general reagents 
 
All general use chemicals were sourced from Sigma (Poole, UK) or BDH Laboratory 
Supplies (Lutterworth, UK). Phosphate buffered saline (PBS; 10X, pH 7.4) was 
purchased from Gibco Life Technologies (Paisley UK) and was diluted 10-fold in 
deionised water prior to use. Formaldehyde solution (16%) was purchased from Agar 
Scientific (Stansted, UK) and was used as a 4% solution diluted in PBS. Bovine serum 
albumin (BSA) was purchased from Jackson ImmunoResearch Laboratories 
(Newmarket, UK) and was diluted in PBS, as stated. In vivo and in vitro proliferation 
assays were performed using 5-ethynyl-2'-deoxyuridine (EdU), provided as part of the 
Click-iT® EdU Alexa Fluor 488® Imaging kit (Invitrogen, Paisley, UK). The kit also 
provided dimethylsulfoxide (DMSO) to reconstitute the EdU stock solution, as well as 
EdU reaction buffer, buffer additive, CuSO4, Alexa Fluor® 488 and Hoechst 33342 for 
EdU detection and nuclear counterstaining. Slides produced during 
immunohistochemistry, immunocytochemistry and EdU experiments were mounted 
using Vectashield or Vectashield with 4’, 6-diamidino-2-phenylindole (DAPI) 
mounting medium (Vector Laboratories, Peterborough, UK). 
 
2.1.2 Antibodies and antisera 
 
Primary antibodies used for immunohistochemistry and immunocytochemistry are 
summarised in Table 2.1. Fluorescein isothiocyanate and Texas Red conjugated 
secondary antibodies (Jackson ImmunoResearch Laboratories) were raised in donkey 
and used at a dilution of 1:400. Donkey serum (Jackson ImmunoResearch 
Laboratories) was diluted to 10% in PBS for use as the blocking solution. 
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Table 2.1. Summary of primary antibodies used in immunohistochemistry and 
immunocytochemistry. 
 
 
 
Primary Antibody Host species Immunogen Source Dilution 
Monoclonal  
anti-α-SMA Mouse 
N-terminal acetylated 
N-terminal decapeptide 
of smooth muscle actin 
Fitzgerald (Acton, 
MA, USA) 1:100 
 
Polyclonal  
anti-desmin 
 
Rabbit Full length human desmin 
Fitzgerald (Acton, 
MA, USA) 1:100 
Polyclonal  
anti-
dipeptidylpeptidase 
4 (DPP4) 
Chicken Human DPP4 (amino acids 547-610) 
 
Chemicon 
(Millipore, 
Watford, UK) 
 
1:200 
Anti-gastrin 
 
Guinea  
Pig 
 
Thyroglobulin 
conjugated C-terminal 
nonapeptide of human 
G17 
Prof Andrea 
Varro, University 
of Liverpool 
1:400 
 
Polyclonal  
anti-H/K ATPase  
 
Rabbit 
GVRCCPGSWWDQ
GLYY (C-terminal 
amino acids 1019-
1034 of porcine H/K 
ATPase α-subunit) 
Calbiochem 
(Merck Chemicals, 
Nottingham, UK) 
1:200 
Polyclonal  
anti-secretogranin-2  Rabbit 
Ovalbumin conjugated 
peptide (N-terminal 
amino acids 1-19 of rat 
and human 
secretogranin-2)  
Pierce Antibodies 
(Thermo 
Scientific, 
Rockford, IL, 
USA) 
1:1000 
Polyclonal 
Anti-vimentin 
Guinea 
Pig 
Purified vimentin from 
Calf lens Fitzgerald (MA) 1:400 
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2.1.3 Primary cell isolation and culture 
 
Cell culture plasticware was purchased from TPP (Trasadingen, Switzerland). Cell 
culture reagents were purchased from Sigma, with the exception of fetal bovine serum 
(FBS) and 0.25% Trypsin-ethylenediaminetetraacetic acid (-EDTA), which were 
purchased from Lonza (Slough, UK), and Collagenase A, which was purchased from 
Roche Diagnostics (Burgess Hill, UK). 
 
2.1.4 Proteins, growth factors and drugs 
 
Recombinant stabilised human PAI-1 was purchased from Calbiochem. This form of 
human PAI-1 has four amino acid substitutions that stabilise the molecule in its active 
conformation, even at elevated temperature and pH. Recombinant human EGF and 
recombinant human IGF-II were purchased from R&D Systems (Abingdon, UK). 
Indomethacin was purchased from Sigma. 
 
2.2 Animals 
 
2.2.1 Animal maintenance  
 
C57BL/6 mice were purchased from Charles River Laboratories (MA, USA), unless 
stated otherwise, one-week prior to use in experimental procedures to allow for 
acclimatization. PAI-1 null (PAI-1-/-) and uPAR null (uPAR-/-) mice were originally 
purchased from JAX® MICE (Maine, USA) then bred in-house (Biomedical Services 
Unit, University of Liverpool) and were on a C57BL/6 background. PAI-1-/- and uPAR-
/- mice are viable, fertile, and do not display any phenotypic abnormalities in the 
absence of challenge (Carmeliet et al., 1993; Bugge et al., 1995). PAI-1-H/Kβ and 
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uPA-H/Kβ mice were also on a C57BL/6 background and were generated and bred as 
discussed in section 2.2.2. All mice were housed in a conventional, non-specific 
pathogen free animal facility, in a temperature, noise and humidity controlled 
environment with a strict 12h:12h light to dark light cycle, in polycarbonate-bottomed 
cages with environmental enrichment. Animals were fed a commercial pellet diet; food 
and water were provided ad libitum. Animals were humanely killed by exposure to a 
rising concentration of CO2 followed by cardiac puncture, in accordance with Home 
Office Schedule 1 to the Animals (Scientific Procedures) Act 1986. Blood was 
collected in 0.109M tri-sodium citrate and plasma recovered by centrifugation (3000g, 
15 min) then stored on ice or at -20oC prior to analysis. For experiments involving 
gastric cells or tissues, an abdominal incision was made down the linea alba to expose 
the viscera. All experiments involving animals were approved by the Animal Welfare 
Committee at The University of Liverpool, and were Home Office licensed under the 
Animals (Scientific Procedures) Act 1986. Unless otherwise stated, experiments were 
performed on mice aged 10-13 weeks.  
 
2.2.2 Generation of PAI-1-H/Kβ, uPA-H/Kβ and PAI-1-/-, TG+ mice 
 
Mice with targeted expression of PAI-1 or uPA to parietal cells had been generated in 
this laboratory, in collaboration with Dr Nikolina Vlatkovic at the University of 
Liverpool (Kenny et al., 2013a). The coding sequence of mouse PAI-1 or uPA cDNA 
had been inserted downstream of approximately 1.1 kilobase pairs of the promoter 
region of the mouse H/K ATPase β-subunit gene (-1082 - +24) to target gene 
expression specifically to parietal cells (Figure 2.1). The resulting founders of PAI-1-
H/Kβ and uPA-H/Kβ mice were cross-bred into C57BL/6 mice and maintained in 
house, by breeding homozygous (transgene +/+) offspring. Targeted expression of the  
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A                                                 B 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Generation of mice with targeted expression of PAI-1 or uPA to 
parietal cells. Representation of the transgene vector used to generate mice with 
targeted expression of A: PAI-1 and B: uPA to parietal cells. Restriction sites at 
Hind III (40) and Afl II (3330) were used to isolate the transgene from the vector. 
 
 
 
 PAI-1 transgene by PAI-1-H/Kβ mice had been confirmed by polymerase chain 
reaction, with positive expression by gastric corpus but not heart, liver, gastric antrum, 
spleen nor kidney. Mice that express only transgenic PAI-1 (PAI-1-/-, TG+) were 
generated by crossing PAI-1-/- with PAI-1-H/Kβ mice, producing a dihybrid (wild-type 
and transgenic PAI-1) heterozygous F1 generation, from which mice with the desired 
genotype were produced in the F2 generation.  
 
 
PmHKBpromoter
(46-1162)
PAI-1mRNA
(1192-3087)
SV40polyA
(3150-3200)
Kan/Neo r
(4227-5021)
BamHI
(1163)
EcoRI
(1186)
Hind III
(40)
Xho I
(31)
Xho I
(1959)
Afl II
HKB/PAI-1
6424 b.p.
(3330)
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2.2.3 Murine Helicobacter felis infection 
 
H. felis (ATCC 49179) was cultured by Ms Debbie Sales (Medical Microbiology, The 
University of Liverpool). Mice were infected with H. felis by Dr Susan Kenny. 
Animals aged 6-8 weeks were gavaged with 0.5ml of a H. felis suspension in TBS 
broth, three times over a 1-2 week period. In order to ensure quality control of the 
bacteria, the optical density of suspension was above 1.5 and H. felis had been 
passaged no more than 5 times. Positive H. felis infection was confirmed by rapid 
antral urease test (Prontodry, Medical Instruments Corporation, Solothrum, 
Switzerland) or by antral histology. After the mice had been infected for 46 weeks 
they were humanely killed together with age- and sex-matched uninfected animals of 
each strain. Tissue was taken for preparation of frozen sections or paraffin-embedded 
sections (section 2.3 and 2.4 respectively). 
 
2.2.4 Indomethacin 
 
In optimisation studies, animals were fed ad libitum or fasted for 18h prior to treatment, 
with access to water ad libitum. Animals were dosed with 100µl of either 20mg/kg 
indomethacin in 5% sodium bicarbonate or vehicle alone, by gavage or by 
intraperitoneal (IP) injection. Animals were humanely killed 6, 17 or 24h after 
treatment, blood taken, and the stomach removed, opened along the lesser curvature 
and washed in PBS. The stomach was then carefully stretched, mucosa side up, on 
filter paper and lesions scored. The length of each lesion was measured using a 
millimetre ruler. Total lesion length for each stomach was calculated as the sum of the 
lengths of each individual lesion. Lesion scores were more consistent using the oral 
route of administration compared to IP injection, and were both higher and more 
consistent 6h after indomethacin compared to 17h. No lesions were present 24h after 
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indomethacin. Similarly there were no apparent lesions on stomachs taken from mice 
that had been fed ad libitum. Therefore in all subsequent studies, indomethacin was 
administered by gavage and animals were killed 6 hours after indomethacin. Following 
lesion scoring and imaging, stomachs were prepared for frozen tissue sections (section 
2.3).  
 
2.3 Preparation of frozen gastric tissue sections 
 
The isolated stomach was opened along the lesser curvature, washed in PBS, carefully 
stretched mucosa side up and pinned on wax, before being fixed at room temperature 
in 4% formaldehyde for 1h. The stomach was then washed in PBS, placed in 20% 
sucrose in PBS overnight at 4oC, washed again in PBS and a strip of corpus and/or 
antrum tissue cut from just below the non-glandular region (for corpus) or just below 
the corpus region (for antrum) to a distance of ~2-3mm distal to this point (Figure 
2.2A). Strips of tissue were placed upright on a cork disc supported between pins, with 
the most distal part of the section in contact with the cork (Figure 2.2B). The tissue 
was fixed onto the cork in embedding compound (CRYO-M-BED, Bright Instrument, 
Huntingdon, UK) by rapid freezing with Cryospray 134 (Bright Instrument). The pins 
were removed and the frozen tissue stored at -80oC. Cryosections of 7µm thickness 
were cut and captured on polylysine coated slides. The position of the tissue on the 
cork was such that serial sectioning through the tissue, parallel to the cork surface, 
produced full thickness  sections of the gastric mucosal and submucosal layers (Figure 
2.2B). Sections were stored at -80oC.   
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A         B 
 
 
 
 
 
Figure 2.2. Arrangement of corpus and antrum tissue taken for cryosectioning.    
A: Strips of corpus and antrum tissue were cut, at a depth of ~2-3mm from proximal 
to  distal cutting loci. B: The tissue strip was placed onto a cork disc between pins for 
freeze-fixing, in such an orientation that cryosectioning produced full thickness 
sections through the mucosal and submucosal layers. 
 
 
 
2.4 Paraffin embedded tissues 
 
Tissues for paraffin embedding were prepared by Dr Susan Kenny. The exposed 
stomach was ligated at the oesophageal and pyloric sphincters, carefully inflated with 
4% formalin (Sigma) in PBS and placed in 4% formalin in PBS for 24h at room 
temperature. A ring of tissue was then cut from corpus and/or antrum, at the same 
locations as for frozen tissue strips. The ring of tissue was placed into a tissue 
processing cassette in 70% ethanol and processed for serial sectioning. These were 
then stained with haematoxylin and eosin (H&E) and, in the case of tissues from H. 
felis experiments, also with Giemsa stain or were immunostained for vimentin. 
Paraffin embedding, sectioning and staining were carried out by The University of 
Liverpool Veterinary Laboratory Services (Histology). 
Corpus 
Antrum 
 
 
  
Submucosal 
Luminal 
 
 
 
 
 
 
~2-3mm 
Mucosal 
~2-3mm 
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2.5 Mouse gastric gland isolation and culture 
 
The procedure used to isolate gastric glands was based on a recently modified method, 
first described by Berglindh & Obrink (Berglindh & Obrink, 1976; Pagliocca et al., 
2008). The exposed stomach was ligated at the oesophageal and pyloric sphincters and 
excised by cutting beyond the ligation points. Adherent tissue was removed and the 
stomach washed in ice-cold Hanks' Balanced Salt Solution (HBSS) with 25mM 
NaHCO3 (used throughout). A small section of non-glandular stomach was removed at 
the tip and the stomach fully inverted by guiding the ligated pyloric sphincter carefully 
through the gap. The opening in the non-glandular stomach was ligated, just beyond 
the junction with the corpus region, so that the entire glandular region formed a fully-
sealed pouch. Collagenase A (0.5mg/ml, 1ml) in HBSS was carefully injected into the 
stomach and the inflated stomach put into ice cold HBSS. Stomachs were washed in 
5ml 37oC HBSS 3 times then incubated in 5ml 1mM dithiothreitol (DTT) in HBSS for 
15 min at 37oC, continuously gassing with 5% CO2 / 95% air and shaking at 100 cpm. 
Stomachs were then washed again 3 times in 37oC HBSS and similarly incubated in 
0.4mg/ml collagenase A in HBSS until they deflated i.e. digestion through the wall (~ 5 
– 30 min). Stomachs were then triturated with pressure from a wide-mouthed pipette 
~10 times. The suspension was decanted and large tissue particles allowed to sediment 
for 45 seconds. The supernatant was then carefully transferred to a new vessel, shaken 
vigorously to release glands then re-sedimented for 45 min, after which the supernatant 
was carefully pipetted and discarded, leaving the sedimented glands in a small volume. 
Glands from each animal were equally divided into 4 wells of a 24-well plate and 
cultured on cover slips in ~2ml Dulbecco’s Modified Eagle’s Medium (DMEM)/Hams 
F12 supplemented with 10% FBS, 1% L-glutamine and 1% antibiotic antimycotic 
solution, in a sterile humidified chamber at 37°C in 5% CO2 / 95% air for 48h, 
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changing the medium after 24h. Glands were then cultured in 1ml / well DMEM/Hams 
F12 supplemented with 1% L-glutamine and 1% antibiotic-antimycotic solution 
(serum-free medium) for 24h, prior to treatment. 
 
2.6 Mouse gastric myofibroblast isolation and culture 
 
The procedure used to isolate gastric myofibroblasts was based on a method developed 
by Wu et al. (Wu et al., 1999). The stomach was rapidly removed and washed in ice 
cold HBSS without Ca2+ and Mg2+ (used throughout). The antrum was isolated and 
placed in ice cold HBSS. The tissue was then cut into pieces of approximately 2.5mm2 
and incubated in 1mM DTT in HBSS for 15 min at room temperature with continuous 
gentle shaking. The tissue pieces were then washed twice in ice cold HBSS and 
incubated in 0.02% EDTA for 30 min at 4oC with continuous gentle shaking. This 
process of washing in HBSS followed by incubation in EDTA was repeated ~7-10 
times. Following denudation of epithelial cells, antral pieces from each animal were 
cultured in a T25cm2 flask in Roswell Park Memorial Institute (RMPI)-1640 medium 
supplemented with 10% FBS, 2% antibiotic antimycotic solution and 1% penicillin-
streptomycin solution (immature myofibroblast medium), in a sterile humidified 
chamber at 37°C in 5% CO2 / 95% air. The culture medium was changed every 24h for 
the first 72h, then every 48-72h, until myofibroblasts were plated to the bottom of the 
flask at ~50% confluence. Tissue pieces were then carefully removed and 
myofibroblasts cultured in DMEM supplemented with 10% FBS, 2% antibiotic 
antimycotic solution, 1% penicillin-streptomycin solution and 1% non-essential amino 
acids (mature myofibroblast medium). Culture medium was changed every 48-72h and 
cells were routinely passaged at confluence by incubation with 0.25% trypsin-EDTA 
for ~7 min, or as soon as cells were fully detached from the flask bottom. 
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2.7 Human myofibroblasts  
 
Myofibroblasts were isolated from the resected antrum of a transplant donor by Dr 
Peter Hegyi, Department of Medicine, University of Szeged, Hungary, with the 
approval of the Ethics Committee of the University of Szeged. The protocol used to 
isolate and culture human myofibroblasts was similar to that used to isolate mouse 
myofibroblasts, the only difference being that the antral mucosal layer was dissected 
from the submucosal and muscle layers and cut into ~1cm2 pieces prior to incubation in 
DTT. Myofibroblasts were isolated and cultured as described in section 2.6. 
 
2.8 PAI-1 enzyme-linked immunosorbent assay  
 
The concentration of PAI-1 in mouse plasma was determined by enzyme-linked 
immunosorbent assay (ELISA) (Murine PAI-1 total antigen assay, Molecular 
Innovations, Novi, MI, USA). Aliquots of neat plasma were plated in duplicate and 
the assay performed according to the manufacturers instructions. Absorbance at 
450nm was detected using a SpectraCount plate reader (Packard Instruments, 
Meriden, CT, USA) and values were corrected by subtracting the mean absorbance of 
the zero standards from all readings. The concentration of PAI-1 in plasma samples 
was read from a standard curve of [PAI-1].  
 
2.9 Immunohistochemistry  
 
Frozen gastric sections (section 2.3) were thawed in deionised water for 30 seconds 
and dehydrated in 50% ethanol for 10 min followed by 75% ethanol for 10 min. 
Sections were rinsed in deionised water, blocked with 10% donkey serum for 30 min 
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and then covered with primary antibody, diluted in 1% BSA in PBS (Table 2.1), and 
incubated overnight at 4oC in a humidified chamber. Negative controls were generated 
by incubating sections with 1% BSA in PBS without primary antibody. The following 
day sections were washed for 5 min in the following series of NaCl solutions: 0.14M, 
0.5M and 0.14M. Sections were then covered with secondary antibody diluted 1:400 
in 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) pH7.6, and 
incubated for 1h in the dark. Sections were protected from the light for the remainder 
of the protocol. Secondary antibody was blotted off and sections were washed in 3 
changes of PBS, 10 min per wash. Sections were mounted with Vectashield containing 
DAPI and slides were stored in the dark at 4oC. 
 
2.10 Immunocytochemistry 
 
Media was removed from cells cultured on cover slips and cells were washed twice 
with PBS then fixed in 4% formaldehyde in PBS for 30 min. Cells were washed twice 
with PBS then permeabilised in PBS with 0.3% BSA and 0.2% Triton X-100 for 30 
min, blocked with 5% BSA for 30 min and 10% donkey serum for 30 min, with two 
washes in PBS between each incubation. Cells were then incubated overnight with 
primary antibody, diluted in PBS (Table 2.1), at 4oC in a humidified chamber. 
Negative controls were generated by simultaneously incubating some cells with PBS 
alone. The following day, primary antibody was removed and cells were washed for 
10 min in the following series of NaCl solutions: 0.14M, 0.5M and 0.14M. Cells were 
then incubated with secondary antibody, diluted 1:400 in 10mM HEPES pH7.6, for 1h 
in the dark. Cells were protected from the light for the remainder of the protocol. 
Secondary antibody was removed and cells were washed in 3 changes of PBS, 10 min 
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per wash. Cover slips were mounted on slides with Vectashield containing DAPI and 
slides were stored in the dark at 4oC. 
 
2.11 EdU incorporation and detection  
 
EdU incorporation and detection was carried out according to the protocol provided 
with the Click-iT® EdU Alexa Fluor® 488 imaging kit. A 10mM EdU stock solution 
was prepared by reconstitution in DMSO. EdU solution was added to cells cultured on 
cover slips at a final concentration of 10µM in culture medium and allowed to incubate 
for 2h in a sterile humidified chamber at 37°C in 5% CO2 / 95% air. The medium was 
then removed and cells washed twice in PBS followed by fixation in 4% formaldehyde 
in PBS for 30 min at room temperature. This was followed by 2 washes with 3% BSA 
in PBS and 2 washes with PBS. Cells were permeabilised with 0.5% Triton X-100 in 
PBS for 20 min at room temperature. The EdU reaction cocktail was prepared by 
combining 1X Click-iT® reaction buffer, CuSO4, Alexa Fluor 488® and 1X reaction 
buffer additive, as specified in the manufacturer’s protocol. Following 
permeabilisation, cells were washed twice with 3% BSA in PBS then incubated with 
EdU reaction cocktail for 30 min at room temperature, in the dark. Cells were protected 
from light throughout the remainder of the protocol. Cells were then washed once with 
3% BSA in PBS then twice with PBS. If immunocytochemistry was being performed 
on the cells, the remainder of the protocol followed the description in section 2.10, 
from the donkey serum blocking step onwards. Otherwise nuclei were counterstained 
with 2µg/ml Hoechst 33342 for 30 min at room temperature. Cells were then washed 
twice with PBS and the cover slips were mounted on slides with Vectashield. Slides 
were stored in the dark at 4oC. 
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2.12 Microscopy and imaging 
 
Slides were examined under a Zeiss Axioplan-2 microscope (Carl Zeiss, Cambridge, 
UK) connected to an Axiocam HRm camera (Carl Zeiss) for imaging. Microscopy and 
imaging were performed at 10X or 40X magnification (air immersion) or 63X 
magnification (oil immersion). Images were processed with AxioVision 4.5 software 
(Carl Zeiss). The identities of slides were masked and slides assigned an arbitrary 
identification number until all samples had been assessed. Reference slides were 
examined at the commencement of and during sessions evaluating graded parameters, 
to reduce intraobserver variability.  
 
The mucosal thickness of DAPI or H&E stained corpus and/or antrum sections was 
determined by imaging at 10X magnification and use of the length measurement tool 
available with Axiovision 4.5. (Figure 2.3). Myofibroblast abundance and parietal cell 
counts were determined under 40X magnification. Myofibroblast abundance was 
evaluated using a grading system of 0 – 4 for vimentin immunostaining (Figure 2.4). 
Parietal cells were quantified as the number of H/K ATPase immunopositive cells 
along full mucosal thickness in the width of the visual field (600µm), and expressed as 
number of parietal cells / 100µm. For all measurements, 5 equidistant fields per 
section were examined, in at least 2 well orientated sections, and the mean or median 
calculated.  
 
For histopathological scores, H&E stained sections were examined under 10X and 40X 
magnification. Inflammation, epithelial defects, foveolar hyperplasia and oxyntic gland 
atrophy were quantified using a previously developed scale (Rogers et al., 2005). 
Inflammation was scored as follows: Grade 0 = no inflammation; Grade 1 = patchy 
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leukocyte infiltration into mucosa / submucosa; Grade 2 = multifocal or coalescing 
mucosal / submucosal leukocyte infiltration; Grade 3 = lymphoid follicles, extension 
into tunica muscularis; Grade 4 = effacing transmural inflammation. Epithelial defects 
were scored as follows: Grade 0 = no defects; Grade 1 = rare dilated glands,           
Grade 2 = frequent dilated glands, surface epithelial tattering; Grade 3 = glandular 
atrophy, surface erosions; Grade 4 = glandular atrophy with ulceration and fibrosis. 
Foveolar hyperplasia scores were defined as: Grade 0 = normal isthmus length, Grade 
1 = ~1.5x, Grade 2 = ~2x, Grade 3 = ~3x, Grade 4 ≥ 4x normal isthmus length. 
Atrophy was quantified as: Grade 0 = no parietal of chief cell loss; Grade 1 = ~ 25% 
parietal cell loss, ~ 50% chief cell loss; Grade 2 = ~ 50 % parietal cell loss, complete 
chief cell loss; Grade 3 = ~ 75% parietal cell loss, complete chief cell loss;             
Grade 4 = > 75% parietal cell loss, complete chief cell loss. Giemsa staining was 
examined under 63X magnification, and graded from 0 – 4 according to the frequency 
of colonised glands and density of colonisation.  
 
2.13 Microarrays 
 
Mouse antral myofibroblasts were isolated, cultured and RNA extracted by Dr Isaly 
Steele (section 2.6). Myofibroblasts used for microarrays were passaged no more than 
4 times. These myofibroblasts were characterised on the basis of α-SMA and                 
vimentin expression by immunocytochemistry and were determined to be 
homogeneous cultures, with >99% of cells expressing these markers of 
myofibroblast differentiation. RNA was extracted using the RNeasy Mini Kit 
(Qiagen, Crawley, UK), according to the manufacturer’s instructions. Reverse 
transcription, labelling, fragmentation and hybridisation of cDNA to the GeneChip® 
Mouse Genome 430 2.0 array (Affymetrix, High Wycombe, UK) and scanning of the  
	  	   75	  
 
A      B 
 
 
 
 
          
Figure 2.3 Measuring mucosal thickness. A. DAPI filter for imaging cellular 
nuclei of frozen corpus sections. B. H&E stained section. In both cases, mucosal 
thickness was determined as the length from the muscularis mucosae to the surface 
of the mucosa. 
 
 
 
 
 
 
 
 
 
 
 
     Grade: 0                 1                       2                      3                       4  
 
Figure 2.4. Myofibroblast abundance. Representative images of each grade used 
to quantify expression of vimentin, a myofibroblast marker. Grade 0: no staining in 
field; grade 1: rare staining (1-2 myofibroblasts per gland, with long spindle-shaped 
morphology); grade 2: mild / moderate staining (multiple long spindle-shaped 
myofibroblasts per gland); grade 3: extensive staining (many myofibroblasts in 
field, some branching morphology); grade 4: heavy staining throughout field 
(branching aggregates of myofibroblasts throughout field).  Scale bar = 50µm. 
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array, using the GeneChip® Scanner 3000 (Affymetrix), was carried out by Dr Lucille 
Rainbow at the Liverpool Genome Facility, according to the protocol provided by               
Affymetrix. Analysis of raw signal intensity values generated by the microarray was 
accomplished using GeneSpring GX 10 (Agilent Technologies, Wokingham, UK). 
Affymetrix Microarray Suite 5.0 (MAS5.0) summary algorithm was used to normalise 
the data and probe sets were assigned a flag of present (P), marginal (M) or absent 
(A), based on normalised signal intensities. Data were compared as two groups: wild-
type (C57BL/6) vs. PAI-1-/- myofibroblasts. Only probe sets that were flagged as 
present in all samples of at least one group were included for further analyses through 
MetaRodent™ pathway analysis software (GeneGo, St Joseph, MI, USA). 
 
2.14 DPP4 activity assays  
 
DPP4 activity of cultured human myofibroblasts was determined using a colorimetric 
assay based on the generation of the chromogenic molecule p-nitroaniline (pNA) via 
cleavage of Gly-Pro-pNA by DPP4 (Nagatsu et al., 1976) A solution of Tris-buffered 
saline (TBS; 30mM Tris, 150mM NaCl, pH 8.0) was prepared as the diluent for these 
experiments. A stock solution of 1mM 4-nitroaniline (pNA; Sigma) was diluted in 
TBS to produce standards. The standards were set at 0, 20, 40, 80 and 160nM pNA. 
The substrate for these experiments was 3mM gly-pro-pNA (Sigma). Following 
plating and treatment of cells, the assay was set-up, with standards, blanks and 
experimental conditions plated in duplicate. Standards were plated at 200µl / well. 
200µl / well TBS was added to cells, following removal of culture medium and 3 
washes with TBS. An additional 100µl TBS was added to cells in the blank wells and 
to the standards and 100µl substrate was added to all other cells. The plate was 
incubated at 37oC for 30 min, then absorbance at 405nm was detected using a 
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SpectraCount plate reader (Packard Instruments, Meriden, CT, USA). Absorbance 
values were corrected by subtracting the mean absorbance of the blank wells from all 
readings. Generation of pNA, equating to DPP4 activity, was read from a standard 
curve of [pNA].  
 
A similar strategy was used to determine DPP4 activity of mouse plasma, using a 
fluorimetric assay based on the generation of the fluorophore 7-amino-4-
methylcoumarin (AMC) via cleavage of the substrate Gly-Pro-7-amido-4-
methylcoumarin hydrobromide (Gly-Pro-AMC; Sigma) by DPP4 (Kato et al., 1978). 
Standards, blanks and experimental conditions were plated in duplicate and 
fluorescence values were averaged. Standards were set at 0, 2, 5, 10 and 20nmol 
AMC, taken from a 1mM stock solution (Sigma) and made up to 40µl / well with 
TBS. Aliquots of neat plasma were added to wells at the required volume and made 
up to 40µl with TBS. An additional 40µl TBS was added to blank wells and standards 
and 40µl 0.1mM Gly-Pro-AMC was added to all other wells. The plate was incubated 
for 20 min at room temperature then fluorescence at 360nm excitation / 460nm 
emission was detected using a FluoroCount plate reader (Packard Instruments, 
Meriden, CT, USA). Values were corrected by subtracting blanks, and generation of 
AMC, equating to DPP4 activity, was read from a standard curve of AMC (nmol). 
 
2.15 Statistics 
 
Group data are presented as mean ± standard error of the mean (SEM), or median ± 
range / interquartile range (IQR) for categorical scores and grades. Comparisons 
between experimental groups were made using an unpaired Student’s t-test or one-
way analysis of variance (ANOVA) with Tukey’s post hoc analysis for multiple 
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comparisons, for parametric data. Comparisons between groups of non-parametric 
data were made using a Mann-Whitney U-test or Kruskal-Wallis ANOVA on ranks 
test with Dunn’s post hoc analysis for multiple comparisons. Differences between 
groups were considered significant at P < 0.05. 
 
  
 
 
 
 
 
 
CHAPTER 3 
 
THE ROLE OF PAI-1 IN DETERMINING 
GASTRIC MUCOSAL MORPHOLOGY 
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3.1 Introduction 
 
Gastric PAI-1, expressed primarily by parietal and ECL cells, is elevated in response to 
H. pylori infection and hypergastrinaemia, both of which alter gastric mucosal 
morphology (Kenny et al., 2008; Keates et al., 2008; Norsett et al., 2011). PAI-1 may 
modulate the tissue remodelling activity of the uPA system, influencing 
proliferation, differentiation, migration and survival of parenchymal and 
mesenchymal cell populations, via uPA-dependent antiproteolytic activity and by 
disrupting signalling via uPAR, as described in sections 1.6.2 and 1.6.3 
respectively. Previous work in this laboratory has demonstrated that PAI-1 
attenuates H. pylori-induced gastric epithelial cell proliferation, by inhibiting uPA- 
mediated proteolytic release of HB-EGF (Kenny et al., 2008). Therefore, the level of 
PAI-1 expression in the gastric mucosa is likely to shape mucosal morphology. 
 
Mice have been generated in this laboratory with targeted expression of PAI-1 to 
parietal cells, driven by the H/K ATPase β-subunit promoter, as described in section 
2.2.2. These mice (PAI-1-H/Kβ), have significantly increased gastric expression of 
PAI-1 mRNA, elevated concentrations of circulating PAI-1, are moderately obese, 
hyperphagic and are resistant to CCK-evoked satiety signals (Kenny et al., 2013a). The 
work in this chapter explores the gastric mucosal phenotype of PAI-1-H/Kβ mice, in 
comparison to commercially available PAI-1-/- and wild-type mice. 
 
3.1.1 Aims and objectives 
 
The aim of this chapter was to determine the role of PAI-1 in influencing gastric corpus 
mucosal morphology. The specific objectives were to: 
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1. determine the concentration of PAI-1 in plasma from C57BL/6, PAI-1-/- and 
PAI-1-H/Kβ mice;  
2. compare gastric corpus mucosal thickness, parietal cell abundance and 
myofibroblast abundance of C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice;  
3. determine the effect of endogenous and exogenous PAI-1 on basal and growth 
factor-stimulated gastric epithelial cell proliferation. 
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3.2 Methods 
 
3.2.1 PAI-1 ELISA 
 
Plasma from C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice aged 9-12 weeks was prepared 
as described in section 2.2.1. Samples were plated in duplicate for the PAI-1 ELISA, 
which was performed as described in section 2.8. 
 
3.2.2 Histology 
 
Stomachs were processed for either frozen sections or paraffin-embedded sections, as 
described in sections 2.3 and 2.4. Paraffin-embedded sections were stained with H&E. 
Frozen sections were prepared for immunofluorescence. 
 
3.2.3 Histological analysis 
 
Corpus mucosal thickness of C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice was determined 
by measuring the distance from the muscularis mucosae to the luminal surface on 
images of H&E or DAPI stained sections, as described in section 2.12. Corpus 
myofibroblasts were identified using vimentin immunofluorescence and their 
abundance was graded from 0 – 4, as described in section 2.12. Parietal cells were 
identified using H/K ATPase immunofluorescence and their abundance was quantified 
as described in section 2.12. 
 
3.2.4 In vitro EdU proliferation assay 
 
Gastric glands were isolated and cultured as described in section 2.5. Cultured 
glands were incubated in serum-free medium for 24 hours prior to treatment with 
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PAI-1, EGF or IGF-II and finally were incubated with 10µM EdU for 2 h, fixed and 
prepared for EdU detection, as described in section 2.11. Epithelial cell 
proliferation in each gland was calculated as the percentage of cells that were EdU 
positive; 10 glands per cover slip were evaluated. 
 
3.2.5 Statistics 
 
Data points for mucosal thickness and parietal cell numbers represent mean values for 
individual animals, whilst data points for vimentin grades represent the median value. 
Group data are presented as mean ± SEM, or median ± IQR for vimentin grades. 
Comparisons between groups were made using a one-way ANOVA with with Tukey’s 
post hoc analysis for multiple comparisons, or Kruskal-Wallis ANOVA on ranks test 
with Dunn’s post hoc analysis for multiple comparisons for vimentin grades, and 
were considered significant at P < 0.05. 
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3.3 Results 
 
3.3.1 PAI-1-H/Kβ mice have elevated concentrations of circulating PAI-1 
 
The mean concentration of PAI-1 in plasma of PAI-1-H/Kβ was ~3-fold higher than 
wild-type plasma (Figure 3.1).  There was no detectable PAI-1 in the plasma of PAI-1-/- 
mice. 
 
3.3.2 PAI-1-H/Kβ mice have increased corpus mucosal thickness  
 
The gastric phenotype of male and female mice was compared, and no obvious 
differences were found. Consequently, here and in the following sections, data from 
male and female mice have been combined to produce the group data. Mean corpus 
mucosal thickness of 53-56 week old PAI-1-H/Kβ mice was ~2-fold higher than 
C57BL/6 and PAI-1-/- mice (Figure 3.2A). Both gland and pit lengths were increased in 
PAI-1-H/Kβ mice, accounting for the increased mucosal thickness (Figure 3.2B). Gross 
mucosal morphology of PAI-1-/- and PAI-1-H/Kβ corpus tissues was otherwise similar 
to wild-type (Figure 3.2A). 
 
3.3.3 Abundance of corpus mucosal myofibroblasts and parietal cells is similar in 
C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice 
 
The median vimentin grade of corpus mucosa from wild-type, PAI-1-/- and PAI-1-H/Kβ 
was similar (Figure 3.3A), representing 1-2 myofibroblasts within the lamina propria 
separating each gland (Figure 3.3B). Myofibroblasts were equally distributed along the 
entire length of the lamina propria in all three strains, aligning with sections of glands 
and pits from base to lumen with similar frequency.  
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Figure 3.1. PAI-1-H/Kβ mice have significantly elevated concentrations of plasma 
PAI-1. The concentration of plasma PAI-1 from C57BL/6, (n = 5), PAI-1-/- (n = 5) and 
PAI-1-H/Kβ (n = 4) mice, aged 9-12 weeks and fed ad libitum, was determined by 
ELISA. PAI-1-H/Kβ mice had significantly higher concentrations of circulating PAI-1 
compared to C57BL/6 mice. As expected, PAI-1-/- mice had no circulating PAI-1. Data 
are expressed as mean ± SEM. **P < 0.01, ***P < 0.001 (one-way ANOVA).  
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  C57BL/6                         PAI-1-/-                   PAI-1-H/Kβ 
 
 
Figure 3.2. PAI-1-H/Kβ mice display mucosal thickening. A: The mean gastric 
corpus mucosal thickness of 53-56 week old PAI-1-H/Kβ mice was increased ~2-fold 
compared to both wild-type and PAI-1-/- mice in the same age range, with no significant 
difference in mucosal thickness between these latter strains. Data for individual 
animals are shown in addition to mean ± SEM. *** P < 0.001 (one-way ANOVA). B: 
Representative H&E images showing increased corpus mucosal thickness of           
PAI-1-H/Kβ mice (scale bars = 200µm). 
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Figure 3.3. Similar corpus mucosal myofibroblast abundance in C57BL/6, PAI-1-/- 
and PAI-1-H/Kβ mice. A: The median vimentin grade of corpus mucosa from 53-56 
week old wild-type, PAI-1-/- and PAI-1-H/Kβ mice was comparable. Data for 
individual animals are shown in addition to median ± IQR. B: Representative images 
of vimentin staining in gastric corpus tissues, showing 1 – 2 myofibroblasts (arrows) 
within the lamina propria between each gland (scale bars = 50µm). 
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Wild-type, PAI-1-/- and PAI-1-H/Kβ corpus contained comparable numbers of parietal 
cells (Figure 3.4A). Parietal cells were distributed similarly in C57BL/6 and PAI-1-/- 
tissues (Figure 3.4B). PAI-1-H/Kβ corpus tissues consisted of regions showing similar 
patterns of parietal cell distribution as wild-type and PAI-1-/- tissues and regions where 
the parietal cell population expanded upwards along the increased gland lengths 
(Figure 3.4B).  
 
3.3.4 Corpus mucosal thickness of 9-12 week old mice is dependent upon breeding 
environment. 
 
To determine whether there were also morphological differences in the gastric 
mucosa of PAI-1-H/Kβ mice at time points earlier than 56-58 weeks, the stomachs 
of 9-12 week old mice were examined. The mean corpus mucosal thickness of 9-12 
week old C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice was compared and was found to be 
similar (Figure 3.5A). The mean corpus mucosal thickness of 9-12 week old C57BL/6 
mice bred at different locations was compared. Mice from Charles River Laboratories 
had a significantly reduced mean mucosal thickness compared to mice bred at Harlan 
Laboratories and mice bred in-house (Figure 3.5B). 
 
3.3.5 Exogenous PAI-1 attenuates growth factor stimulated gastric epithelial cell 
proliferation 
 
The increased corpus mucosal thickness of PAI-1-H/Kβ mice described above raises 
the question of whether PAI-1 regulates epithelial cell proliferation. To test this 
directly, studies were undertaken using cultured gastric glands. Proliferation of 
isolated gastric glands was examined using an EdU-based assay.                                    
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Figure 3.4. Similar parietal cell abundance in C57BL/6, PAI-1-/- and PAI-1-H/Kβ 
mice. A: The mean number of parietal cells per 100µm of full thickness corpus mucosa 
from 53-56 week old wild-type, PAI-1-/- and PAI-1-H/Kβ was similar. Data for 
individual animals are shown in addition to mean ± SEM. B: Representative images 
of H/K ATPase immunopositive cells within gastric corpus mucosal tissue from wild-
type, PAI-1-/- and PAI-1-H/Kβ mice (scale bars = 200µm). 
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Figure 3.5. Corpus mucosal thickness of mice aged 9-12 weeks is influenced by 
breeding location. A: Similar corpus mucosal thickness of 9-12 week old C57BL/6, 
PAI-1-/- and PAI-1-H/Kβ mice bred in-house. B: C57BL/6 mice purchased from 
Charles River Laboratories had significantly reduced corpus mucosal thickness 
compared to mice purchased from Harlan Laboratories and mice bred in-house.  Data 
for individual animals are shown in addition to mean ± SEM. * P < 0.05, ** P < 0.01 
(one-way ANOVA).  
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Contaminating myofibroblasts were initially identified in gastric gland cultures by 
positive vimentin staining and were found to be consistently rare, at no more than 
5% of the total cell population. Basal EdU incorporation into cycling C57BL/6, 
PAI-1-/- and PAI-1-H/Kβ epithelial cells within the isolated gastric glands was 
comparable (Figure 3.6B).  
 
Gastric glands isolated from C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice were treated 
with 20nM PAI-1, with or without 1ng/ml EGF or 100ng/ml IGF-II, for a total period 
of 20 hours, including 2 hours incubation with 10µM EdU. Exogenous PAI-1 had no 
effect upon EdU incorporation in any mouse strain (Figure 3.7A-F). Exogenous EGF 
stimulated EdU incorporation into wild-type and PAI-1-/- gastric glands (Figure 3.7A & 
C). Exogenous IGF-II also stimulated EdU incorporation into gastric glands from all 
strains (Figure 3.7B, D & F). Exogenous PAI-1 attenuated EGF- and IGF-II-stimulated 
EdU incorporation into wild-type gastric glands (Figure 3.7A & B). PAI-1 attenuated 
EGF-stimulated EdU incorporation into PAI-1-/- gastric glands (Figure 3.7C) and 
IGF-II-stimulated EdU incorporation into PAI-1-H/Kβ gastric glands (Figure 3.7F). 
    
3.4 Discussion 
 
The work in this chapter describes the gastric corpus mucosal phenotype of PAI-1-/- 
and PAI-1-H/Kβ mice compared to wild-type, in order to determine the role of PAI-1 in 
shaping gastric mucosal morphology. The data revealed that PAI-1-H/Kβ mice 
develop age-dependent increases in corpus mucosal thickness, independent of changes 
in parietal cell numbers. This implies that another corpus mucosal cell population is            
l 
 
	  	   92	  
 
 
 
 
 
 
         A            
  
     
 
 
 
 
 
 
 
 
 
 
 
 
         B 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Isolated gastric glands from C57BL/6, PAI-1-/- and PAI-1-H/Kβ 
mice exhibit similar incorporation of EdU. A: Examples of EdU positive (green 
nuclei) and EdU negative (blue nuclei) gastric epithelial cells. EdU incorporation 
was calculated as the percentage of nuclei that were EdU positive. B: Basal 
incorporation of EdU into isolated gastric glands from C57BL/6 (n = 12), PAI-1-/- 
(n = 14) and PAI-1-H/Kβ (n = 15) mice was similar. Data are expressed as mean ± 
SEM.  
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Figure 3.7. Basal EdU incorporation into C57BL/6, PAI-1-/- and PAI-1-H/Kβ 
gastric glands is unaltered by exogenous PAI-1. A & B: Effect of PAI-1 (n = 7), EGF 
(n = 7), EGF plus PAI-1 (n = 3), IGF-II (n = 9) and IGF-II plus PAI-1 (n = 4) on EdU 
incorporation into wild-type gastric glands, compared to untreated glands (n = 12). 
EGF and IGF-II significantly stimulated EdU incorporation. Exogenous PAI-1 did not 
alter basal EdU incorporation but attenuated growth factor-stimulated EdU 
incorporation. C & D Comparison repeated using PAI-1-/- glands (n = 4-14). 
Exogenous PAI-1 attenuated EGF-stimulated EdU incorporation. E & F: Comparison 
repeated using PAI-1-H/Kβ glands (n = 6-15). Exogenous PAI-1 attenuated IGF-II-
stimulated EdU incorporation. Concentrations used: 20nM PAI-1, 1ng/ml EGF and 
100ng/ml IGF-II, each for 20 hours total incubation period. Data are expressed as 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA).  
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expanded in PAI-1-H/Kβ tissue. Further immunohistochemical characterisation of the 
major epithelial cell populations, including ECL cells, chief cells, mucous neck cells, 
proliferating isthmal cells and pit cells, in corpus tissue of PAI-1-H/Kβ mice compared 
to C57BL/6 and PAI-1-/- mice would provide a more complete understanding of the 
histological basis of increased mucosal thickness in response to elevated gastric 
expression of PAI-1. The concentration of plasma PAI-1 in each mouse strain was also 
determined. Predictably, PAI-1-/- mice had no detectable circulating PAI-1. PAI-1-H/Kβ 
mice had circulating PAI-1 concentrations approximately 3-fold higher than wild-type. 
The mean concentration of plasma from C57BL/6 and PAI-1-H/Kβ mice was of a 
similar order as reported in previous studies (Kenny et al., 2013a).  
 
In terms of epithelial cell dynamics underlying increases in mucosal thickness observed 
in PAI-1-H/Kβ corpus tissue, one possibility is that apoptosis is suppressed in response 
to increased gastric PAI-1 expression. PAI-1 has been shown to negatively-regulate 
apoptosis of various normal and malignant cell populations, including breast epithelial 
cells, human umbilical vein endothelial cells (HUVECs), vascular smooth muscle cells 
(VSMCs), neuronal cells, neutrophils, lung fibroblasts, prostate cancer cells, 
promyelocytic leukaemia cells and fibrosarcoma cells (Kwaan et al., 2000; Soeda et 
al., 2001; Chen et al., 2004; Lademann et al., 2005; Soeda et al., 2006; Suzuki et al., 
2008; Romer et al., 2008; Horowitz et al., 2008; Zmijewski et al., 2011; Zhang et al., 
2013). Similarly, increased expression of PAI-2 by AGS gastric cancer cells is 
associated with a reduction in H. pylori-induced apoptosis (Varro et al., 2004). 
However, PAI-1 has also demonstrated a pro-apoptotic effect on various cell 
populations (Al-Fakhri et al., 2003; Xiang et al., 2005; Balsara et al., 2006; Chen et al., 
2008; Hu et al., 2009; Wu et al., 2009). Furthermore, the basal rate of non-surface 
corpus epithelial cell apoptosis is already very low (Court et al., 2003; Przemeck et al., 
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2007; Przemeck et al., 2008; Duckworth et al., 2012). However, increased mucosal 
thickness develops over 53-56 weeks, so further small reductions in apoptosis could 
accumulate to increase mucosal thickness over this time period. This warrants further 
investigation. 
 
An alternative hypothesis for increased corpus mucosal thickness in PAI-1-H/Kβ mice 
is that epithelial cell proliferation is increased in PAI-1-H/Kβ corpus tissue. This 
hypothesis is supported by various studies examining the relationship between PAI-1 
expression and proliferation rates in vivo. In a murine arterial injury model, PAI-1 
expression correlated with VSMC proliferation and neointimal formation, proposed to 
be mediated by the proliferative effects of fibrinogen accumulation (Suzuki et al., 
2008). Similarly, PAI-1 expression correlated with in vivo proliferation of murine 
mammary carcinoma cells and fibrosarcoma cells, and consequently with 
tumourigenesis (Gutierrez et al., 2000; Jing et al., 2012). Conversely, increased 
expression of PAI-1 was shown to repress prostate cancer tumourigenesis in 
athymic mice (Soff et al, 1995). Although PAI-1 negatively regulated hepatocyte 
and cholangiocyte proliferation in anti-Fas and bile duct ligation models of liver 
injury, PAI-1 promoted proliferation in the more severe carbon tetrachloride liver 
injury model (Shimizu et al., 2001; Wang et al., 2005; von Montford et al., 2010). 
These contrary results indicate both tissue-specific and microenvironment-specific 
roles for PAI-1 in proliferation. Future studies to determine proliferation in the gastric 
corpus mucosa of PAI-1-H/Kβ mice compared to PAI-1-/- and C57BL/6 mice, utilising 
assays examining in vivo incorporation of EdU into gastric epithelial cells, would 
provide clarification on the role of proliferation in determining the gastric mucosal 
phenotype of PAI-1-H/Kβ mice. 
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The finding that corpus mucosal thickness of wild-type mice aged 9-12 weeks, which 
had been bred in-house, was increased compared to mice aged 53-56 weeks, which had 
been bred externally, raised the question of whether differences in mucosal thickness 
observed in these studies might have been determined by factors relating to the 
breeding environment. A direct comparison revealed that mice bred at one source had a 
significantly reduced mean mucosal thickness compared to mice bred at 2 other 
sources, suggesting that the breeding environment influenced the gastric phenotype. 
This is supported by variations in the thickness of corpus mucosal tissue of C57BL/6 
mice reported in previous studies, ranging from 278µm to 682µm (Farrell et al., 2002; 
Aihara et al., 2003; Fukui et al., 2006; Park et al., 2008; Van der Burg et al., 2011; 
Lu et al., 2011).  
 
Variations in the gastric phenotype of mice bred at separate locations could be due 
to differences in gut microbiota. A previous study showed that gnotobiotic mice had 
shortened gastric glands compared to specific pathogen free mice and mice 
colonised by altered Schaedler flora (Schmitz et al., 2011). This was associated 
with a reduction in the number of proliferating cells and loss of the prezymogenic 
cell population. Future studies could examine gastric morphological features of 
gnotobiotic C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice, eliminating the confounding 
factor of commensal bacteria in the comparative analysis of gastric phenotypes. 
However, comparisons between 53-56 week old PAI-1-/- and PAI-1-H/Kβ mice in this 
study remain valid, given that these mice were bred at the same location over many 
generations. 
 
In order to elucidate the mechanism by which either local increases in corpus mucosal 
PAI-1 expression or elevated circulating PAI-1 stimulates mucosal thickening, the 
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possibility that PAI-1 directly stimulates epithelial cell proliferation was investigated 
using cultured isolated gastric glands. Proliferation of both PAI-1-/- and PAI-1-H/Kβ 
epithelial cells was similar to wild type, as determined by EdU incorporation, implying 
that neither autocrine nor paracrine PAI-1 secretion on its own stimulates epithelial cell 
proliferation. Furthermore, exogenous PAI-1 had no effect on gastric epithelial cell 
proliferation. Although PAI-1 did not affect basal epithelial cell proliferation, 
exogenous PAI-1 did attenuate growth factor stimulated proliferation.  
 
A direct anti-proliferative role of PAI-1 has been reported in a number of previous 
in vitro studies. PAI-1 was shown to inhibit basal and growth factor-stimulated 
proliferation of isolated mouse aortic endothelial cells, via interactions of the PAI-1-
uPA-uPAR complex with LRP, and modulation of the PI3K/Akt signalling pathway 
(Ploplis et al., 2004; Balsara et al., 2006). Similarly, PAI-1 supressed proliferation 
of fibroblasts via the PI3K/Akt signalling pathway (Kortlever et al., 2006; Ardite et 
al., 2012). Exogenous PAI-1 inhibited proliferation of lung cancer cells and 
HUVECs, but not prostate cancer cells (Chorostowska-Wynimko et al., 2010). 
Contrary to the reports of anti-proliferative effects of PAI-1 on cell populations, the 
PAI-1-uPA complex stimulated proliferation of a gastric adenocarcinoma line via 
increased very low density lipoprotein receptor expression, and isolated VSMCs 
over-expressing PAI-1 exhibited increased proliferation, via activation of NF-κB and 
MAPK signalling pathways (Chen et al., 2006; Di et al., 2010).  
 
The varied effects of PAI-1 on proliferation of cell populations highlights the 
importance of cell phenotype, the microenvironment and activated signalling 
cascades in determining the role of PAI-1 in regulating proliferation. Furthermore, 
the effects of PAI-1 on modulating cell and tissue dynamics are highly dose-
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dependent. This may explain the observation that exogenous PAI-1 suppressed   
IGF-II-stimulated proliferation of wild-type gastric glands, whilst increased 
expression of PAI-1 in the gastric mucosa of PAI-1-H/Kβ mice was not sufficient to 
elicit such an effect. EGF signalling pathways may be more sensitive to the inhibitory 
effects of PAI-1, since EGF failed to stimulate significant proliferation of PAI-1-H/Kβ 
gastric glands.  
  
Since PAI-1 did not directly stimulate proliferation of gastric epithelial cells, this raises 
the question as to whether PAI-1 mediates an indirect proliferative mechanism in the 
gastric mucosa. One possibility is that hyperphagia in PAI-1-H/Kβ mice stimulates 
proliferation of the gastric mucosa over 53-56 weeks. Feeding is known to stimulate 
proliferation of the corpus mucosa, via the trophic effects of gastrin (Johnson, 1977; 
Ohning et al., 1996). However, plasma gastrin of PAI-1-H/Kβ mice is not significantly 
different to that of wild-type mice, so increases in mucosal thickness are unlikely to be 
gastrin-dependent (Kenny et al., 2013a). 
 
An alternative hypothesis is that PAI-1 regulates myofibroblast activity, modulating 
myofibroblast-epithelial interactions to stimulate proliferation.  Previous studies have 
identified a reciprocal epithelial-myofibroblast interaction, mediated by epithelial cell 
derived MMP-7, that stimulates proliferation of both gastric epithelial cells and 
myofibroblasts in hypergastrinaemia and in H. pylori infection (McCaig et al., 2006; 
Varro et al., 2007). IGF-II was identified as a myofibroblast-derived growth factor 
stimulating proliferation of both epithelial cells and myofibroblasts. Similar to MMP-7, 
gastric epithelial cell expression of PAI-1 is increased by gastrin, and gastric PAI-1 is 
elevated in hypergastrinaemia and in H. pylori infection (Herszenyi et al, 1997; 
Kenny et al., 2008; Keates et al., 2008; Ikeda et al., 2009; Norsett et al., 2011). The 
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abundance of corpus mucosal myofibroblasts was investigated to establish whether 
PAI-1 mediates a similar proliferative response. Increases in corpus mucosal thickness 
were independent of changes in myofibroblast numbers in PAI-1-H/Kβ mice. This does 
not exclude the possibility of altered gene expression by PAI-1-H/Kβ myofibroblasts; 
the effect of PAI-1 on myofibroblast gene expression is examined in chapter 4 of this 
thesis. 
 
In summary, the data presented in this chapter suggest that PAI-1 might act via indirect 
mechanisms to stimulate proliferation in the gastric corpus mucosa, independent of 
changes in parietal cell and myofibroblast abundance. Potential mechanisms by which 
PAI-1 might regulate myofibroblast-epithelial interactions to modulate epithelial cell 
proliferation will be investigated in the next chapter. Other aspects of the gastric 
phenotype of PAI-1-/- and PAI-1-H/Kβ mice require investigation, including responses 
to chronic Helicobacter infection and gastric mucosal protection; these will be 
investigated in chapters 5 and 6 respectively. 
 
 
3.5 Conclusions 
 
1. Plasma PAI-1 concentrations are elevated in PAI-H/Kβ mice. 
2. PAI-1-H/Kβ mice develop age-dependent thickening of the gastric mucosa, 
independent of changes in parietal cell numbers or corpus mucosal 
myofibroblast abundance. 
3. The breeding environment influences the corpus mucosal thickness of 
C57BL/6 mice. 
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4. Endogenous PAI-1 expression has no effect upon gastric epithelial cell 
proliferation. 
5. Exogenous PAI-1 has no effect upon basal gastric epithelial cell 
proliferation, but attenuates growth factor-stimulated proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER 4 
 
REGULATION OF GASTRIC MUCOSAL 
MYOFIBROBLAST-EPITHELIAL 
INTERACTIONS BY PAI-1 
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4.1 Introduction                
 
Myofibroblasts reside within the lamina propria of the gastrointestinal mucosa, 
interacting with epithelial cells and other stromal cells, via direct cell-cell 
communication and paracrine secretions, and also with the ECM (Valentich & 
Powell, 1994; Powell et al., 1999; Wu et al., 1999; Powell et al., 2011). 
Gastrointestinal myofibroblasts are thus important regulators of epithelial cell 
dynamics, integrating signals between epithelial cells and other subepithelial 
mesenchymal cell populations (Valentich & Powell, 1994; Powell et al., 2005). 
These interactions define the mucosal microenvironment. Proteins secreted by 
myofibroblasts influence the activity of epithelial cells, in physiological and 
pathophysiological settings. The phenotype of myofibroblasts is reciprocally 
determined by the microenvironment in which they reside. 
 
A particularly well-characterised mediator of epithelial-myofibroblast interactions 
in the gastric mucosa is MMP-7. Expression of MMP-7, which is secreted by 
epithelial cells, is increased in response to H. pylori infection and 
hypergastrinaemia (Wroblewski et al., 2003; Varro et al., 2007). Subsequently 
myofibroblast and epithelial cell proliferation, and myofibroblast migration, is 
stimulated via MMP-7 release of IGF-II from IGF binding protein (IGFBP)-5, both 
of which are released by myofibroblasts (Hemers et al., 2005; McCaig et al., 2006; 
Varro et al., 2007). Another important mediator of gastric epithelial-mesenchymal 
interactions is TGF-β, which increases myofibroblast abundance via 
transdifferentiation of fibroblasts, in the primary gastric carcinoma 
microenvironment, and mesothelial cells in peritoneal metastases (Fuyuhiro et al., 
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2011; Lv et al., 2013). Consequently, migration, invasion and metastasis of cancer 
cells are increased (Fuyuhiro et al., 2010; Fuyuhiro et al., 2012; Lv et al., 2013).   
 
The role of the microenvironment in determining the phenotype of gastric 
myofibroblasts is highlighted by previous studies showing distinct differences in 
gene expression, secretomes and dynamics of CAMs compared to ATMs and NTMs 
(Holmberg et al., 2012; Balabanova, 2012; Holmberg et al., 2013). These changes 
are functionally significant, in terms of influencing epithelial cell dynamics. The 
secretomes of CAMs stimulate increased proliferation, migration and invasion of 
gastric cancer cells, in part due to a decrease in TGFβ-induced gene-h3, leading to 
increased IGF-II activity, and increased MMP activity (Holmberg et al., 2012; 
Holmberg et al., 2013). 
 
The results of the previous chapter indicated that PAI-1 might positively regulate 
proliferation of gastric epithelial cells via an indirect mechanism. One possibility is 
that PAI-1 influences myofibroblast gene expression, causing secretion of proteins 
that modulate gastric epithelial cell dynamics. This chapter compares the 
phenotypes of myofibroblasts in gastric mucosal microenvironments free of PAI-1 
compared to those in PAI-1-positive microenvironments. 
 
4.1.1 Aims and objectives 
 
The aim of the work in this chapter was to characterise the transcriptomes of gastric 
myofibroblasts from wild-type and PAI-1-/- mice, with a view to identifying 
myofibroblast-secreted proteins that might be responsible for differences in gastric 
mucosal function in the two strains. The specific objectives were to: 
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1. compare global gene expression profiles of cultured gastric myofibroblasts 
from C57BL/6 and PAI-1-/- mice; 
2. characterise the phenotypes of C57BL/6 and PAI-1-/- antral mucosal 
myofibroblasts in situ; 
3. characterise the phenotypes of dissociated C57BL/6 and PAI-1-/- antral 
myofibroblasts; 
4. examine the functional significance of differences in the phenotypes of 
C57BL/6 and PAI-1-/- antral myofibroblasts. 
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4.2 Methods 
 
4.2.1 Gene expression microarray analysis 
 
Normalisation and analysis of raw signal intensities generated by the GeneChip® 
Mouse Genome 430 2.0 arrays was accomplished using Affymetrix MAS5.0 summary 
algorithm in GeneSpring GX 10. Three microarrays were performed for each mouse 
strain, using material from single animals for each sample. Data were grouped and 
averaged by mouse strain, to compare global gene expression by cultured antral 
C57BL/6 and PAI-1-/- myofibroblasts, described in section 2.13. These myofibroblasts 
had been passaged no more than 4 times. Only probe sets that were present in all 
samples of C57BL/6 or PAI-1-/- myofibroblasts were included in the comparative 
analysis. Differentially expressed probe sets were identified using an unpaired t-test 
with Benjamini-Hochberg correction (significant at P < 0.05), using cut-off value of 
±3-fold change, and the corresponding genes and gene products were identified by 
putting the entity list through MetaRodent™. The Gene Ontology database 
(www.geneontology.org) was used to identify differentially expressed transcripts with 
an extracellular gene product. 
 
4.2.2 Immunofluorescence 
 
Immunohistochemistry was performed on mouse antral tissue sections, as described in 
section 2.9. Immunocytochemistry was performed on dissociated mouse or cultured 
human antral myofibroblasts, according to the methods described in section 2.10. 
Mouse antral myofibroblasts were isolated and acutely cultured, as described in 
section 2.6, by dividing denuded antral pieces from each animal into 2 wells of a 24 
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well plate. Mouse antral myofibroblasts for immunocytochemistry were not passaged. 
Human myofibroblasts were passaged no more than 10 times.  
 
4.2.3 Dipeptidyl peptidase 4 activity assays 
 
Human NTMs were passaged no more than 12 times and were plated at the required 
number in a 94 well plate. DPP4 activity of human myofibroblasts or mouse plasma 
was assayed as described in section 2.14. 
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4.3 Results 
 
4.3.1 Gastric myofibroblasts from PAI-1 null mice have a global gene 
expression profile distinct from wild-type gastric myofibroblasts 
 
Whole mouse genome microarrays were used to compare global gene expression 
profiles of wild-type and PAI-1-/- gastric myofibroblasts, in order to identify 
differentially-regulated transcripts. Quality control analysis confirmed that the 
arrays could be reliably compared to each other (Figure 4.1). Principal component 
analysis showed distinct clustering of samples based on mouse strain (Figure 4.2A). 
The array data was filtered to include only probe-sets present in all samples of 
C57BL/6 or PAI-1-/- myofibroblasts for further analyses, producing a data-set of 
22311 entities. The normalised signal intensity of each entity was grouped and 
averaged by mouse strain, revealing a distinct profile of gene expression by wild-
type and PAI-1-/- gastric myofibroblasts (Figure 4.2B).  
 
A list of differentially expressed probe-sets was generated comparing mean 
normalised signal intensities of C57BL/6 and PAI-1-/- samples. Entities were 
considered differentially expressed if P < 0.05 (unpaired t-test; Benjamini-
Hochberg correction) and fold-change was ≥ 3 or ≤ -3, to increase the power of the 
data analysis and generate a workable list of transcripts. A fold change value of ±3 
was considered sufficiently stringent against the detection of false-positives in the 
lower range of absolute expression values, whilst being sensitive enough to detect 
significant changes in highly expressed transcripts. After putting the entity list 
through MetaRodent™, a total of 1767 gene products were identified as being           
n 
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Figure 4.1. Quality control analysis indicates similar performance across all 
microarrays. A:  Box whisker plot of normalised signal intensities across the 6 
microarrays showed a similar distribution of signal intensities for each sample. B: 
Normalised signal intensities of hybridisation control entities were similar across all 
microarrays. A single red line represents each of the 6 samples and 8 control entities 
are plotted. 
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Figure 4.2. Gastric myofibroblasts from C57BL/6 and PAI-1-/- mice show 
distinct global gene expression profiles. A: Principal component analysis showed 
clustering of samples by mouse strain, based on separation by principal component 
1. B: Profile plot of normalised signal intensities of individual entities, grouped by 
mouse strain and averaged, showed distinct gene expression profiles by gastric 
myofibroblasts from C57BL/6 and PAI-1-/- mice. The data were filtered from whole 
microarray data to include only entities present in all samples of C57BL/6 or     
PAI-1-/- myofibroblasts.  
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differentially expressed. The relative expression of transcripts encoding known 
markers of stromal cell differentiation was analysed, revealing 8 differentially 
expressed markers by C57BL/6 and PAI-1-/- gastric myofibroblasts (Table 4.1). In 
order to identify potential PAI-1 dependent modulators of the tissue 
microenvironment, the dataset was also filtered by gene ontology to generate a list 
of 223 differentially expressed transcripts with an extracellular gene product. The 
20 most differentially expressed transcripts are shown in Table 4.2.  
 
4.3.2 Antral myofibroblasts exist as a heterogeneous population of vimentin- 
and desmin-expressing cells 
 
In order to validate the data derived from gene expression microarrays, the 
expression of two known stromal lineage markers in mouse antral sections and in 
dissociated mouse antral myofibroblasts was investigated by immunofluorescence. 
Although there were remaining stocks of cultured C57BL/6 myofibroblasts used in 
the microarrays, stocks of PAI-1-/- myofibroblasts were used up during extraction of 
RNA for microarray analysis. For this reason, freshly dissociated myofibroblasts 
were prepared for validation studies. Vimentin was selected as a routine 
myofibroblast identifier and desmin was selected on the basis of a large fold-change 
difference in mRNA expression by PAI-1-/- antral myofibroblasts relative to 
C57BL/6 antral myofibroblasts (Table 4.1).  The expression of desmin mRNA had 
in fact been flagged as absent in all samples of C57BL/6 myofibroblasts using 
Affymetrix MAS5.0 summary algorithm in GeneSpring GX 10. Characterisation of 
α-SMA expression by immunofluorescence was also attempted, but this was 
uninformative owing to non-specific staining by the secondary antibody. There         
Aa 
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Table 4.1. Expression of transcripts encoding markers of stromal cell 
differentiation. There was differential expression of a number of myofibroblast 
markers by cultured PAI-1-/- antral myofibroblasts relative to C57BL/6 antral 
myofibroblasts (unpaired t-test, Benjamini-Hochberg correction, P < 0.05). Of the 
transcripts shown, genes that were differentially expressed by less than 3-fold 
difference in either direction were considered to be uninformative. 
 
 
Affymetrix ID Gene Symbol Gene Product 
Fold-
change 
(PAI-1-/- : 
C57BL/6) 
1426731_at Des Desmin 75 
1422340_a_at Actg2 Gamma-smooth muscle actin 20 
1444105_at Acta2 Alpha-smooth muscle actin 15 
1437218_at Fn1 Fibronectin 3.1 
1433768_at Palld Palladin 2.3 
1450641_at Vim Vimentin 1.8 
1419309_at Pdpn Podoplanin 1.7 
1420653_at Tgfb1 Transforming growth factor beta-1 1.5 
1417439_at Cd248 Endosialin -1.3 
1446951_at P4ha3 Prolyl 4-hydroxylase subunit alpha-3 -3.3 
1450757_at Cdh11 Cadherin-11 -3.8 
1417234_at Mmp11 Stromelysin 3  (Matrix metalloproteinase-11)  -4.1 
1416298_at Mmp9 Matrix metalloproteinase-9 -11 
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Table 4.2. Top 20 transcripts encoding extracellular proteins differentially 
expressed by cultured PAI-1-/- antral myofibroblasts compared to cultured wild 
type antral myofibroblasts. There were a total of 223 genes, classified as 
‘extracellular’ by gene product ontology, that were significantly differentially 
expressed by PAI-1-/- antral myofibroblasts compared to wild type (unpaired t-test, 
Benjamini-Hochberg correction, P < 0.05, fold-change ≥ 3 or ≤ -3). The table shows 
the top 20 transcripts, ranked by fold change in either direction, with ‘extracellular’ 
annotation up- or down-regulated in PAI-1-/- myofibroblasts relative to wild type.  
Affymetrix ID Gene Symbol Gene Product 
Fold- 
change 
(PAI-1-/- : 
C57BL/6) 
1425546_a_at Trf Serotransferrin 626 
1452004_at Calca Calcitonin gene-related peptide 1 209 
1449319_at Rspo1 R-spondin-1 156 
1452065_at Vstm2a V-set and transmembrane domain-containing protein 2A 126 
1416697_at Dpp4 Dipeptidyl peptidase 4 109 
1460238_at Msln Mesothelin 71 
1460049_s_at 1500015O10Rik Augurin -67 
1452968_at Cthrc1 Collagen triple helix repeat-containing protein 1 -68 
1447862_x_at Thbs2 Thrombospondin-2 -71 
1439260_a_at Enpp3 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 
family member 3 
-76 
1448147_at Tnfrsf19 Tumour necrosis factor receptor superfamily member 19 -82 
1430313_at Adamtsl1 ADAMTS-like protein 1 -93 
1417936_at Ccl9 C-C motif chemokine 9 -102 
1448136_at Enpp2 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 
family member 2 
-120 
1418511_at Dpt Dermatopontin -126 
1419083_at Tnfsf11 Tumour necrosis factor ligand superfamily member 11 -136 
1419728_at Cxcl5 C-X-C motif chemokine 5 -145 
1455893_at Rspo2 R-spondin-2  -164 
1450708_at Scg2 Secretogranin-2 -688 
1416211_a_at Ptn Pleiotrophin -3667 
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were two distinct populations of vimentin- and desmin-expressing cells with typical                                    
myofibroblast-like spindle-shaped morphology within the lamina propria of both 
C57BL/6 and PAI-1-/- antral sections (Figure 4.3). Cells expressing both vimentin 
and desmin were rare and expressed one of the signals only weakly. Dissociated 
antral myofibroblasts from PAI-1-/- mice similarly expressed vimentin and desmin 
to varying degrees (Figure 4.4).  
 
4.3.3 Secretogranin-2 and dipeptidyl peptidase 4 are expressed by dissociated 
PAI-1-/- antral myofibroblasts 
 
To further validate the microarray data, expression of proteins encoded by 
differentially expressed transcripts was determined in mouse antral sections and 
dissociated mouse antral myofibroblasts from PAI-1-/- mice. Despite strenuous 
efforts, attempts to dissociate myofibroblasts from C57BL/6 mice were 
unsuccessful, so it was not possible to perform validations on wild-type 
myofibroblasts. Secretogranin-2 was selected to validate a transcript                  
down-regulated in PAI-1-/- antral myofibroblasts relative to wild-type 
myofibroblasts (Table 4.2), and had in fact been flagged as absent in PAI-1-/- antral 
myofibroblasts using Affymetrix MAS5.0 summary algorithm. Secretogranin-2 is 
of particular interest as recent findings indicate that it is expressed by normal 
human gastric myofibroblasts and is a marker for a neuroendocrine-like phenotype 
of these cells, including the capacity for regulated secretion. This phenotype is lost 
in some gastric CAMs, particularly those from patients with advanced disease 
(Balabanova, 2012). In antral tissues of C57BL/6 and PAI-1-/- mice, secretogranin-2 
was expressed by a sub-population of G-cells and by neurons, but not by 
myofibroblasts (Figures 4.5 & 4.6).  
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A      Merged                              Desmin                            Vimentin 
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Figure 4.3. There are two distinct populations of desmin- and vimentin-
expressing cells in mouse antral lamina propria. A: Desmin and vimentin 
immunopositive myofibroblast-like cells were located within the lamina propria of 
wild type antral tissue. There were few weakly co-localising cells (*). There were 
distinct populations of cells expressing either desmin (arrowheads) or vimentin 
(arrows). B: Similarly, two separate populations of desmin- and vimentin-
expressing cells were seen in the lamina propria of PAI-1-/- antral tissue, with few 
weakly co-localising cells. Scale bars = 50µm. 
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Figure 4.4. Dissociated antral myofibroblasts from PAI-1-/- mice express 
vimentin and desmin to varying degrees. Primary cultures of myofibroblasts 
isolated from antral tissue of PAI-1-/- mice consisted of a heterogeneous population 
of vimentin and desmin expressing cells. A: Cells strongly expressing vimentin but 
not expressing desmin. B: Mixed sample consisting of a cell strongly expressing 
desmin but very weakly expressing vimentin and a cell expressing vimentin but not 
desmin. C: A sample of cells co-expressing desmin and vimentin. Scale bars = 
50µm. 
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Figure 4.5. Secretogranin-2 is expressed by endocrine cells and neurons in 
antral mucosal tissue. A: Secretogranin-2 immunopositive cells consisted of 
endocrine cells (arrowheads) and neurons (arrows) in wild-type antral mucosa. 
Secretogranin-2 did not co-localise with vimentin-expressing cells. B: Similarly, 
secretogranin-2 was expressed by endocrine cells and neurons, but not by vimentin-
expressing cells, in PAI-1-/- antral tissue. Scale bars = 50µm. 
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Figure 4.6. Secretogranin-2 is expressed by some G-cells. A: A sub-population of 
G-cells in wild type antrum expressed secretogranin-2, accounting for 
secretogranin-2 expressing antral endocrine cells (arrows). B: Similarly some, but 
not all, G-cells of PAI-1-/- antral tissue expressed secretogranin-2. All   
secretogranin-2 expressing endocrine cells were G-cells. Secretogranin-2 
expressing neurons are also seen in this image. Scale bars = 50µm. 
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Unexpectedly, given the microarray findings, secretogranin-2 was expressed by 
dissociated PAI-1-/- antral myofibroblasts (Figure 4.7A).  
 
Expression of DPP4 was investigated following its identification as an up-regulated 
transcript in PAI-1-/- antral myofibroblasts relative to wild-type myofibroblasts    
(Table 4.2), having been flagged as absent in C57BL/6 myofibroblasts. DPP4 was 
not detected by immunohistochemistry in any cell type in wild-type or PAI-1-/- 
antral mucosal sections (data not shown). However, DPP4 was expressed by 
dissociated PAI-1-/- antral myofibroblasts, where it was localised across the entire 
surface of cells (Figure 4.7B). 
 
4.3.4 Expression of desmin, secretogranin-2 and dipeptidyl peptidase 4 by 
dissociated PAI-1-H/Kβ antral myofibroblasts is similar to PAI-1-/- 
myofibroblasts 
 
The expression of desmin, secretogranin-2 and DPP4 was then studied in 
dissociated antral myofibroblasts from PAI-1-H/Kβ stomach, since these 
represented cells derived from a PAI-1 enriched microenvironment. Similar to   
PAI-1-/- myofibroblasts, isolated PAI-1-H/Kβ antral myofibroblasts existed as a 
heterogeneous population of vimentin and desmin expressing cells, with varying 
degrees of co-localisation of these two signals (Figure 4.8). Expression of 
secretogranin-2 and DPP4 by PAI-1-H/Kβ antral myofibroblasts was also similar to 
PAI-1-/- myofibroblasts (Figure 4.9). 
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Figure 4.7. Dissociated antral myofibroblasts from PAI-1-/- mice express 
secretogranin-2 and dipeptidyl peptidase 4. A: Antral myofibroblasts from    
PAI-1-/- mice were secretogranin-2 immunopositive. Secretogranin-2 was seen as 
particulate staining within the cytoplasm, representing expression by secretory 
vesicles. B: A DPP4 expressing antral myofibroblast isolated from PAI-1-/- 
stomach. DPP4, a membrane bound protease, was expressed across the entire 
surface of cells. Scale bars = 50µm. 
 
 
 
 
 
 
 
 
 
PAI-1-/- 
PAI-1-/- 
	  	   120	  
 
 
 
 
 
A       Merged                            Desmin                          Vimentin 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Dissociated antral myofibroblasts from PAI-1-H/Kβ  mice consist of 
a mixed population of vimentin- and desmin-expressing cells. A: A cluster of 
cells expressing vimentin but not desmin. These cells had a more rounded 
morphology than other cells in the population. B: A spindle-shaped cell expressing 
desmin but only weakly expressing vimentin. C:  A mixed sample of desmin-
expressing cells, co-expressing vimentin to varying degrees. Scale bars = 50µm. 
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A         Merged                      Secretogranin-2                  Vimentin 
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Figure 4.9. Dissociated antral myofibroblasts from PAI-1-H/Kβ mice express 
secretogranin-2 and dipeptidyl peptidase 4. A: Secretogranin-2 immunopositive 
PAI-1-H/Kβ antral myofibroblasts. B: DPP4 was expressed across the surface of 
antral myofibroblasts isolated from PAI-1-H/Kβ stomach. Scale bars = 50µm. 
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4.3.5 Treatment of human antral myofibroblasts with exogenous PAI-1 does 
not affect dipeptidyl peptidase 4 activity  
 
Immunocytochemical analysis determined that cultured human antral 
myofibroblasts, characterised on the basis of positive α-SMA and vimentin                
expression, did not express desmin (Figure 4.10). DPP4 was expressed across the 
entire surface of all human antral myofibroblasts (Figure 4.11). The hypothesis that 
PAI-1 negatively regulates expression of DPP4 by antral myofibroblasts was tested 
by comparing the DPP4 activity of PAI-1 treated and untreated cultured human 
antral myofibroblasts, using a colorimetric enzymatic assay. The chromogenic 
molecule pNA was generated via cleavage of Gly-Pro-pNA by DPP4 (Nagatsu et 
al., 1976). The relationship between the number of myofibroblasts plated and DPP4 
activity was linear (Figure 4.12A).  
 
DPP4 activity of myofibroblasts plated for 48 and 72 hours was constant but 
increased after 96 hours of plating (Figure 4.12A) There was no significant 
difference in DPP4 activity of myofibroblasts treated with 50nM PAI-1 for 3, 5 or 7 
days compared to untreated myofibroblasts (Figure 4.12B).  
 
4.3.6 DPP4 activity of PAI-1-H/Kβ mouse plasma is elevated compared to wild-
type and PAI-1-/- plasma 
 
A fluorimetric enzymatic assay based on the generation of AMC via cleavage of 
Gly-Pro-AMC by DPP4 was used to compare DPP4 activity of plasma from 
C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice (Kato et al., 1978). Fluorescence 
developed consistently, in a linear manner, over a 30 min assay period (Figure 
4.13A). DPP4 activity of plasma from PAI-1-H/Kβ mice was significantly elevated  
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Figure 4.10. Cultured human gastric myofibroblasts express α-smooth muscle 
actin and vimentin, but not desmin. A: Myofibroblasts that were isolated from a 
human gastric biopsy were α-SMA immunopositive. B: These myofibroblasts also 
strongly expressed vimentin, but did not express desmin. Scale bars = 50µm. 
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Figure 4.11. Cultured human gastric myofibroblasts express DPP4 across the 
entire cell surface. A: High power magnification (x40) of cultured human gastric 
myofibroblasts demonstrated that these cells expressed DPP4 on the cell surface. B: 
Low power magnification (x10) imaging illustrated that the entire population of 
cells expressed DPP4. Scale bars = 50µm (high power) and 200µm (low power). 
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Figure 4.12. DPP4 activity of cultured human myofibroblasts treated with 
50nM PAI-1 is similar to untreated cells.  A: There was a linear relationship 
between the number of myofibroblasts plated and DPP4 activity of the cultured 
cells. The cells were assayed 48, 72 or 96 hours after plating. There was an increase 
in DPP4 activity of myofibroblast cultures plated for 96 hours, compared to 48 and 
72 hours. B: 10000 myofibroblasts were plated and treated with 50nM PAI-1 24 
hours later.  DPP4 activity was assayed 3, 5 and 7 days after treatment. PAI-1 
treatment had no significant effect on DPP4 activity at any of these time points. 
Data represent the mean of at least 3 individual experiments ± SEM.  
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Figure 4.13. DPP4 activity of plasma from PAI-1-H/Kβ  mice is elevated 
compared to wild type and PAI-1-/- plasma. A: DPP4 activity of 2, 5 and 10µl 
mouse plasma remained constant up to 30 min assay duration, developing 
fluorescence via the generation of AMC in a linear manner. B: DPP4 activity of 5µl 
plasma from C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice was assayed over a 20 min 
period. DPP4 activity of PAI-1-H/Kβ plasma was significantly higher than 
C57BL/6 and PAI-1-/- plasma. Data for individual animals are shown in addition to 
mean ± SEM.  * P < 0.05 (one-way ANOVA). 
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compared to both wild-type and PAI-1-/- plasma (Figure 4.13B). There was no 
difference in DPP4 activity of C57BL/6 and PAI-1-/- plasma.  
 
4.4 Discussion 
 
It is known that gastric epithelial and stromal cells express PAI-1, and that 
expression of PAI-1 is elevated at the site of gastroduodenal ulcers, in chronic 
gastritis, in hypergastrinaemia and in gastric cancer (Tanaka et al., 1991; Nakamura 
et al., 1992; Wodziński et al., 1993; Nekarda et al., 1994; Farinati et al., 1996; 
Herszenyi et al., 1997; Plebani et al., 1997; Kaneko et al., 2003; Kenny et al., 
2008; Keates et al., 2008; Ikeda et al., 2009; Norsett et al., 2011). The influence of 
PAI-1 on gastric myofibroblast gene expression and subsequently on myofibroblast-
epithelial interactions had not previously been investigated. The aim of the work 
described in this chapter was to identify potential myofibroblast-derived modulators 
of the gastric mucosal microenvironment, expression of which is influenced by 
gastric PAI-1 expression. Global gene expression profiles of wild-type and PAI-1-/- 
antral myofibroblasts were compared, and differentially expressed transcripts of 
secreted proteins were identified to uncover potential PAI-1-regulated modulators 
of the gastric mucosal microenvironment. Microarray analysis indicated that global 
gene expression profiles of C57BL/6 and PAI-1-/- myofibroblasts were distinct from 
each other, with a large number of differentially expressed transcripts.  
 
The MAS5.0 summary algorithm was used to normalise raw signal intensity data 
generated by the microarray. This is Affymetrix’s proprietary pre-processing 
algorithm, adjusting signal intensity values to remove noise due to inherent 
technical variations in the processing of microarray chips, including background 
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subtraction and chip-wise normalisation (Hubbell et al., 2002). Since the 
microarrays were processed simultaneously, normalisation of batch effects was not 
an issue. Unlike other pre-processing algorithms, the MAS5.0 summary algorithm 
uses mismatch probes to generate calls for each probe set, allowing exclusion of non-
expressed transcripts from the analysis. To further eliminate noise from the analysis, 
undetected transcripts were filtered by selecting only those entities flagged as 
present in all samples of C57BL/6 or PAI-1-/- myofibroblasts. An arbitrary fold-
change cut-off value of ? 3 or ? -3 was selected, to define differentially expressed 
transcripts. This approach does not take into account the fact that signal intensity 
values of transcripts that are expressed at low levels will be subject to much greater 
error, increasing the chance of false-positive detection at any arbitrary fold-change 
cut-off value, whilst the detection rate of highly expressed transcripts that are 
differentially expressed is insufficient. A better method might involve defining an 
appropriate fold-change cut-off value for each transcript, as a function of its 
absolute expression level relative to other transcripts in the same range of 
expression level (Mutch et al., 2002). However, it is important to consider that 
many potential false-positives are eliminated from the analysis by using the 
MAS5.0 summary algorithm, combining detection calls and fold-change cut-off 
values to identify differentially expressed transcripts, making this both a selective and 
sensitive algorithm (Pepper et al., 2007). 
 
Gastric myofibroblasts cultured for gene expression analysis had been characterised 
on the basis of positive α-SMA and vimentin expression by immunocytochemistry. 
The microarray data confirmed expression of the corresponding transcripts. 
Vimentin and α-SMA have been used previously to characterise mouse and human 
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gastric myofibroblasts by immunohistochemistry (Wu et al., 1999; Fuyuhiro et al., 
2011; Holmberg et al., 2012). Expression of these proteins marks cells as having 
characteristics of both fibroblasts and smooth muscle cells: the classical definition 
of the myofibroblast (Majno et al., 1971). A more rigorous definition of the 
myofibroblast has since been argued based on expression of α-SMA and at least 
three other markers, which may include γ-SMA, vimentin, desmin, endosialin, 
palladin 4Ig, prolyl-4 hydroxylase, podoplanin, cadherin-11 or negative markers 
such as epithelial cytokeratins, smoothelin, CD14, CD31 and CD34 (De Wever et 
al., 2008). The microarray data revealed that cultured gastric myofibroblasts from 
C57BL/6 and PAI-1-/- mice met these criteria. 
 
Immunofluorescence was used to characterise expression of desmin by antral 
myofibroblasts on the basis that PAI-1-/- myofibroblasts, but not C57BL/6 
myofibroblasts, had been shown to express desmin mRNA. Unexpectedly, this led 
to the discovery of a mixed population of desmin- and vimentin-expressing 
myofibroblast-like cells in both C57BL/6 and PAI-1-/- antral sections. Furthermore, 
acutely cultured antral PAI-1-/- and PAI-1-H/Kβ myofibroblasts were shown to 
variably express desmin by immunocytochemistry. This is consistent with a 
previous study reporting that a mixed population of desmin-positive and desmin-
negative myofibroblasts were identified, migrating out of denuded gastric mucosa 
(Wu et al., 1999). This is the first time that a heterogeneous myofibroblast 
population, in terms of the expression of desmin, has been identified in situ within 
the lamina propria of gastric mucosa.  
 
Previous studies report conflicting results regarding the expression of desmin by 
gastrointestinal myofibroblasts. In a previous study undertaken in this laboratory, a 
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total of 30 human myofibroblast lines were examined, including gastric CAMs, 
ATMs and NTMs, all of which were α-SMA and vimentin-positive but desmin-
negative (Holmberg et al., 2012). The results reported in this chapter are consistent 
with these observations. In C57BL/6 mice, desmin-negative myofibroblasts 
appeared within the corpus mucosa and submucosa following cryo-ulceration 
(Ashurst et al. 2008). Normal colonic pericryptal myofibroblasts have been 
identified as being desmin-negative, whereas desmin-expressing myofibroblasts 
appeared focally in adenomatous and hyperplastic polyps (Adegboyega et al., 
2002). Conversely, desmin-positive myofibroblasts have been identified along the 
normal canine gastrointestinal tract, yet myofibroblasts of canine gastrointestinal 
tumour stroma were desmin-negative, except those adjacent to the muscularis 
mucosae (Mukaratirwa et al., 2003). This led the authors to propose that 
myofibroblasts in canine tumour stoma derive primarily from fibroblasts, with few 
originating from smooth muscle cells of the muscularis mucosae. The desmin-
positive myofibroblasts observed in mouse antral sections and in culture may derive 
from smooth muscle cells of the muscularis mucosae, vasculature or submucosal 
muscle layers. Further characterisation of these cells in terms of expression of 
smooth muscle markers, such as smooth muscle myosin, would help to elucidate 
this point. Furthermore, it has been suggested that ultrastructural examination may 
better identify features of ‘true myofibroblasts’, and distinguish cells that are more 
characteristic of smooth muscle cells that might otherwise be identified as 
myofibroblasts by immunofluorescence (Eyden, 2008).  
 
It is becoming increasingly apparent that myofibroblasts exist as a heterogeneous 
population of cells derived from and with features of multiple precursors, including 
fibroblasts, mesenchymal stem cells, smooth muscle cells, pericytes, epithelial 
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cells, myoepithelial cells, endothelial cells, fibrocytes, adipocytes and stellate cells 
(Powell et al., 2005; De Wever et al., 2008; Powell et al., 2011). The classical 
characterisation of myofibroblasts based on expression of α-SMA and vimentin is 
therefore seen to fail to adequately describe the complexity of myofibroblast 
populations in normal and pathophysiological tissues. This formed the basis of the 
proposal of more stringent criteria to distinguish myofibroblasts from other 
myofibroblast-like cells, such as CAFs and activated fibroblasts (De Wever et al., 
2008; Eyden, 2008). The existence of a heterogeneous myofibroblast population in 
mouse antrum is supported by the observation that transcripts of several stromal 
cell markers were differentially expressed by wild-type and PAI-1-/- cultured antral 
myofibroblasts, including α-SMA and desmin, the expression of which was 
significantly elevated by PAI-1-/- myofibroblasts. This may be indicative of a more 
smooth muscle cell-like phenotype of this population of cells, which were 
selectively cultured from PAI-1-/- antral tissue.  
 
Myofibroblasts adapt to their microenvironment, allowing them to participate in 
tissue remodelling by taking on a contractile and secretory phenotype in granulation 
tissue and supporting carcinogenesis in tumour stroma. Given the 
microenvironment-dependent phenotypic plasticity of myofibroblasts, adaptations 
to culture conditions would not be surprising. For example, it has recently been 
reported that the proportion of α-SMA-expressing myofibroblasts decreased with 
serial passage of gastric fibroblast/myofibroblast cultures, and the myofibroblast 
population could be recovered by supplementation with conditioned medium from 
scirrhous gastric carcinoma cells, via TGF-β (Fuyuhiro et al., 2011). 
Myofibroblasts used for microarray studies had been passaged 3 or 4 times. 
Therefore, it seems possible that the expression of secretogranin-2 and DPP4 
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observed in cultured antral myofibroblasts, but not by myofibroblasts in antral 
sections, provides a further example of adaptation to culture conditions. 
Furthermore, adaptation to culture conditions is likely to occur rapidly, since 
acutely cultured myofibroblasts used for microarray validations also expressed 
secretogranin-2 and DPP4.  
 
The phenomenon of cellular adaptation to culture conditions is well documented. 
Studies examining global gene expression profiles of cultured cells and 
corresponding intact tissues have shown that although primary cell cultures are 
more similar to original tissues than immortalised cell lines, significant changes in 
gene expression still occur (Dairkee et al., 2004; Sandberg & Ernberg, 2005). The 
limitations of two-dimensional cultures to recapitulate the complexity of 
interactions between stromal cells, parenchymal cells and the ECM necessarily 
leads to genetic, transcriptional and post-translational adaptations (Ross et al., 
2000; Roschke et al., 2003; Irish et al., 2004; Birgersdotter et al., 2005). The 
question arises as to whether cultured mouse antral myofibroblasts develop a 
neuroendocrine-like phenotype, marked by expression of secretogranin-2, and 
regulated secretion of certain proteins, such as DPP4. The neuroendocrine-like 
phenotype of human myofibroblasts has been well-characterised, based on 
expression of secretogranin-2 and the capacity for regulated secretion, which is lost 
in some gastric cancer patients with poor survival (Balabanova, 2012).  
 
To confirm that secretogranin-2 expression by gastric myofibroblasts is induced in 
culture, transgenic mice could be generated with the green fluorescent protein 
(GFP) reporter gene coupled to the secretogranin-2 promoter. Based on this 
hypothesis, myofibroblasts in ex vivo antral tissue would express minimal levels of 
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GFP, whilst expression by cultured antral myofibroblasts would be significantly 
elevated. Furthermore, adaptation of gastric myofibroblasts to a neuroendocrine-
like phenotype in culture may be a physiologically relevant model of the 
phenotypic adaptations during wound healing and inflammation. To explore this 
hypothesis, wounded and chronically inflamed tissues from GFP-secretogranin-2 
reporter mice could be examined ex vivo, to determine whether myofibroblasts 
express secretogranin-2 in these microenvironments.   
 
Certain limitations exist in the approach that was taken to validate the microarray 
data by immunocytochemistry, in that myofibroblasts used for the validations were 
freshly dissociated and acutely cultured, whilst those used to prepare material for 
the microarrays had been passaged 3 or 4 times. As discussed above, it is now clear 
that mouse myofibroblasts exist as a heterogeneous population of desmin-positive 
and desmin-negative cells, quite distinct from the situation in humans (Holmberg et 
al., 2012). This raises the possibility of subclone selection in culture. Together with 
the phenotypic plasticity of cultured myofibroblasts, this highlights the need to use 
myofibroblasts with similar passage histories for gene or protein expression 
analysis and subsequent validation studies, and also to characterise myofibroblasts 
on the basis of expression of multiple markers, including α-SMA, vimentin and 
desmin, to confirm that these populations are equivalent and the validations are 
therefore valid.  
 
In terms of potential modulators of epithelial cell proliferation, DPP4 was of 
particular interest. DPP4 cleaves IGF-I, generating a truncated form that has 
impaired IGF-I receptor-activating potential and a greater affinity for IGFBP-3 (Lin 
et al., 2010). Microarray data revealed that DPP4 mRNA was expressed by PAI-1-/- 
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cultured antral myofibroblasts but not C57BL/6 myofibroblasts, leading to the 
hypothesis that DPP4 is down-regulated by PAI-1, increasing epithelial cell 
proliferation by increasing the bioavailability of active IGF-I. To determine the 
effect of increased PAI-1 concentrations on myofibroblast DPP4 activity, cultured 
human myofibroblasts were treated with exogenous PAI-1 and DPP4 activity was 
assayed at various time-points following treatment. PAI-1 did not significantly alter 
DPP4 activity 3, 5 or 7 days after treatment with PAI-1. Furthermore, PAI-1-H/Kβ 
mouse plasma had elevated DPP4 activity compared to wild-type and PAI-1-/- 
plasma, which provides no support for the hypothesis that PAI-1 negatively 
regulates DPP4. However, plasma DPP4 activity may not reflect the total 
expression of DPP4 by cells, given that this only represents the bioavailability of 
the truncated soluble DPP4 isoform, and does not provide information about cell-
surface bound DPP4.  
 
Future investigations might be directed towards identifying other differentially 
expressed transcripts in the microarray data that could influence epithelial cell 
proliferation. One striking candidate is pleiotrophin, the most differentially 
expressed transcript by C57BL/6 myofibroblasts compared to PAI-1-/- 
myofibroblasts. Pleiotrophin mRNA had in fact been flagged as absent in PAI-1-/- 
myofibroblasts, indicating a potential positive regulatory role for PAI-1. 
Pleiotrophin is a developmental growth factor, known to promote neurite 
outgrowth, and is mitogenic in a range of other tissues, stimulating fibroblasts, 
endothelial cells and epithelial cells (Rauvala, 1989; Li et al., 1990; Courty et al., 
1991; Wellstein et al., 1992; Fang et al., 1992; Laaroubi et al., 1994; Choudhuri et 
al., 1997). It is of interest that the microarray data indicated that midkine, a protein 
related to pleiotrophin with 45% sequence homology, was also significantly 
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differentially expressed by C57BL/6 antral myofibroblasts compared to PAI-1-/- 
myofibroblasts, being flagged as absent in PAI-1-/- myofibroblasts. Pilot studies 
were conducted to investigate the effect of IP administration of pleiotrophin on 
gastric epithelial cell proliferation in vivo, using an EdU based assay, but these did 
not produce any positive data. It would be useful to characterise the relative 
expression of pleiotrophin and midkine in wild-type and PAI-1-/- gastric tissues, 
using Western blotting and quantitative polymerase chain reaction (qPCR), and 
assays to investigate the mitogenic potential of pleiotrophin in the gastric mucosa in 
vivo require more optimisation. Similar approaches may also be used to investigate 
the functional significance of other differentially expressed transcripts in the 
microarray data. 
 
The data presented in this chapter provides novel insights into the characteristics of 
myofibroblasts resident in mouse antral tissues. Two highly heterogeneous 
populations of myofibroblasts can be found in mouse gastric mucosa, with distinct 
global gene expression profiles. One of these expresses markers suggestive of a 
more smooth-muscle cell-like differentiation. Furthermore, the data raise the 
possibility that myofibroblasts adapt to culture conditions by developing a 
neuroendocrine-like phenotype, which may be relevant to the compromised gastric 
mucosal microenvironment, such as in Helicobacter infection and NSAID-induced 
injury. Based on these observations indicating the complexity of gastric 
myofibroblast phenotypes, a major outcome of these studies was clarification of 
how studies on gastric myofibroblasts need to be designed and validated, to ensure 
that equivalent populations are investigated. 
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4.5 Conclusions 
 
1. Cultured antral mucosal myofibroblasts from wild-type and PAI-1-/- mice 
have distinct global gene expression profiles. 
2. Mouse antral mucosal myofibroblasts exist as a heterogeneous population of 
vimentin- and desmin-expressing cells, in situ and in acutely dissociated cell 
culture. 
3. Mouse antral mucosal myofibroblasts may develop a neuroendocrine-like 
phenotype in culture conditions. 
4. Exogenous PAI-1 does not influence the DPP4 activity of cultured human 
antral myofibroblasts. 
5. DPP4 activity of PAI-1-H/Kβ mouse plasma is increased, compared to wild-
type and PAI-1-/- plasmas. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 5 
 
THE ROLE OF PAI-1 IN 
HISTOPATHOLOGICAL RESPONSES 
TO CHRONIC H. FELIS INFECTION 
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5.1 Introduction 
 
PAI-1 influences inflammatory responses to, and outcomes of, various infections. On 
the one hand, PAI-1 expression correlates with worse outcomes in sepsis, and 
carriers of the 4G allele of PAI-1 polymorphism, associated with increased 
expression of PAI-1, have a poorer prognosis following pneumonia-induced sepsis 
(Mesters et al., 1996; Tani et al., 2001; Raaphorst et al., 2001; Madach et al., 2010). 
However, expression of PAI-1 associated with systemic Yersinia enterocolitica 
infection, Klebsiella pneumoniae infection, Haemophilus influenzae infection and 
pneumonia caused by Pseudomonas areuginosa, is associated with effective host 
immune responses, bacterial clearance and improved outcomes, whilst PAI-1 does 
not effect host responses to Streptococcus pneumoniae infection (Rijneveld et al., 
2003; Renckens et al., 2007; Lim et al., 2011; Wang et al., 2013). Gastric expression 
of PAI-1 is elevated in response to Helicobacter infection (Herszenyi et al, 1997; 
Kenny et al., 2008; Keates et al., 2008; Ikeda et al., 2009). The functional significance 
of increased expression of PAI-1 in the stomach during Helicobacter infection remains 
to be determined. 
 
Previous work in this laboratory has shown that gastric PAI-1 acts as an orexigenic 
agent, attenuating CCK-evoked gut-brain satiety signals (Kenny et al., 2013a). Given 
that gastric PAI-1 expression is increased during Helicobacter infection, it was 
proposed that PAI-1 counteracts inflammation-induced anorexigenic signals in 
response to Helicobacter infection, maintaining energy balance in the face of chronic 
gastritis (Kenny et al., 2013a). The work in this chapter explores the role of PAI-1 in 
histopathological responses to H. felis infection in mice, and in particular the possibility 
that PAI-1 also maintains gastric mucosal homeostasis.  
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5.1.1 Aims and objectives 
 
The aim of this chapter was to determine the gastric histopathological responses to H. 
felis infection in PAI-1-/- and PAI-1-H/Kβ mice compared to C57BL/6 mice, 48 weeks 
after initial infection. The specific objectives were to: 
1. determine antral colonisation by H. felis and antral morphology following 
chronic H. felis infection of PAI-1-/- and PAI-1-H/Kβ mice compared to wild-
type mice; 
2. determine the degree of H. felis-induced corpus inflammation of PAI-1-/- and 
PAI-1-H/Kβ mice compared to wild-type mice;    
3. determine changes in corpus mucosal myofibroblast abundance following 
chronic H. felis infection of PAI-1-/- and PAI-1-H/Kβ mice compared to wild-
type mice; 
4. determine corpus mucosal thickness, foveolar hyperplasia, oxyntic gland 
atrophy and epithelial defects, in response to chronic H. felis infection of      
PAI-1-/- and PAI-1-H/Kβ mice compared to wild-type mice. 
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5.2 Methods 
 
5.2.1 H. felis infection 
 
Male and female C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice aged 6-8 weeks were 
infected with a suspension of H. felis in TBS broth, as described in section 2.2.3. 
Animals were humanely killed after 48 weeks alongside age-matched uninfected mice 
of each strain, and gastric tissues were harvested for histological analysis. Infected and 
uninfected treatment groups consisted of 6 – 9 animals of each strain.  
 
5.2.2 Histology 
 
Stomachs were prepared for either frozen sections or paraffin-embedded sections, as 
described in sections 2.3 and 2.4 respectively. Paraffin-embedded sections were stained 
with H&E, Giemsa stain or were vimentin immunostained whilst frozen sections were 
stained with Texas Red-conjugated-secondary antibody directed against vimentin 
primary antibody, to identify mucosal myofibroblasts. 
 
5.2.3 Histopathological scoring 
 
Colonisation of antral glands with Giemsa-positive H. felis was quantified on a scale of 
0 – 4, as described in section 2.12. Similarly, corpus mucosal myofibroblast abundance 
was graded from 0 – 4, based on the number of vimentin-immunopositive cells, as 
described in section 2.12. Antral and corpus mucosal thickness was determined using 
AxioVision 4.5 software, as described in section 2.12. Sections stained with H&E were 
used to characterise tissue morphology and corpus histopathological features were 
quantified on a scale from 0 - 4, as described previously (Rogers et al., 2005; section 
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2.12). Both frozen and paraffin-embedded sections (n = 6 – 9 per group) were used to 
quantify corpus mucosal thickness and myofibroblast abundance whilst only paraffin-
embedded sections (n = 3 – 5 per group) were used to quantify inflammation, epithelial 
defects, foveolar hyperplasia, oxyntic gland atrophy and antral Giemsa staining. 
 
5.2.4 Statistics 
 
For histopathological scores and Giemsa scores, data points represent individual 
animals and group data are presented as median ± range or IQR. Comparisons between 
experimental groups were made using a two-tailed Mann-Whitney U-test or Kruskal-
Wallis ANOVA on ranks test with Dunn’s post hoc analysis for multiple comparisons, 
and were considered significant at P < 0.05.  
 
Antral and corpus mucosal thickness of individual animals was calculated as the mean 
of at least 10 measurements and group data are presented as mean ± SEM. 
Comparisons between experimental groups were made using a one-way ANOVA with 
Tukey’s post hoc analysis for multiple comparisons, and were considered significant at 
P < 0.05. 
 
 
 
 
 
	  	   142	  
5.3 Results 
 
5.3.1 H. felis colonises antral mucosa but does not alter antral morphology of 
C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice 
 
Wild-type, PAI-1-/- and PAI-1-H/Kβ mice were chronically infected with H. felis to 
investigate the role of PAI-1 in Helicobacter-stimulated preneoplastic changes in 
the stomach. Bacterial colonisation was determined by quantifying Geimsa-stained 
H. felis in antral mucosa. The rationale behind investigating antrum, but not corpus, 
for colonisation was based on previous studies reporting that chronic H. felis 
infection results in antral-predominant colonisation in a number of mouse strains, 
including C57BL/6 (Sakagami et al., 1996; Wang et al., 1998; Takaishi et al., 2009; 
Duckworth et al., 2012). The antral glands of all C57BL/6 and PAI-1-/- mice were 
colonised by H. felis at 48 weeks post-inoculation. Colonisation of PAI-1-/- antrum 
tended to be elevated compared to C57BL/6 mice, but this did not reach statistical 
significance (Figure 5.1). Antral glands of all but one of the PAI-1-H/Kβ mice were 
colonised by H. felis. However, the mouse that was negative for H. felis 
colonisation did show phenotypic changes typical of infection suggesting that this 
particular mouse had been infected and had cleared the bacteria. There was no 
significant difference in antral H. felis colonisation of C57BL/6 and PAI-1-H/Kβ 
mice (Figure 5.2). Giemsa-stained antral tissues from age-matched uninfected mice 
were also examined and were found to be H. felis negative.  
 
Antral mucosal morphology was similar in C57BL/6 and PAI-1-/- mice. Antral 
glands of both C57BL/6 and PAI-1-/- mice were slightly, but not significantly,        
m 
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Figure 5.1. Colonisation of PAI-1-/- antral mucosa by H. felis tends to be 
elevated compared to wild-type 48 weeks after initial infection. A: 
Representative image of C57BL/6 antral mucosa colonised by Giemsa-stained      
H. felis 48 weeks after infection. Generally 1-2 bacteria were present in some antral 
gland lumen. B: Most PAI-1-/- antral gland lumen were colonised by many bacteria 
following 48 weeks of infection. H. felis colonies are illustrated by arrows, within 
the lumen of gastric glands. C: Antral mucosal colonisation with H. felis tended to 
be higher in PAI-1-/- compared to wild-type mice, but this did not reach statistical 
significance. All animals showed antral colonisation. Data for individual animals 
are shown in addition to group median ± range.  
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Figure 5.2. H. felis colonises the antral mucosa of most PAI-1-H/Kβ mice 48 
weeks after initial infection. A: Colonisation of C57BL/6 antral mucosa by H. 
felis 48 weeks after infection. B: Similar to wild-type mice, some PAI-1-H/Kβ 
antral glands were colonised by 1-2 bacteria following 48 weeks of infection. C: 
Antral mucosa of all but one of the PAI-1-H/Kβ mice was colonised by H. felis 48 
weeks after inoculation. The mouse lacking antral H. felis did show gastric 
phenotypic changes typical of infection however. There was no significant 
difference in antral H. felis colonisation of C57BL/6 and PAI-1-H/Kβ mice. Data 
for individual animals are shown in addition to group median ± IQR.  
 
C5
7B
L/6
PA
I-1
-H
/K
! 
0
1
2
3
4
G
ie
m
sa
 s
co
re
	  	   145	  
lengthened following H. felis infection, but morphology was otherwise unaltered      
(Figure 5.3). PAI-1-H/Kβ antral morphology was similar to C57BL/6 and was 
unchanged following H. felis infection (Figure 5.4). 
 
5.3.2 Absence of PAI-1 protects against H. felis-stimulated corpus 
preneoplastic changes 
 
Corpus mucosal morphology was similar in uninfected C57BL/6 and PAI-1-/- mice 
(Figure 5.5A & B). In response to chronic H. felis infection, C57BL/6 mice 
displayed severe histopathological changes typical of atrophic gastritis, including 
extensive inflammatory cell infiltration, mucosal thickening, foveolar hyperplasia, 
replacement of parietal and chief cell populations with mucous epithelium and 
glandular architectural abnormalities (Figure 5.5C & D). Corpus tissue from H. felis 
infected PAI-1-/- mice also showed marked inflammatory cell infiltration and had 
features typical of early progression to atrophic gastritis, including low-grade 
foveolar hyperplasia and occasional slight gland dilation. The chief cell population 
was depleted but the parietal cell population was largely preserved                  
(Figure 5.5E & F). 
 
Quantification of histopathological features revealed that PAI-1-/- mice were 
protected against the development of epithelial defects, foveolar hyperplasia, 
oxyntic gland atrophy, increases in corpus mucosal thickness and increases in 
corpus myofibroblast abundance in response to H. felis infection (Figure 5.6B - F).  
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Figure 5.3. Antral morphology of wild-type and PAI-1-/- mice is similar, 
regardless of H. felis infection status. A: H&E stained section of uninfected 
C57BL/6 antrum. B: Uninfected PAI-1-/- antrum had similar morphology to wild-
type antrum. C: H. felis infected C57BL/6 antrum had similar morphology to 
uninfected tissue, with slightly lengthened glands. D: H. felis infected PAI-1-/- 
antrum was also similar to uninfected tissue. E: Mean antral mucosal thickness of 
53-56 week old C57BL/6 and PAI-1-/- mice was similar. Antral mucosal thickness 
of aged matched C57BL/6 and PAI-1-/- mice infected with H. felis for 48 weeks was 
slightly increased, but this did not reach significance. Data are expressed as mean ± 
SEM; n = 3 - 5 per group. Scale bars = 200µm. 
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Figure 5.4. Wild-type and PAI-1-H/Kβ mice have similar antral morphology. 
A: Representative image of H&E stained uninfected C57BL/6 antrum. B: 
Uninfected PAI-1-H/Kβ antrum was similar to wild-type. C: H. felis infected 
C57BL/6 antrum, with similar morphology to uninfected tissue. D: Morphology of 
PAI-1-H/Kβ antrum was also unaffected by H. felis infection E: Mean antral 
mucosal thickness of 53-56 week old PAI-1-H/Kβ mice was equivalent to wild-
type. Chronic H. felis infection had no effect on antral mucosal thickness. Data are 
expressed as mean ± SEM; n = 3 - 5 per group. Scale bars = 200µm. 
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Figure 5.5. C57BL/6 mice show more severe corpus histopathological changes 
than PAI-1-/- mice in response to 48 weeks of H. felis infection. A: 
Representative H&E image of corpus tissue from an uninfected 53-56 week old 
C57BL/6 mouse. B: Age matched uninfected PAI-1-/- mice had similar corpus 
morphology to wild type mice. C & D: Corpus tissue from C57BL/6 mice infected 
with H. felis for 48 weeks was hypertrophic, with foveolar hyperplasia (f), 
replacement of parietal and chief cells with mucous epithelium, glandular dilation 
and distortion (d) and marked inflammatory cell infiltration, particularly as 
aggregates in the submucosa (i). Glandular regions had invaded into the submucosa 
(g). E & F: Corpus tissue from H. felis infected PAI-1-/- mice also showed marked 
inflammatory cell infiltration, particularly as submucosal aggregates (i), some 
lower grade foveolar hyperplasia (f) and occasional mild gland dilation (d). Parietal 
cells were largely preserved following infection in PAI-1-/- mice, whilst the chief 
cell population was diminished. Scale bars = 200µm. 
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                      Male     female       Male female 
               uninfected mice                       H. felis infected mice 
 
Figure 5.6. Absence of PAI-1 protects against H. felis-stimulated corpus 
preneoplastic changes. A: Chronic H. felis infection elicited inflammatory 
responses in wild-type and PAI-1-/- mice. Changes in inflammatory scores in 
infected PAI-1-/- mice compared to uninfected PAI-1-/- mice did not reach 
significance however. B - F: C57BL/6, but not PAI-1-/- mice, developed significant 
corpus epithelial defects, foveolar hyperplasia, glandular atrophy, increases in 
corpus mucosal thickness and increases in corpus mucosal myofibroblast 
abundance in response to 48 weeks of H. felis infection. Data for individual animals 
are shown in addition to median ± range or IQR, or mean ± SEM (mucosal 
thickness only). * P < 0.05, ** P < 0.01 (Kruskal-Wallis test); *** P < 0.001 (one-
way ANOVA). 
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5.3.3 PAI-1-H/Kβ mice are protected against H. felis-stimulated corpus 
preneoplastic changes 
 
In uninfected PAI-1-H/Kβ mice, the corpus mucosal thickness was increased 
compared with C57BL/6 mice and there was low-grade foveolar hyperplasia 
(Figure 5.7B). Corpus tissue of chronically infected PAI-1-H/Kβ mice had marked 
inflammatory cell infiltration and features indicative of early stages of progression 
towards atrophic gastritis, including low-grade foveolar hyperplasia and minor 
glandular structural defects. The chief cell population was depleted but parietal 
cells were preserved (Figure 5.7D).  
 
Corpus histopathological scores revealed that distinct from wild-type mice,         
PAI-1-H/Kβ mice were protected against the development of H. felis-stimulated 
epithelial defects, foveolar hyperplasia, oxyntic gland atrophy, increases in mucosal 
thickness and increases in corpus mucosal myofibroblast abundance               
(Figure 5.8B - F).  
 
5.4 Discussion  
 
The work in this chapter builds upon previous reports of increased expression of 
PAI-1 by gastric epithelial cells in response to H. pylori infection (Herszenyi et al, 
1997; Kenny et al., 2008; Keates et al., 2008; Ikeda et al., 2009). PAI-1 is thought 
to modulate the tissue remodelling activity of the uPA system, so it was 
hypothesised that altering the expression of PAI-1 would modify the development 
of H. felis pathology. The data presented in this chapter provides novel insights into  
 
	  	   151	  
 
 
 
A                                             B   
                
      
 
 
 
              
 
 
 
       
C                                             D  
 
 
 
 
 
 
 
 
 
 
Figure 5.7. PAI-1-H/Kβ mice develop low-grade corpus histopathology in 
response to chronic H. felis infection. A: H&E stained corpus tissue from an 
uninfected 53-56 week old C57BL/6 mouse. B: Corpus tissue from age matched 
uninfected PAI-1-H/Kβ mice was hypertrophic compared to C57BL/6 corpus, with 
mild foveolar hyperplasia (f). C: H&E stained C57BL/6 corpus tissue following 48 
weeks of H. felis infection, showing features typical of atrophic gastritis. D: Corpus 
tissue from PAI-1-H/Kβ mice infected with H. felis for 48 weeks displayed marked 
inflammation (i), low grade-foveolar hyperplasia (f) and some mild glandular 
architectural defects (d). Parietal cells, but not chief cells, were preserved. Scale 
bars = 200µm. 
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                 C57BL/6              PAI-1-H/Kβ                                 C57BL/6              PAI-1-H/Kβ 
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Figure 5.8. Increased gastric PAI-1 protects against H. felis-stimulated corpus 
preneoplastic changes. Chronic H. felis infection elicited inflammatory responses 
in wild-type and PAI-1-H/Kβ mice. Changes in inflammatory scores in infected 
PAI-1-H/Kβ mice compared to uninfected PAI-1-H/Kβ mice did not reach 
significance however. B - F: PAI-1-H/Kβ mice were protected against the 
development of corpus epithelial defects, foveolar hyperplasia, glandular atrophy, 
increases in corpus mucosal thickness and increases in corpus mucosal 
myofibroblast abundance in response to 48 weeks of H. felis infection. Data for 
individual animals are shown in addition to median ± range or IQR, or mean ± 
SEM (mucosal thickness only). * P < 0.05, ** P < 0.01 (Kruskal-Wallis test, or one-
way ANOVA for mucosal thickness). 
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the role of PAI-1 in the development of Helicobacter-stimulated preneoplastic 
morphology in the stomach, with both PAI-1-/- and PAI-1-H/Kβ mice showing 
protection against corpus histopathological changes. 
 
The results presented here are consistent with previous reports of the gastric 
morphological changes seen in C57BL/6 mice in response to chronic H. felis 
infection. The first study to investigate mucosal histological changes in response to 
12 months of H. felis infection in C57BL/6 mice reported hyperplasia, associated 
with significant thickening of the mucosa resulting from lengthening of gastric pits 
and glands, marked parietal cell loss, glandular dilation, lymphocytic infiltration 
and glandular invasion into the submucosa (Fox et al., 1996). These corpus 
phenotypic changes were replicated in C57BL/6 mice following 48 weeks of 
infection in this experiment. Similar results have been reported in studies 
examining corpus morphology following various durations of infection, including 
sustained active chronic gastritis and progressive histological changes characterised 
by mucosal hyperplasia, loss of parietal and chief cells, mucous cell metaplasia, 
gland dilation and, in some cases, cystic glandular invasion into submucosa 
(Sakagami et al., 1996; Fox et al., 1997; Wang et al., 1998; Lichtenberger et al., 
1999; Dial et al., 2000; Fox et al., 2002; Court et al., 2003; Cai et al., 2005; 
Takaishi et al., 2009; Schmitz et al., 2011). Furthermore, the data on antral 
histology presented in this chapter are consistent with previously reported 
observations, describing preserved mucosal morphology in chronically H. felis 
infected C57BL/6 mice (Sakagami et al., 1996). Some studies have reported a mild 
to moderate lengthening of antral glands, but no other histological changes in the 
antrum of C57BL/6 mice in response to H. felis infection (Fox et al., 1997; 
Duckworth et al., 2012). In this study, antral glands of H. felis infected C57BL/6 
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mice were slightly lengthened compared to uninfected animals, but this did not 
reach statistical significance.  
 
Previous studies have highlighted the importance of gender in responses to H. felis 
infection of C57BL/6 mice. Female mice showed augmented inflammatory and 
histopathological responses to H. felis infection compared to male mice and, 
distinct from male mice, increased corpus epithelial cell proliferation and apoptosis 
in response to infection (Court et al., 2003). Both male and female mice were used 
in this study and data from each were combined in comparative statistical analyses, 
as there were no major gender differences. Future experiments might include 
increased numbers of male and female mice, so that the effect of gender in PAI-1-
modulated responses to H. felis infection might be revealed. Furthermore, given 
that the animals in this study were split into two groups for tissue processing, either 
for frozen sections or paraffin embedded sections, some of the analyses would 
benefit from increased animal numbers in each group. Nevertheless, where it was 
possible to assess the same parameter in both frozen and paraffin embedded 
sections, both groups yielded similar results, indicating that the analyses were 
robust and allowing data from the groups to be collated. 
  
The data presented in this chapter suggest that expression of PAI-1 influences the 
degree of antral colonisation by H. felis 48 weeks after initial infection. Antral 
mucosae of PAI-1-/- mice tended to be colonised by greater numbers of H. felis than 
C57BL/6 mice. A recent study described a similar relationship between CD24 
expression and H. felis colonisation, with CD24 null mice having a higher 
percentage of infected antral glands than wild-type mice (Duckworth et al., 2012). 
This higher-degree of colonisation was associated with an attenuated corpus 
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inflammatory response and protection against corpus hyperplasia and parietal cell 
atrophy. Previous studies have also described a positive relationship between 
retention of H. felis within the antral mucosa and attenuated corpus atrophic 
responses (Sakagami et al., 1996; Wang et al., 1998). It is likely that host-responses 
to H. felis infection that stimulate clearance of the bacteria also promote the 
development of glandular atrophy, and that these responses are at least partially 
mediated by PAI-1.  
 
Both PAI-1-/- and PAI-1-H/Kβ mice were protected against the development of H. 
felis-stimulated increases in corpus mucosal thickness, oxyntic gland atrophy, 
foveolar hyperplasia and epithelial defects, implying that both absence of PAI-1 and 
increased PAI-1 expression protect against preneoplastic morphological changes in 
response to infection. This indicates that the balance between protective and 
aggressive mechanisms mediated by PAI-1 in Helicobacter-stimulated 
preneoplastic histopathogenesis is dependent on the levels of gastric PAI-1 
expression, producing a U-shaped correlation between gastric PAI-1 expression and 
protection. These results are consistent with the “PAI-1 paradox” in cancer, 
described in section 1.6.6. This dose-dependent behaviour of PAI-1 can be 
explained by its complex biology, involving both uPA-dependent anti-proteolytic 
activity and mechanisms independent of uPA. At levels expressed in wild-type 
mice, deleterious mechanisms predominate, whilst at levels expressed by           
PAI-1-H/Kβ mice, protective mechanisms become dominant.  
 
In terms of the potential mechanisms by which PAI-1 influences the gastric 
outcome of H. felis infection, an obvious candidate would be modulation of the 
immune response. Although both PAI-1-/- and PAI-1-H/Kβ mice demonstrated an 
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inflammatory response to infection, further experiments are needed to determine 
the precise nature of cytokine and chemokine responses. It has been postulated that 
H. felis infection stimulates an autoimmune response against the corpus mucosa 
rather than a direct inflammatory response against the bacteria, hence the separation 
between the site of colonisation and the site of pathology (Sakagami et al., 1996). 
An association between H. pylori infection and a gastric autoimmune response has 
been reported (Negrini et al., 1991; Negrini et al., 1997), mediated by a Th1 
immune response (Bamford et al., 1998). PAI-1 has been shown to modulate the 
balance between Th1 and Th2 immune responses in response to nasal allergy 
challenge, LPS and staphylococcal enterotoxin B, in favour of Th2 responses 
(Sejima et al., 2005; Renckens et al., 2006). uPA is required for the induction of 
both Th1 and Th2 immune responses (Gyetko et al., 2002; Gyetko et al., 2004). 
Therefore PAI-1 might act through uPA to modulate host immune responses.  
 
A similar association between immune responses and expression of leptin has been 
reported. Similar to PAI-1, leptin is an adipokine that is also secreted by the gastric 
mucosa, expression of which is increased by H. pylori infection (Bado et al., 1998; 
Breidert et al., 1999; Azuma et al., 2001). Leptin treatment has been shown to 
promote autoimmune encephalomyelitis in mice, switching the cytokine response 
from Th2 to Th1 profile (Matarese et al., 2001). In terms of energy balance, PAI-1 
and leptin have opposite effects; leptin is an anorexigenic agent, potentiating CCK-
evoked satiety signals via vagal afferents, whilst PAI-1 endows resistance against 
these satiety signals (Matson et al., 1997; Barrachina et al., 1997; Wang et al., 
1997; Matson & Ritter, 1999; Emond et al., 1999; Kenny et al., 2013a). Similarly, 
at levels expressed by PAI-1-H/Kβ mice, PAI-1 might oppose the effects of leptin, 
promoting non-autoimmune Th2 responses, whilst at levels expressed by C57BL/6 
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mice, PAI-1 expression may favour the Th1 autoimmune profile. In common with 
other physiological and pathophysiological roles of PAI-1, regulation of immune 
responses is likely to be tissue-specific, as well as dose-dependent, which could 
account for the contrary observations seen in PAI-1 deficient mice in response to 
nasal allergy challenge, LPS and staphylococcal enterotoxin B compared to the 
hypothesised role in Helicobacter infection (Sejima et al., 2005; Renckens et al., 
2006). 
 
A number of studies point towards Th1 immune responses being an important 
modulator of Helicobacter-stimulated atrophic pathology and bacterial clearance. 
Production of IFN-γ by Th1 cells has been associated with Helicobacter-stimulated 
preneoplasia and clearance of the infection (Sayi et al., 2009). Furthermore, 
suppression of Th1 responses by PGE2 has been shown to protect against 
Helicobacter-stimulated preneoplasia and promote persistent infection (Toller et al., 
2010). Induction of Th2 immune responses by concurrent helminth infection has 
been shown to be protective against Helicobacter-induced gastric atrophy, despite a 
robust inflammatory response and a high-degree of colonisation (Fox et al., 2000; 
Du et al., 2006), mirroring the response seen in PAI-1-/- mice. Characterisation of 
the cytokine and chemokine expression profiles of H. felis infected PAI-1-/-,        
PAI-1-H/Kβ and C57BL/6 corpus tissue, by microarray and/or qPCR, would 
provide clarification as to whether PAI-1 modulates the immune response to 
infection. Furthermore, analysis of serum antibody responses to H. felis in 
C57BL/6, PAI-1-/- and PAI-1-H/Kβ mice would also be useful, to explore this 
hypothesis.  
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In terms of myofibroblast recruitment to the corpus mucosa in response to H. felis 
infection, both PAI-1-/- and PAI-H/Kβ mice had attenuated responses. This may be 
relevant to the reduced histopathological response seen in these mice. Previous 
studies have implied an important role for mucosal myofibroblasts in supporting 
epithelial and immune responses to Helicobacter infection, driving preneoplastic 
histopathogenesis. Studies investigating responses to Helicobacter infection in 
humans and in rodent models have identified myofibroblasts as a source of COX-2, 
bFGF and IGF-II, and as essential activators of Th17 cells, suggesting that 
myofibroblasts modulate inflammatory, immune and proliferative responses to 
infection (Fu et al., 1999; Nakamura et al., 2002; Kim et al., 2004a; McCaig et al., 
2006; Pinchuk et al., 2013). An examination of the microarray data generated in the 
previous chapter might reveal other gene products secreted by gastric 
myofibroblasts that could modulate epithelial and immune cell responses to 
Helicobacter infection. Future studies might include an analysis of global gene 
expression profiles of laser capture microdissected gastric myofibroblasts from 
chronically infected C57BL/6, PAI-1-/- and PAI-H/Kβ gastric mucosal tissues, to 
identify differentially expressed PAI-1-regulated transcripts and pathways that may 
be of significance to Helicobacter-stimulated pathology. 
 
PAI-1 is profibrotic in various organs and is associated with increased 
myofibroblast abundance (Oda et al., 2001; Matsuo et al., 2005; Tuan et al., 2008; 
Hu et al., 2009; Senoo et al., 2010; Bauman et al., 2010; Ghosh & Vaughan, 2012). 
Conversely, and further illustrating the paradoxical nature of PAI-1 biology, aged 
PAI-1-deficient mice develop spontaneous cardiac fibrosis, associated with 
increased numbers of fibroblasts and endothelial-to-mesenchymal transition derived 
myofibroblasts (Ghosh et al., 2010). The data presented in this chapter suggest that 
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absence of PAI-1 and local increases in mucosal PAI-1 expression attenuate the 
recruitment of myofibroblasts in response to Helicobacter infection, providing 
novel insights into the relationship between PAI-1 and myofibroblast numbers in 
the stomach.  
 
In summary, the data presented in this chapter indicate that gastric PAI-1 protects 
against H. felis-stimulated histopathogenesis at elevated levels expressed in PAI-H/Kβ 
mice, compared to wild-type mice, whilst absence of PAI-1 is also protective. This 
raises the question of whether PAI-1 protects the gastric mucosa against acute 
mucosal injury with a similar profile. This will be investigated in the next chapter. 
 
5.5 Conclusions 
 
1. Absence of PAI-1 facilitates persistent colonisation of the antral mucosa by 
H. felis. 
2. Chronic H. felis infection does not alter antral mucosal morphology, 
regardless of PAI-1 expression. 
3. Absence of PAI-1 protects against H. felis-stimulated preneoplastic 
histopathogenesis. 
4. Elevated gastric expression of PAI-1 protects against H. felis-stimulated 
preneoplastic histopathogenesis. 
5. Absence of PAI-1 and elevated gastric expression of PAI-1 protect against 
increases in corpus mucosal myofibroblast abundance in response to H. felis 
infection. 
 
 
  
 
 
 
 
 
 
 
CHAPTER 6 
 
ROLE OF THE uPA SYSTEM IN 
GASTRIC MUCOSAL RESPONSES TO 
INTRAGASTRIC INDOMETHACIN 
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6.1 Introduction 
 
The uPA system modulates responses to tissue injury and regulates wound healing, 
through its roles in fibrinolysis and tissue remodelling, as described in section 1.6.4. 
The extracellular proteolytic activities of MMPs, and the inhibitory activities of tissue 
inhibitors of metalloproteinases (TIMPs), are known to regulate gastric mucosal 
injury, inflammation and healing. Expression of MMPs and TIMPs, and their 
activities, are altered in models of gastric mucosal injury, where MMP-2 and TIMP-1 
are protective, whilst TIMP-2, MMP-1, MMP-3, MMP-9 and MMP-13 are deleterious 
(Baragi et al., 1997; Lempinen et al., 2000; Ganguly et al., 2005; Kim et al., 2011; 
Singh et al., 2011; Pradeepkumar Singh et al., 2011; Sharma et al., 2012). However, 
little is known about the role of the uPA system in gastric mucosal protection, 
responses to gastric mucosal injury and gastric mucosal healing.  
 
The myofibroblast is an important mediator of wound repair. Myofibroblasts respond 
to tissue injury by migrating into the damaged tissue, where they generate force to 
contract the wound, produce ECM components and secrete various paracrine factors, 
including extracellular proteases and their inhibitors, growth factors, cytokines, 
chemokines and lipid products, to support re-epithelialisation, epithelial and stromal 
cell function and ECM remodelling activity during the wound healing process 
(Mahida et al., 1997; Serini & Gabbiani, 1999; Powell et al., 1999; Wu et al., 1999; 
Tomasek et al., 2002). In the previous chapter, it was shown that both absence of    
PAI-1 and increased gastric expression of PAI-1 attenuated myofibroblast recruitment 
to the gastric mucosa in H. felis infection. The role of the uPA system in myofibroblast 
recruitment following gastric mucosal injury remains to be elucidated. 
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NSAIDs elicit gastric mucosal injury via attenuation of prostaglandin-mediated 
gastric cytoprotective mechanisms, direct cytotoxic effects and other prostaglandin-
independent mechanisms (Wallace, 2008; Laine et al., 2008, Takeuchi, 2012). 
Consequently, both topical indomethacin, via intragastric administration, and 
systemically administered indomethacin produce gastric mucosal injury 
(Djahanguiri, 1969; Morise et al., 1999; Lempinen et al., 2000).  
 
Previous studies in this laboratory have demonstrated that PAI-1 is elevated in the 
gastric mucosa of aspirin and NSAID-treated patients and in ethanol and 
indomethacin-treated mice (Kenny et al., 2013b). Furthermore, PAI-1 is protective in 
an ethanol-induced model of gastric mucosal injury, whereas elevated gastric uPA and 
absence of uPAR aggravate ethanol-induced lesion development (Kenny, 2008; Kenny 
et al., 2013b). In this chapter, various mouse models are used to investigate the role of 
PAI-1, uPA and uPAR in the development of, and healing from, indomethacin-induced 
gastric mucosal injury. 
 
6.1.1 Aims and objectives 
 
The aim of the work in this chapter was to elucidate the role of the uPA system in 
responses to NSAID-induced injury and in healing of these lesions. The specific 
objectives were to: 
1. quantify the development of indomethacin-induced gastric mucosal 
haemorrhagic lesions in PAI-1-/-, PAI-1-H/Kβ, PAI-1-/-,TG+, uPA-H/Kβ and 
uPAR-/- mice compared to wild-type mice; 
2. determine the effects of exogenous PAI-1 on the development of indomethacin-
induced gastric mucosal haemorrhagic lesions; 
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3. compare changes in gastric mucosal myofibroblast abundance during healing 
of indomethacin-induced gastric mucosal haemorrhagic lesions in C57BL/6, 
PAI-1-/-, PAI-1-H/Kβ, PAI-1-/-,TG+, uPA-H/Kβ and uPAR-/- mice.  
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6.2 Methods 
 
6.2.1 Generation of PAI-1-/-,TG+ mice 
 
Mice expressing transgenic PAI-1 in the gastric mucosa, but otherwise null for PAI-1 
(PAI-1-/-, TG+) were generated by crossing PAI-1-/- with PAI-1-H/Kβ mice, as described 
in section 2.2.2.  
 
6.2.2 Indomethacin-induced lesions 
 
Male mice aged 10-13 weeks were dosed with indomethacin or vehicle, killed and 
stomachs prepared for lesion scoring, as described in section 2.2.4. In experiments 
involving PAI-1 or saline pre-treatment, animals were dosed by IP injection with 100µl 
of 2.5nmol/kg PAI-1 in saline (0.9% w/v NaCl) or saline alone, followed immediately 
by 20mg/kg intragastric indomethacin or vehicle.  
 
6.2.3 Histology  
 
Stomachs from indomethacin or vehicle treated mice were prepared for frozen sections 
followed by H&E staining, as described in section 2.3.  
 
6.2.4 Immunohistochemical assessment of myofibroblast abundance 
 
Male mice aged 10-12 weeks were dosed intragastrically with 10mg/kg indomethacin, 
20mg/kg indomethacin or vehicle, and were killed 6 hours, 3 days, 5 days or 7 days 
after treatment. Stomachs were prepared for frozen sections (section 2.3) and sections 
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prepared for immunohistochemical evaluation of vimentin abundance (sections 2.9 and 
2.12). Similarly, some sections were prepared for desmin immunohistochemistry, 
applying the same grading system used for vimentin to quantify abundance. 
 
6.2.5 Statistics 
 
Results are presented both as individual data points and group mean ± SEM, or median 
± range / interquartile range (IQR) for vimentin and desmin grades.  Comparisons 
were made using an unpaired two-tailed Student’s t-test or one-way ANOVA with 
Tukey’s post hoc analysis for multiple comparisons, or Kruskal-Wallis ANOVA on 
ranks test with Dunn’s post hoc analysis for multiple comparisons for vimentin and 
desmin grades, and were considered significant at P < 0.05. 
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6.3 Results  
 
6.3.1 Intragastric indomethacin induces deep haemorrhagic lesions within the 
gastric mucosa 
 
A model of indomethacin-induced gastric mucosal damage was employed to 
investigate the roles of PAI-1, uPA and uPAR using genetically modified mice. Initially, 
the protocol was optimised using C57BL/6 mice. In a previous study, intragastric 
indomethacin induced haemorrhagic lesions in a dose dependent manner from 5mg/kg 
to 20mg/kg and lesions were apparent between 6 and 18 hours after indomethacin 
administration (Morise et al., 1999). In the present study, indomethacin administered 
by gavage at a dose of 20mg/kg produced significant lesions in C57BL/6 mice after 6 
hours (Figure 6.2). There were multiple linear lesions, mostly within the corpus mucosa 
(Figure 6.1A). Histologically, these haemorrhagic lesions represented loci with deep 
mucosal injury and substantial epithelial cell death and exfoliation (Figure 6.1B).  
 
6.3.2 Myofibroblast abundance during healing from indomethacin induced lesions 
 
Myofibroblasts are known to be important mediators of wound healing, so their 
abundance in the gastric mucosa following indomethacin-induced injury was 
evaluated. The abundance of vimentin-expressing cells was not significantly different 
to untreated controls 3 or 5 days after intragastric indomethacin. After 7 days, there was 
a marked increase in vimentin-expressing cells within the corpus of 2 out of the 3 mice 
examined (Figure 6.3D). However, it became apparent during the course of these initial 
experiments that it would not be possible to continue with this procedure, owing to a 
mortality rate of >30% when animals were killed more than 24 hours after 20mg/kg        
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Figure 6.1. Deep mucosal haemorrhagic lesions develop following intragastric 
indomethacin. A: Multiple mucosal haemorrhagic lesions 6 hours after 
indomethacin treatment (arrows). The lesions were mostly limited to corpus tissue 
on all but the most severely injured tissues. B: H&E stained corpus from vehicle 
and indomethacin treated mice showed substantial epithelial cell loss and deep 
mucosal necrosis in haemorrhagic loci 6 hours after a 20mg/kg intragastric dose of 
indomethacin (indicated by arrow). Damage did not extend into the muscularis 
mucosae and submucosa. Scale bars = 200µm.  
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Figure 6.2 Intragastric indomethacin induces the development of 
significant haemorrhagic lesions. Lesion scores were significantly higher 6 
hours after treatment with 20mg/kg indomethacin compared to vehicle treated 
controls. Data for individual animals are shown in addition to mean ± SEM.   
** P < 0.01 (unpaired t-test). 
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Fig 6.3. Increased corpus mucosal myofibroblast abundance 7 days after 
20mg/kg intragastric indomethacin in some wild-type mice. A: Representative 
image of full corpus mucosal thickness vimentin immunostaining from a vehicle 
treated C57BL/6 mouse. B: Full corpus mucosal thickness vimentin distribution 
from a C57BL/6 mouse treated with 20mg/kg indomethacin, showing a marked 
increase in mucosal myofibroblasts 7 days after intragastric indomethacin. C: 
Representative image of full corpus mucosal thickness desmin staining, typically 
seen in all treatment groups. D: The abundance of corpus mucosal myofibroblasts 
markedly increased in 2 out of 3 C57BL/6 mice, 7 days after 20mg/kg 
indomethacin. E: In an experiment using 10mg/kg indomethacin to treat C57BL/6 
mice, the abundance of corpus mucosal myofibroblasts remained unchanged up to 7 
days.  F: The abundance of corpus mucosal desmin expressing cells did not change 
significantly up to 7 days after intragastric indomethacin administration. Data for 
individual animals are shown in addition to median ± range or IQR. Scale bars = 
100µm.  
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intragastric indomethacin. Post-mortem examination of the gastrointestinal tract 
revealed extensive intestinal bleeding in mice that had died during the course of these 
experiments. The experiment was repeated using 10mg/kg indomethacin, to investigate 
whether this dose of indomethacin could affect myofibroblast abundance during 
healing whilst eliminating mortality from the procedure. All animals survived 
following this dose of indomethacin. The abundance of both vimentin and desmin-
expressing cells within the corpus mucosa was analysed by immunohistochemistry and 
was not significantly different to untreated controls 6 hours or 7 days after 
indomethacin (Figure 6.3E-F). 
 
6.3.3 Gastric PAI-1 protects against indomethacin-induced mucosal injury 
 
Three separate genetically modified mouse models were used to investigate the role of 
PAI-1 in the development of indomethacin-induced haemorrhagic lesions, using the 
protocol optimised in C57BL/6 mice. In PAI-1-/- mice, significant lesions were 
produced by intragastric indomethacin compared to vehicle treated controls and 
furthermore, these mice developed significantly more lesions in response to 
indomethacin than C57BL/6 mice (Figure 6.4). 
 
To investigate the effect of increasing the expression of gastric PAI-1 on the 
development of indomethacin-induced gastric mucosal injury, the experiment was 
carried out in PAI-1-H/Kβ mice. PAI-1-H/Kβ mice did not develop significant lesions 
compared to vehicle treated controls (Figure 6.5), implying protection against injury by 
PAI-1. 
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Figure 6.4. Absence of PAI-1 exacerbates the formation of indomethacin-induced 
haemorrhagic lesions. A: Representative images of stomachs 6 hours after 
intragastric administration of 20mg/kg indomethacin to wild type and PAI-1-/- mice. 
Generally PAI-1-/- mice had visibly more extensive mucosal injury than C57BL/6 
mice. B: All PAI-1-/- mice developed lesions in response to intragastric 
indomethacin. PAI-1-/- mice, as a group, responded to indomethacin treatment with 
more severe gastric mucosal injury than wild-type animals. Data for individual 
animals are shown in addition to mean ± SEM. ** P < 0.01 (one-way ANOVA).   
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To further elucidate the role of PAI-1 encoded by the transgene in protection against 
indomethacin-induced gastric mucosal injury, PAI-1-H/Kβ and PAI-1-/- mice were 
crossbred, and the offspring backcrossed into PAI-1-/- mice to produce a strain in which 
only transgenic PAI-1 was expressed, i.e. null for wild-type PAI-1 (PAI-1-/-, TG+). These 
mice developed significant lesions in response to intragastric indomethacin, with 
significantly higher lesions scores than C57BL/6 mice (Figure 6.6). 
 
6.3.4 Exogenous PAI-1 exacerbates indomethacin-induced gastric mucosal 
injury 
 
To further elucidate the action of PAI-1 in gastric mucosal protection, the effect of 
exogenous PAI-1 on the development of indomethacin-induced haemorrhagic 
lesions was investigated. C57BL/6 mice were dosed with either 2.5nmol/kg PAI-1 or 
saline by IP injection followed immediately by 20mg/kg indomethacin or vehicle by 
gavage.  Mice treated with PAI-1 developed significantly more extensive mucosal 
damage than saline treated mice in response to intragastric indomethacin (Figure 6.7). 
 
6.3.5 Increased gastric expression of uPA has no effect upon the development 
of indomethacin-induced gastric mucosal injury 
 
To investigate the effect of increasing the expression of gastric uPA on the development 
of indomethacin-induced gastric mucosal injury, the experiment was carried out in 
uPA-H/Kβ mice. Utilising the same promoter used to drive expression of transgenic 
PAI-1 in PAI-1-H/Kβ mice, these mice express transgenic uPA in addition to wild-type 
uPA in gastric parietal cells. uPA-H/Kβ mice had a similar response to intragastric 
indomethacin as C57BL/6 mice in terms of lesion formation (Figure 6.8). 
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Figure 6.5 PAI-1-H/Kβ mice are protected against indomethacin-induced gastric 
mucosal injury. A: PAI-1-H/Kβ mice generally had visibly very weak mucosal 
injury or no visible injury in response to 20mg/kg intragastric indomethacin B: 
PAI-1-H/Kβ mice were protected against indomethacin-induced mucosal injury, 
with no significant increase in total lesion score compared to vehicle treated 
animals. Data for individual animals are shown in addition to mean ± SEM.  
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    A  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  C57BL/6           PAI-1-/-, TG+ 
 
 
                 B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Transgenic PAI-1 alone does not convey protection against 
indomethacin-induced gastric mucosal injury. A: Representative images of 
stomachs 6 hours after an intragastric dose of 20mg/kg indomethacin to wild type 
mice and mice expressing gastric transgenic PAI-1 but not wild type PAI-1       
(PAI-1-/-, TG+). Generally PAI-1-/-, TG+ mice had visibly more extensive mucosal 
injury than C57BL/6 mice. B: All PAI-1-/-,TG+ mice developed haemorrhagic lesions 
in response to intragastric indomethacin. As a group, these mice developed more 
severe mucosal injury than wild type mice. Data for individual animals are shown 
in addition to mean ± SEM.* P < 0.05 (one-way ANOVA).   
C5
7B
L/6
 ve
hic
le
C5
7B
L/6
 in
do
me
th
ac
in
PA
I-1
 -/-
 TG
+ v
eh
icl
e
PA
I-1
 -/-
 TG
+ i
nd
om
eth
ac
in
0
20
40
60
*
Le
si
on
 s
co
re
	  	   175	  
 
     A 
 
  
 
 
 
 
 
 
 
 
 
       
              
 
 
 
      Saline + indomethacin          PAI-1 + indomethacin 
 
          
         B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Exogenous PAI-1 exacerbates indomethacin-induced gastric 
mucosal injury. A: Representative images of C57BL/6 stomachs 6 hours after an 
IP injection of saline or 2.5nmol/kg PAI-1 immediately followed by 20mg/kg 
intragastric indomethacin.  Generally mice treated with PAI-1 developed more 
extensive mucosal injury than mice treated with saline. B: All mice treated with 
PAI-1 developed haemorrhagic lesions in response to intragastric indomethacin. As 
a group, mice treated with PAI-1 developed significantly more indomethacin-
induced lesions than those treated with saline. Data for individual animals are 
shown in addition to mean ± SEM. * P < 0.05, ** P < 0.01 (one-way ANOVA). 
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6.3.6 Absence of the uPA receptor tends to exacerbate indomethacin-induced 
gastric mucosal injury. 
 
To elucidate the role of uPAR in the development of indomethacin-induced lesions, 
uPAR-/- mice were dosed with indomethacin. Significant lesions were produced by 
intragastric indomethacin in uPAR-/- mice, compared to vehicle treated mice (Figure 
6.9B). There was much variability in the lesion scores of uPAR-/- mice in response to 
indomethacin, with some animals developing a high degree of mucosal damage, and 
generally uPAR-/- mice developed more extensive lesions than C57BL/6 mice (Figure 
6.9A & B). This did not reach statistical significance however (Figure 6.9B). 
 
6.4 Discussion 
 
NSAID-induced gastrointestinal bleeding is a significant clinical issue. 
Hospitalisations due to haemorrhagic ulcer complications are rising amongst the 
elderly population, in which NSAID use is most prevalent (Higham et al., 2002). 
The annual incidence of upper gastrointestinal complications associated with 
NSAID use is approximately 1%-1.5%, and mortality rates due to chronic NSAID 
treatment are estimated at between 0.045% and 0.083% (Tramer et al., 2000; Lanas 
et al., 2005; Laine et al., 2008). The uPA system critically regulates responses to 
tissue injury via its effects on fibrinolysis and tissue remodelling, yet little is             
currently known about the role of uPA, uPAR and PAI-1 in gastric mucosal injury 
and gastric mucosal healing. In a previous study, gastric PAI-1 was shown to be 
protective against gastric mucosal damage induced by ethanol, whereas increased 
gastric uPA expression and absence of uPAR both exacerbated lesion development            
a     
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Figure 6.8 uPA-H/Kβ mice have similar responses to intragastric indomethacin 
as wild-type mice. A: Representative images of stomachs 6 hours after an 
intragastric dose of 20mg/kg indomethacin to C57BL/6 and uPA-H/Kβ mice, 
showing a similar extent of mucosal damage in both strains. B: Wild-type and  
uPA-H/Kβ mice develop lesions to a similar degree. Data for individual animals are 
shown in addition to mean ± SEM.  
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Figure 6.9 uPAR-/- mice tend to develop more extensive gastric mucosal 
damage in response to intragastric indomethacin. A: Representative images of 
C57BL/6 and uPAR-/- stomachs 6 hours after 20mg/kg intragastric indomethacin. 
Visible mucosal injury of uPAR-/- stomachs was generally more extensive than wild 
type. B: Some uPAR-/- mice developed severe mucosal injury in response to 
intragastric indomethacin. However, the elevation in mean total lesion score of 
uPAR-/- mice as a group compared to wild type did not reach significance, owing to 
a large degree of variability in this strain. Data for individual animals are shown in 
addition to mean ± SEM. * P < 0.05 (one-way ANOVA).   
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(Kenny, 2008; Kenny et al., 2013b). The work presented in this chapter points to a 
role for PAI-1 in protection against indomethacin-induced gastric mucosal injury. 
 
Mucosal expression of uPA and PAI-1 has been shown to be increased and tPA 
expression decreased at the site of gastric and duodenal ulcers, with uPA being 
highest in patients with the greatest bleeding tendency (Wodziński et al., 1993; 
Herszenyi et al., 1997). Earlier studies provided evidence of increased mucosal 
plasminogen activator activity at gastric ulcer sites and increased plasma PAI-1 in 
patients with gastric ulcer (Cox et al., 1967; Kurose et al., 1990). Together these 
results imply a role for the fibrinolytic system in gastric mucosal injury. 
Furthermore, increased fibrinolytic activity of gastric juice and of the mucosa has 
been reported in gastroduodenal ulcer haemorrhage and elevated fibrinolysis has 
been associated with adverse outcomes in patients with upper gastrointestinal 
bleeding (Nilsson et al., 1975; Vreeburg et al., 2001; Gutierrez et al., 2001). 
Inhibition of fibrinolysis, which was significantly elevated at the ulcer edge mucosa 
by plasminogen activator activity, attenuated haemorrhage in a rat model of gastric 
ulcer (Stenberg et al., 1983a; Stenberg et al., 1983b). The findings presented in this 
chapter, together with evidence from previous studies, suggest that PAI-1 restrains 
fibrinolysis thereby decreasing haemorrhagic gastric mucosal injury. 
 
The importance of PAI-1 in stabilising the haemostatic response in vivo is 
highlighted by the existence of bleeding disorders in patients with PAI-1 deficiency 
(Schleef et al., 1989; Diéval et al., 1991; Lee et al., 1993; Minowa et al., 1999; 
Kuhli et al., 2005). PAI-1 is produced by platelet aggregates in the thrombus and 
binds platelet-associated fibrin, rendering it resistant to lysis and so maintaining the 
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integrity of the clot (Braaten et al., 1993). Increased bioavailability of PAI-1 at 
haemorrhagic loci might optimise the fibrinolytic response for haemostasis and 
rapid remodelling of the wound towards healing. Absence of PAI-1 may facilitate 
persistent fibrinolysis and maintain haemorrhage at lesion loci, accounting for the 
widespread lesions seen in PAI-1-/- gastric mucosa 6 hours after indomethacin 
treatment.  
 
One possibility for the similarities between gastric mucosal responses to 
indomethacin in wild-type and uPA-H/Kβ mice is that a compensatory reduction in 
gastric tPA expression, either as a result of expression of the uPA transgene or 
following indomethacin treatment, results in no net difference in the rate of 
fibrinolysis in the gastric mucosa of uPA-H/Kβ mice. To address this possibility, D-
dimer ELISA was performed on plasma samples from each of the treatment groups, 
to assess fibrinolytic activity following indomethacin treatment of each mouse 
strain. Unfortunately, this assay failed to yield meaningful results. An evaluation of 
gastric tPA expression by uPA-H/Kβ mice may help to clarify this point. 
Alternatively, gastric mucosal fibrinolytic activity in response to indomethacin 
treatment of each mouse strain could be determined by incubating samples of the 
gastric mucosa on fibrin plates (Jespersen & Astrup, 1983).  
 
An alternative hypothesis for the mechanism through which the uPA system exerts its 
effects on gastric mucosal injury is by modulating vascular permeability. Previous 
studies demonstrated that plasmin inhibitors attenuated the development of gastric 
mucosal lesions in response to 50% ethanol and 1% ammonia in rats and that this 
protection was associated with suppression of the increase in mucosal vascular 
permeability, independent of a prostaglandin-mediated mechanism (Murakami et al., 
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1989; Yoo et al., 1989). Furthermore, antithrombin-III has been shown to attenuate 
fibrinolytic activity and increased microvascular permeability and also protect against 
gastric mucosal injury in response to repeated electrical stimulation of the small 
arterial wall (Kurose et al., 1994). This suggests a role for plasmin in the development 
of gastric mucosal injury. The inhibitory activity of PAI-1 in the generation of plasmin 
may therefore account, at least in part, for the protective role of PAI-1, via a reduction 
in plasmin-induced increases in mucosal vascular permeability in response to 
indomethacin. 
 
In order to elucidate the role of gastric PAI-1 in cytoprotection, indomethacin-induced 
lesion formation in response to transgenic PAI-1 alone was investigated. Responses to 
intragastric indomethacin in PAI-1-/-, TG+ mice were similar to PAI-1-/- mice, implying 
that the contribution of wild-type PAI-1 to the overall expression of PAI-1 in the 
stomachs of PAI-1-H/Kβ mice is essential for the gastric cytoprotective phenotype seen 
in this strain. Furthermore, expression of the transgene alone does not produce enough 
PAI-1 in the stomach to endow any protection against indomethacin-induced lesion 
development, rendering these mice more susceptible to gastric mucosal injury than 
wild-type mice. In a previous study, it was shown that gastric tissue of PAI-1-H/Kβ 
mice expresses significantly more total PAI-1 mRNA than that of wild-type mice 
(Kenny et al., 2013a). It would be useful to extend this analysis to look at total PAI-1 
mRNA expression by gastric tissues of PAI-1-/- and PAI-1-/-, TG+ mice and also to 
quantify the expression of total PAI-1 protein by gastric tissues of wild-type, PAI-1-/-, 
PAI-1-H/Kβ and PAI-1-/-, TG+ mice, to establish whether responses to indomethacin are 
directly linked to the generation of PAI-1 by gastric tissues.  
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Contrary to the effects of increased gastric PAI-1, exogenous PAI-1 exacerbated 
lesion development when administered by IP injection. There are a number of issues 
that need to be kept in mind in interpreting these observations. For one thing, the 
present studies used a stabilised mutant of human PAI-1, while PAI-1-H/Kβ mice 
over-express the wild-type mouse sequence. There are potential differences in 
glycosylation, folding of the stabilised active form compared to the latent form and 
species-specific structures of the exogenous and endogenous proteins that may 
account for the apparent differences mucosal protection. In addition, PAI-1 may 
exhibit a U-shaped dose-response curve. This principle underpins the concept of 
adaptive cytoprotection, whereby exposure of the gastric mucosa to a low dose of a 
necrotising agent (mucosal irritant) or mild stress actually primes the cytoprotective 
mechanisms, so that the mucosa is protected against exposure to a more noxious dose 
of the same or another necrotising agent or severe stress.  
 
Adaptive cytoprotection has been widely attributed to an increase in prostaglandin-
mediated gastroprotective mechanisms in vivo and in isolated gastric cells (Konturek 
et al., 1982; Robert et al., 1983; Orihata et al., 1989; Brzozowski et al., 2000; 
Takeuchi et al., 2001; Tsutsumi et al., 2003). Given that increased expression of   
PAI-1 has been shown to protect against indomethacin-induced injury, the protection 
afforded by gastric PAI-1 must be independent of prostaglandin production. Some 
studies have reported that there is still an adaptive cytoprotective response following 
suppression of prostaglandin production with NSAIDs, so it may be that gastric PAI-1 
elicits adaptive cytoprotection via alternative mechanisms, such as the formation of a 
protective layer of surface epithelial debris, modulation of surface-active phospholipid 
availability, heat shock protein induction, stimulation of mucus and/or bicarbonate 
production, by increasing NO production or by increasing the rate of epithelial cell 
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restitution in response to mucosal injury (Hawkey et al., 1988; Wallace, 1988; 
Nakamura et al., 1991; Lugea et al., 1994; Mutoh et al., 1995; Konturek, 1997; 
Tanaka et al., 2004; Gambero et al., 2007). The precise nature of how PAI-1 might act 
as an irritant to the gastric mucosa, eliciting cytoprotection at low concentrations such 
as those produced by expression of both wild-type and transgenic PAI-1, but 
exacerbating indomethacin-induced injury at high exogenous concentrations, requires 
further investigation.  
 
An alternative hypothesis for the opposing effects of gastric PAI-1 expression and 
exogenous PAI-1 administration involves the cytoprotection-mediating activity of the 
vagus nerve. Animals having undergone acute surgical vagotomy consistently 
developed more severe mucosal lesions in response to various necrotising agents, had 
impaired prostaglandin and glutathione production in response to a necrotising dose of 
ethanol and displayed a reversal of cytoprotection by various mediators, including 
prostaglandins, β-carotene, atropine and cimetidine (Mozsik et al., 1991; Suto et al., 
1992; Karadi et al., 1999; Karadi et al., 2001; Mozsik et al., 2001). An increase in 
vascular permeability in response to exposure to necrotising agents following 
vagotomy has been proposed to account, at least in part, for the more severe responses 
seen in these animals (Mozsik et al., 1992; Karadi et al., 1999; Karadi et al., 2001). 
Furthermore, both endogenous and exogenous CCK, acting via CCK-1 receptors, 
have been shown to be gastroprotective via a mechanisms involving vagal capsaicin-
sensitive afferent fibres and cholinergic efferent fibres and eliciting a local hyperaemic 
response mediated by CGRP and NO (Evangelista & Maggi, 1991; Konturek et al., 
1995; Heinemann et al., 1996). Taken together, the results of these studies imply a 
crucial role for stimulation of the vago-vagal reflex by CCK in gastric cytoprotection. 
A previous study has shown that IP administration of PAI-1, at the same dose used in 
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these experiments, inhibited the satiety effects of CCK and was associated with a 
reduction in the number of c-fos-expressing neurons in the nucleus tractus solitarius, a 
marker of vagal afferent neuronal activation (Kenny et al., 2013a). This implies that 
IP administration of PAI-1 at this dose inhibits activation of the vago-vagal reflex by 
CCK, and may account for the more severe indomethacin-induced gastric mucosal 
injury observed after exogenous PAI-1. Studies might now be conducted in wild-type 
mice to examine the effects of CCK alone and co-administration of CCK and PAI-1 
on the development of indomethacin-induced injury, to test this hypothesis.  
 
CCK-stimulated vago-vagal reflexes are attenuated in PAI-1-H/Kβ mice (Kenny et 
al., 2013a), so inhibition of this pathway by gastric PAI-1 seems at odds with the 
gastroprotection seen in these mice. Local gastroprotective activity of PAI-1 produced 
at the mucosa might have a net dominant effect over the inhibition of cytoprotection 
mediated by the vagus nerve. The potential contribution of gastric PAI-1 to 
gastroprotection via inhibition of extracellular plasmin generation has been discussed 
and may account for the balance towards cytoprotection in PAI-1-H/Kβ mice. 
Alternatively, it is possible that mucosal PAI-1 influences intracellular signalling via 
uPAR, favouring cytoprotective mechanisms such as enhanced epithelial cell 
proliferation and/or migration, suppression of extracellular protease synthesis by 
epithelial or stromal cells, suppression of hydrochloric acid secretion or enhanced 
secretion of mucus and/or bicarbonate. PAI-1-stimulated cytoprotective intracellular 
signalling pathways via uPAR could account for the more severe mucosal injury 
observed in uPAR-/- mice in response to intragastric ethanol (Kenny, 2008) and the 
tendency towards increased lesion development in response to indomethacin observed 
in this study.  
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The data presented in this chapter provides new insights into the role of the uPA 
system, particularly PAI-1, in gastric mucosal protection and responses to NSAID 
injury. This information has potential translational utility; in elucidating balance of 
expression of components of the uPA system that optimally protects the gastric 
mucosa against NSAID injury, therapeutic agents may be developed that prime the 
uPA system for gastroprotection. Such agents would reduce the risks associated with 
NSAID treatment, improving clinical outcomes for patients requiring chronic NSAID 
treatment.  
 
6.5 Conclusions 
 
1. Gastric PAI-1 is protective against indomethacin-induced mucosal injury. 
2. Gastric PAI-1 may act via uPAR to protect the gastric mucosa against 
indomethacin-induced mucosal injury. 
3. Exogenous PAI-1 exacerbates indomethacin-induced gastric mucosal injury. 
4. Increased gastric uPA expression has no effect upon the development of 
indomethacin-induced mucosal injury. 
5. Increases in corpus mucosal myofibroblast abundance become apparent 
between 5 and 7 days after injury induced by 20mg/kg intragastric 
indomethacin. 
 
 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 7 
 
DISCUSSION 
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7.1 Overview 
 
The main findings of this thesis are: a) mice over-expressing PAI-1 in the gastric 
mucosa develop age-dependent increases in corpus mucosal thickness, 
independently of changes in parietal cell or myofibroblast abundance; b) mucosal 
hyperplasia in these mice is not due to a direct trophic action of PAI-1 on gastric 
epithelial cells; c) there is a highly heterogeneous population of myofibroblast-like 
cells in the mouse antral mucosa; d) mouse antral myofibroblasts in culture express 
markers of a neuroendocrine-like phenotype; e) both absence of PAI-1 and over-
expression of gastric PAI-1 protect against mucosal responses to murine H. felis 
infection; f) absence of PAI-1 exacerbates the development of lesions in a murine 
model of acute gastric injury induced by intragastric indomethacin, whilst (g) 
expression of PAI-1 in the stomach of transgenic mice protects against 
indomethacin-induced injury; h) increased expression of gastric uPA has no effect 
upon indomethacin-induced injury, whilst i) mice lacking uPAR tend to develop 
more lesions. 
 
7.2 Conceptual advances and future studies  
 
The uPA system has well characterised roles in regulating tissue homeostasis, 
wound healing, fibrosis, inflammation, and cancer, via regulation of plasmin-
mediated extracellular proteolysis as well its effects upon cell adhesion, migration 
and signalling (Andreasen et al., 2000; Smith & Marshall, 2010). However, its role 
in gastric mucosal tissue homeostasis and responses to acute and chronic challenges 
has not been investigated. This work presented in this thesis contributes to the 
elucidation of the role of PAI-1 in acute responses to gastric mucosal injury and 
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chronic Helicobacter-induced preneoplastic histopathology, as well as its role in 
shaping gastric corpus mucosal morphology in the absence of challenge. This thesis 
showed that PAI-1 is protective both in acute responses to NSAID-induced gastric 
injury, and in responses to chronic H. felis infection. Furthermore, absence of PAI-1 
was also protective against H. felis-induced histopathogenesis. Increased gastric 
PAI-1 expression induced age-dependent increases in mucosal thickness, in the 
absence of challenge. However, the epithelial cell dynamics underlying these 
gastric mucosal phenotypes remains to be established.  
 
The work presented in this thesis demonstrated that PAI-1 does not directly 
modulate proliferation of gastric epithelial cells. Previous work in this laboratory 
determined that PAI-1 suppresses Helicobacter-stimulated proliferation of gastric 
epithelial cells, via inhibition of uPA-mediated proteolytic release of HB-EGF 
(Kenny et al., 2008).  However, it is still not known how PAI-1 regulates 
proliferation in vivo. It might be hypothesised that PAI-1 stimulates proliferation in 
vivo, based on the observation that PAI-1-H/Kβ mice develop increased corpus 
mucosal thickness. This could be relevant to the role of PAI-1 in protection against 
gastric mucosal injury, a situation where accelerated epithelial restitution would be 
beneficial (Lacy & Ito, 1984; Konturek, 1990). Furthermore, absence of PAI-1 
might inhibit Helicobacter-induced proliferation, a hallmark of early pre-neoplastic 
histopathogenesis (Lynch et al., 1995; Fox et al., 1996; McNamara & El-Omar, 
2008), and may account in part for the protection seen in PAI-1-/- mice. In order to 
test these hypotheses, determination of in vivo epithelial cell proliferation in the 
gastric mucosa of unchallenged PAI-1-H/Kβ mice compared to wild-type and    
PAI-1-/- mice, in chronically H. felis-infected wild-type, PAI-1-/- and PAI-1-H/Kβ 
mucosa and in acute responses to indomethacin-induced injury of the gastric 
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mucosa of wild-type, PAI-1-/- and PAI-1-H/Kβ mice is required. Incorporation of 
EdU into the gastrointestinal mucosa in live animals has been used as a marker of 
in vivo epithelial cell proliferation previously (Salic & Mitchison, 2008). Similar 
methods were used in this thesis, in pilot studies investigating whether pleiotrophin 
stimulates proliferation in vivo. This method could be expanded into the proposed 
studies.  
 
Another important element of epithelial cell dynamics that could be relevant to the 
phenotypes reported in this thesis is apoptosis. PAI-1 may influence epithelial cell 
turnover via modulation of apoptosis in the gastric mucosa, contributing to 
increased mucosal thickness of PAI-1-H/Kβ mice. Similarly, modulation of 
apoptosis by PAI-1 may contribute to the resistance against injurious responses to 
acute and chronic gastric mucosal insult observed in PAI-1-H/Kβ mice. 
Helicobacter-stimulated preneoplastic histopathogenesis is associated with 
increased apoptosis of gastric epithelial cells (Moss et al., 1996; Wang et al., 1998; 
Court et al., 2003). Similarly, acute gastric mucosal injury is associated with 
increases in epithelial apoptosis, and agents that prevent mucosal injury work in 
part by attenuating this increase in apoptosis (Piotrowski et al., 1997; Slomiany et 
al., 1997; Jones et al., 2008; Hirata et al., 2009). Based on the results presented in 
this thesis, it might be hypothesised that PAI-1 negatively regulates apoptosis, thus 
protecting the gastric mucosa. Since the basal rate of epithelial cell apoptosis is 
already very low in the gastric mucosa, a highly sensitive method would need to be 
employed to detect and quantify apoptotic cells. A qPCR-based method has been 
developed for the absolute quantification of apoptotic DNA in a population of cells, 
which might be used to compare total quantities of apoptotic cells in freshly 
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isolated gastric epithelial cell populations from whole corpus tissues (Hooker et al., 
2012).  
 
Another factor to consider in interpreting the phenotypes reported in PAI-1-H/Kβ 
mice is that these mice are likely to develop adaptive changes to persistent 
elevations in gastric PAI-1 expression, which might confound the analysis. In order 
to determine the effects of increased gastric PAI-1 in isolation on gastric mucosal 
responses to insult, models of inducible transgenic PAI-1 need to be developed. A 
commonly used technique for temporally controlled gene expression in transgenic 
mouse models is the tamoxifen-inducible Cre-loxP recombination system, which 
can be used to activate transgenes prenatally and postnatally (Hayashi & McMahon, 
2002). Using this technology, expression of the gastric PAI-1 transgene could be 
induced immediately prior to administration of indomethacin. This model could 
also be used to determine the role of increased gastric PAI-1 in shaping the adult 
gastric mucosal phenotype during mucosal morphogenesis in the developing mouse 
stomach, by inducing the gastric PAI-1 transgene at various stages of embryonic 
and postnatal development. These studies may provide some insights into early 
influences on the development age-dependent increases in corpus mucosal 
thickness in PAI-1-H/Kβ mice.  
 
One of the approaches used in this thesis to investigate how PAI-1 might modulate 
the mucosal microenvironment was to examine corpus mucosal myofibroblast 
abundance of wild-type, PAI-1-/- and PAI-1-H/Kβ mice. This was determined in the 
unchallenged gastric mucosa, in responses to Helicobacter infection and in 
responses to indomethacin-induced injury. The rationale for this was that 
myofibroblasts are important mediators of epithelial-mesenchymal interactions 
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involved in regulating the gastrointestinal mucosal microenvironment (Valentich & 
Powell, 1994; Powell et al., 1999; Wu et al., 1999; Powell et al., 2005; Powell et 
al., 2011). Myofibroblast abundance was not altered in the absence of PAI-1 or by 
increased gastric PAI-1 expression under basal conditions, but in response to 
Helicobacter infection, both absence of PAI-1 and increased gastric PAI-1 
expression protected against increased myofibroblast abundance. Attempts were 
also made to characterise changes in myofibroblast abundance in response to 
indomethacin treatment, but changes were only detectable beyond the ethical end-
point, owing to mortality associated with responses to indomethacin. Therefore, 
alternative approaches are required to investigate gastric mucosal myofibroblast 
dynamics in response to indomethacin treatment, to provide further elucidation into 
the role of PAI-1 in regulating myofibroblast recruitment to the gastric mucosa. 
 
One possible alternative approach could be based on long-term three-dimensional 
models of cultured gastric glands that have recently been developed, in which the 
stem cell niche is maintained by interactions between epithelial cells and 
myofibroblasts, for up to 3 months (Katano et al., 2013). This is currently the best 
available model for recapitulating the gastric mucosal microenvironment in vitro 
and could potentially be informative in characterising myofibroblast responses to 
acute gastric epithelial injury. However, certain inherent limitations exist with this 
model, including loss of diversity of differentiated gastric epithelial cell 
populations, accelerated epithelial cell turnover and lack of stromal complexity 
compared to the intact gastric gland. Nevertheless, three-dimensional cultures of 
gastric glands from wild-type, PAI-1-/- and PAI-1-H/Kβ mice could be established, 
to compare features of the longer-term responses to epithelial injury, such as 
myofibroblast recruitment and epithelial dynamics. 
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Questions still remain as to how expression of PAI-1 in the gastric mucosa 
modulates the mucosal microenvironment, which may be relevant to the basal 
epithelial cell turnover, responses to Helicobacter infection and responses to 
indomethacin-induced injury. Secretomes of gastric epithelial cells and 
myofibroblasts, as well as other stromal cells, determine the gastric 
microenvironment, hence if PAI-1 were to modulate expression of secreted 
proteins, the microenvironment would be altered. In order to investigate the effects 
of PAI-1 in the gastric microenvironment on myofibroblast gene expression, 
particularly relating to secreted proteins, whole genome microarrays were 
undertaken on wild-type and PAI-1-/- gastric myofibroblasts. The rationale for this 
work was to identify differentially expressed transcripts of secreted proteins that 
might modulate gastric epithelial cell turnover, based on the observation that     
PAI-1-H/Kβ mice develop increased corpus mucosal thickness. As discussed in 
chapter 4, further work is required to identify such transcripts from the microarray 
data and test the functional significance of their secretion into the gastric mucosal 
microenvironment. Transcripts of particular interest include DPP4 and pleiotrophin, 
for which some initial functional studies were undertaken during the preparation of 
this thesis. Furthermore, the microarray data could be examined to identify 
differentially expressed transcripts that might be significant in protection against 
indomethacin-induced injury by gastric expression of PAI-1, or in protection 
against Helicobacter-induced histopathology. 
 
A major limitation in interpreting the physiological relevance of the microarray data 
is that it is increasingly recognised that myofibroblasts are likely to adapt to culture 
conditions, deviating from their in vivo phenotypes. Furthermore, it is likely that 
heterogeneity of the gastric mucosal myofibroblast population in vivo is lost in 
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culture owing to selective adaptation to the in vitro microenvironment. These 
phenomena, discussed in more detail in section 4.4, highlight the benefits of 
performing studies in vivo, or at least of developing in vitro models that recapitulate 
the complexity of epithelial-stromal interactions in vivo. Based on this reasoning, it 
might be preferable to use laser capture microdissection to select all myofibroblasts 
from intact tissue samples, in order to conduct gene expression studies in the future. 
This approach has been used successfully to characterise gene expression by 
isolated gastric CAFs, whole gastric cancer stroma, gastric cancer cells and specific 
gastric epithelial cell populations (Kazumori et al., 2001; Wu et al., 2005; Resnick 
et al., 2006; Makino et al., 2008; Sung et al., 2011). This technique could be used 
to extract gastric mucosal myofibroblasts from Helicobacter-infected and 
indomethacin-treated mice, as well as from unchallenged mice, to identify 
differentially expressed transcripts that might be relevant to the phenotypes 
reported in this thesis. 
 
A more direct measurement of altered secretomes from PAI-1-/- and PAI-1-H/Kβ 
myofibroblasts, compared to wild-type, might involve utilising proteomic 
techniques, such as isobaric tags for relative and absolute quantification or stable 
isotope labeling by amino acids in cell culture, on conditioned media from low 
passage cultured gastric myofibroblasts. These techniques have previously been 
used to compare the secretomes of gastric CAMs with those of ATMs (Holmberg et 
al., 2012; Holmberg et al., 2013). These techniques might also be used to 
characterise the secretomes of gastric epithelial cells and other gastric mucosal 
stromal cell populations. Information about the secretomes of gastric epithelial 
cells, myofibroblasts and other stromal cell populations might then be integrated to 
generate a model of the gastric mucosal microenvironment in the unchallenged 
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mucosa, in responses to Helicobacter infection and responses to indomethacin-
induced injury, and its modulation by gastric PAI-1 expression. Alternatively, 
proteomic analysis of conditioned media from three-dimensional gastric gland 
cultures might be utilised, as an integrated model of epithelial-myofibroblast 
interactions in the mucosal microenvironment.  
 
The data presented in this thesis imply that myofibroblasts in the antral mucosa 
exist as a highly heterogeneous population. It is possible that phenotypically 
distinct myofibroblasts and myofibroblast-like cells differentially regulate the 
gastric mucosal microenvironment. Further phenotypic characterisation of the 
antral mucosal myofibroblast population might facilitate functional studies on these 
cells. Following identification of cell-specific markers, it might be possible in 
future to ablate individual populations of myofibroblasts and myofibroblast-like 
cells, using techniques similar to those used to target and ablate parietal cells and 
peritoneal fibroblasts (Li et al., 1996; Okada et al., 2003; Powell et al., 2011). In 
this way, the functional significance of these myofibroblast sub-populations in the 
unchallenged gastric mucosa and in responses to Helicobacter and indomethacin 
might be determined.  
 
It is important to consider that other stromal cell populations, as well as 
myofibroblasts, shape the gastric mucosal microenvironment. Paracrine secretions 
from inflammatory, immune and vascular cells, as well as endocrine and neural inputs, 
are key determinants of epithelial-stromal interactions maintaining basal mucosal 
morphology and responses to acute and chronic mucosal insults. With this in mind, 
future work might be directed towards investigating inflammatory responses during 
indomethacin-induced gastric mucosal injury in the mouse strains used in this thesis. 
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Pro-inflammatory cytokines and PGE2 stimulate expression of uPA and uPAR by 
gastric fibroblasts, whilst indomethacin suppresses their expression (Iwamoto et al., 
2003). Furthermore, expression of gastric PAI-1 is increased in biopsies from patients 
treated with NSAIDs compared to non-NSAID treated patients, and in response to 
indomethacin in mice (Kenny et al., 2013b). This might imply a role for the uPA 
system in the acute inflammatory response to gastric injury, and may in part account 
for the deleterious effect of indomethacin on the gastric mucosa. 
 
The molecular mechanisms that mediate protection by PAI-1 in responses to acute 
and chronic insult remain to be determined. PAI-1 is able to modulate molecular 
interactions via uPAR, independently of interactions with uPA, as well as via uPA-
mediated molecular interactions (Andreasen et al., 2000; Smith & Marshall, 2010). 
Some insight has been gained into the role of uPAR in mediating protection against 
mucosal injury. The data presented in this thesis showed that uPAR-/- mice tended to 
develop more extensive mucosal injury in response to indomethacin. In previous 
studies conducted in this laboratory, uPAR-/- mice developed significantly more 
severe gastric mucosal injury in response to ethanol (Kenny, 2008). These 
observations suggest that uPAR might mediate protective mechanisms induced by 
increased gastric expression of PAI-1. Interpreting the role of uPA in regulating the 
balance between gastric mucosal defence and injury is less straightforward;      
uPA-H/Kβ mice developed lesions with similar severity as wild-type mice in 
response to indomethacin, but developed significantly more severe injury in 
response to ethanol (Kenny, 2008).  In order to gain similar insights into the role 
uPA- and uPAR-mediated pathways of PAI-1 activity in Helicobacter infection, 
chronic H. felis studies need to be conduced in uPAR-/- and uPA-H/Kβ mice. Given 
that gastric expression of both uPA and uPAR are elevated in response to 
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Helicobacter infection, increases in gastric PAI-1 expression might function to 
counteract deleterious activities of these proteins, such as proliferation via EGFR 
(Kenny et al., 2008). 
 
Certain point mutations in the PAI-1 gene are known to render the protein deficient 
in vitronectin binding activity (PAI-1Q123K or PAI-1Q123K,R101A ), LRP-binding 
activity (PAI-1R76E) or tPA/uPA-inhibiting activity (PAI-1R346M,M347S or PAI-1R346A) 
(Shubeita et al., 1990; Lawrence et al., 1994; Stefansson et al., 1998; Xu et al., 
2004). Utilising the same methodology used to generate PAI-1-/-,TG+ mice (see 
section 2.2.2), mice expressing these PAI-1 mutant isoforms in the gastric mucosa 
could be generated, free of systemic and gastric wild-type PAI-1 expression. A 
similar strategy has been used to generate transgenic mice expressing PAI-1 mutant 
isoforms under the control of the murine preproendothelin-1 promoter (Eren et al., 
2007). Responses to chronic H. felis infection and to indomethacin-induced injury 
by mice expressing mutated PAI-1, compared to PAI-1-/-,TG+ mice, might elucidate 
the relative contributions of proteolytic and non-proteolytic pathways of PAI-1 
regulatory activities in histopathological responses to Helicobacter infection and in 
responses to indomethacin. 
 
Some of the results presented in this thesis support previous studies reporting the 
paradoxical nature of PAI-1 biology, which renders its role in any tissue 
microenvironment highly dependent upon its bioavailability. In this thesis, both 
absence of PAI-1 and increased PAI-1 protected against Helicobacter-induced 
gastric histopathology. Whilst endogenous gastric PAI-1 expression had no effect 
upon IGF-II stimulated proliferation of gastric epithelial cells, exogenous PAI-1 
suppressed its effects. Furthermore, contrary to the protective effects of gastric    
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PAI-1, exogenous PAI-1 exacerbated lesion development in response to 
indomethacin. However, many factors need to be considered when interpreting the 
results of experiments using exogenous PAI-1. Given the complex biology of    
PAI-1, deviations from the molecular structure of endogenous PAI-1, such as 
glycosylation, stability and species-specific protein structure, might have profound 
effects upon the molecular interactions of exogenous PAI-1 within the gastric 
mucosal microenvironment, so that it may not represent the physiological activities 
of endogenous PAI-1 in the gastric mucosa. This again highlights the benefits of 
developing robust in vivo models of inducible PAI-1 expression, to investigate the 
role of PAI-1 in regulating the gastric mucosal microenvironment and determining 
gastric mucosal responses.  
 
Taken together, the data presented in this thesis deliver evidence of a broadly 
protective role of PAI-1 in the gastric mucosa. Although the mechanisms through 
which PAI-1 modulates the gastric mucosal microenvironment to endow protection 
against acute and chronic insults may be distinct from each other, a common 
therapeutic strategy for the prevention of NSAID-induced gastric injury, ulcer 
complications and progression of Helicobacter-induced gastric preneoplasia might 
be emerging, aimed at specifically increasing PAI-1 bioavailability in the gastric 
mucosa. 
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Affymetrix	  ID	   Gene	  Symbol	   Gene	  Title	  
Fold-­‐
change	  
(PAI-­‐1-­‐/-­‐	  :	  
C57BL/6)	  
1434484_at	   1100001G20Rik	   RIKEN	  cDNA	  1100001G20	  gene	   -­‐6	  
1460049_s_at	   1500015O10Rik	   RIKEN	  cDNA	  1500015O10	  gene	   -­‐67	  
1456158_at	   2610109H07Rik	   RIKEN	  cDNA	  2610109H07	  gene	   -­‐9	  
1427054_s_at	   Abi3bp	   ABI	  gene	  family,	  member	  3	  (NESH)	  binding	  protein	   -­‐40	  
1421171_at	   Adam12	   a	  disintegrin	  and	  metallopeptidase	  domain	  12	  (meltrin	  alpha)	   -­‐61	  
1447946_at	   Adam23	   a	  disintegrin	  and	  metallopeptidase	  domain	  23	   -­‐5	  
1444628_at	   Adam33	   a	  disintegrin	  and	  metallopeptidase	  domain	  33	   4	  
1419476_at	   Adamdec1	   ADAM-­‐like,	  decysin	  1	   4	  
1456901_at	   Adamts20	  
a	  disintegrin-­‐like	  and	  metallopeptidase	  
(reprolysin	  type)	  with	  thrombospondin	  type	  
1	  motif,	  20	  
-­‐15	  
1452595_at	   Adamts4	  
a	  disintegrin-­‐like	  and	  metallopeptidase	  
(reprolysin	  type)	  with	  thrombospondin	  type	  
1	  motif,	  4	  
-­‐3	  
1437785_at	   Adamts9	  
a	  disintegrin-­‐like	  and	  metallopeptidase	  
(reprolysin	  type)	  with	  thrombospondin	  type	  
1	  motif,	  9	  
-­‐8	  
1430313_at	   Adamtsl1	   ADAMTS-­‐like	  1	   -­‐93	  
1417765_a_at	   Amy1	   amylase	  1,	  salivary	   -­‐4	  
1439066_at	   Angpt1	   angiopoietin	  1	   -­‐6	  
1455224_at	   Angptl1	   angiopoietin-­‐like	  1	   -­‐8	  
1417130_s_at	   Angptl4	   angiopoietin-­‐like	  4	   -­‐3	  
1451478_at	   Angptl7	   angiopoietin-­‐like	  7	   8	  
1416371_at	   Apod	   apolipoprotein	  D	   -­‐4	  
1432466_a_at	   Apoe	   apolipoprotein	  E	   -­‐5	  
1427996_at	   BC028528	   cDNA	  sequence	  BC028528	   -­‐13	  
1422168_a_at	   Bdnf	   brain	  derived	  neurotrophic	  factor	   13	  
1422912_at	   Bmp4	   bone	  morphogenetic	  protein	  4	   7	  
1450759_at	   Bmp6	   bone	  morphogenetic	  protein	  6	   10	  
1429273_at	   Bmper	   BMP-­‐binding	  endothelial	  regulator	   3	  
1435541_at	   Btc	   betacellulin,	  epidermal	  growth	  factor	  family	  member	   4	  
1451620_at	   C1ql3	   C1q-­‐like	  3	   5	  
1431079_at	   C1qtnf2	   C1q	  and	  tumor	  necrosis	  factor	  related	  protein	  2	   8	  
1422606_at	   C1qtnf3	   C1q	  and	  tumor	  necrosis	  factor	  related	  protein	  3	   -­‐47	  
1417050_at	   C1qtnf4	   C1q	  and	  tumor	  necrosis	  factor	  related	  protein	  4	   -­‐4	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1431856_a_at	   C1qtnf6	   C1q	  and	  tumor	  necrosis	  factor	  related	  
protein	  6	  
-­‐3	  
1416051_at	   C2	   complement	  component	  2	  (within	  H-­‐2S)	   15	  
1423954_at	   C3	   complement	  component	  3	   -­‐7	  
1418021_at	   C4b	   complement	  component	  4B	  (Childo	  blood	  group)	   -­‐6	  
1418037_at	   C4bp	   complement	  component	  4	  binding	  protein	   28	  
1451625_a_at	   C8g	   complement	  component	  8,	  gamma	  polypeptide	   -­‐6	  
1452004_at	   Calca	   calcitonin/calcitonin-­‐related	  polypeptide,	  alpha	   209	  
1422639_at	   Calcb	   calcitonin-­‐related	  polypeptide,	  beta	   3	  
1419691_at	   Camp	   cathelicidin	  antimicrobial	  peptide	   -­‐9	  
1419473_a_at	   Cck	   cholecystokinin	   13	  
1417789_at	   Ccl11	   chemokine	  (C-­‐C	  motif)	  ligand	  11	   -­‐35	  
1420380_at	   Ccl2	   chemokine	  (C-­‐C	  motif)	  ligand	  2	   -­‐11	  
1418126_at	   Ccl5	   chemokine	  (C-­‐C	  motif)	  ligand	  5	   -­‐39	  
1421228_at	   Ccl7	   chemokine	  (C-­‐C	  motif)	  ligand	  7	   -­‐21	  
1419684_at	   Ccl8	   chemokine	  (C-­‐C	  motif)	  ligand	  8	   -­‐9	  
1417936_at	   Ccl9	   chemokine	  (C-­‐C	  motif)	  ligand	  9	   -­‐102	  
1417314_at	   Cfb	   complement	  factor	  B	   -­‐8	  
1450876_at	  
Cfh	  ///	  
LOC1000480
18	  
complement	  component	  factor	  h	  ///	  similar	  
to	  complement	  component	  factor	  H	   5	  
1434201_at	   Chrdl1	   chordin-­‐like	  1	   3	  
1425769_x_at	   Cklf	   chemokine-­‐like	  factor	   -­‐3	  
1418980_a_at	   Cnp	   2',3'-­‐cyclic	  nucleotide	  3'	  phosphodiesterase	   -­‐3	  
1418599_at	   Col11a1	   collagen,	  type	  XI,	  alpha	  1	   -­‐5	  
1446326_at	   Col1a2	   collagen,	  type	  I,	  alpha	  2	   -­‐6	  
1448590_at	   Col6a1	   collagen,	  type	  VI,	  alpha	  1	   -­‐9	  
1452250_a_at	   Col6a2	   collagen,	  type	  VI,	  alpha	  2	   -­‐32	  
1424131_at	   Col6a3	   collagen,	  type	  VI,	  alpha	  3	   -­‐25	  
1434667_at	   Col8a2	   collagen,	  type	  VIII,	  alpha	  2	   -­‐6	  
1448735_at	   Cp	   ceruloplasmin	   -­‐4	  
1460248_at	   Cpxm2	   carboxypeptidase	  X	  2	  (M14	  family)	   9	  
1426951_at	   Crim1	   cysteine	  rich	  transmembrane	  BMP	  regulator	  1	  (chordin	  like)	   4	  
1437056_x_at	   Crispld2	   cysteine-­‐rich	  secretory	  protein	  LCCL	  domain	  containing	  2	   -­‐19	  
1425155_x_at	   Csf1	   colony	  stimulating	  factor	  1	  (macrophage)	   6	  
1416953_at	   Ctgf	   connective	  tissue	  growth	  factor	   27	  
1452968_at	   Cthrc1	   collagen	  triple	  helix	  repeat	  containing	  1	   -­‐68	  
1453282_at	   Cxadr	   coxsackie	  virus	  and	  adenovirus	  receptor	   3	  
1419209_at	   Cxcl1	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  1	   -­‐4	  
1418930_at	   Cxcl10	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  10	   -­‐9	  
1417574_at	   Cxcl12	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  12	   -­‐8	  
1421404_at	   Cxcl15	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  15	   -­‐21	  
1449984_at	   Cxcl2	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  2	   -­‐7	  
1419728_at	   Cxcl5	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  5	   -­‐145	  
1442340_x_at	   Cyr61	   cysteine	  rich	  protein	  61	   -­‐3	  
1416697_at	   Dpp4	   dipeptidylpeptidase	  4	   109	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1418511_at	   Dpt	   dermatopontin	   -­‐126	  
1448613_at	   Ecm1	   extracellular	  matrix	  protein	  1	   3	  
1433474_at	   Edil3	   EGF-­‐like	  repeats	  and	  discoidin	  I-­‐like	  domains	  3	   -­‐7	  
1419332_at	   Egfl6	   EGF-­‐like-­‐domain,	  multiple	  6	   -­‐61	  
1426541_a_at	   Endod1	   endonuclease	  domain	  containing	  1	   4	  
1436799_at	   Enox1	   ecto-­‐NOX	  disulfide-­‐thiol	  exchanger	  1	   -­‐5	  
1448136_at	   Enpp2	   ectonucleotide	  pyrophosphatase/phosphodiesterase	  2	   -­‐120	  
1439260_a_at	   Enpp3	   ectonucleotide	  pyrophosphatase/phosphodiesterase	  3	   -­‐76	  
1421114_a_at	   Epyc	   epiphycan	   -­‐6	  
1434606_at	   Erbb3	   v-­‐erb-­‐b2	  erythroblastic	  leukemia	  viral	  oncogene	  homolog	  3	  (avian)	   5	  
1419431_at	   Ereg	   epiregulin	   6	  
1417688_at	   Fam20c	   family	  with	  sequence	  similarity	  20,	  member	  C	   3	  
1460251_at	   Fas	   Fas	  (TNF	  receptor	  superfamily	  member	  6)	   3	  
1422540_at	   Fbln1	   fibulin	  1	   -­‐20	  
1438375_at	   Fbln2	   Fibulin	  2,	  mRNA	  (cDNA	  clone	  MGC:6112	  IMAGE:3490759)	   4	  
1460412_at	   Fbln7	   fibulin	  7	   -­‐3	  
1449545_at	   Fgf18	   fibroblast	  growth	  factor	  18	   6	  
1449826_a_at	   Fgf2	   fibroblast	  growth	  factor	  2	   6	  
1422916_at	   Fgf21	   fibroblast	  growth	  factor	  21	   -­‐5	  
1438405_at	   Fgf7	   fibroblast	  growth	  factor	  7	   -­‐14	  
1438718_at	   Fgf9	   fibroblast	  growth	  factor	  9	   23	  
1420847_a_at	   Fgfr2	   fibroblast	  growth	  factor	  receptor	  2	   -­‐4	  
1424599_at	   Fgl1	   fibrinogen-­‐like	  protein	  1	   -­‐6	  
1456084_x_at	   Fmod	   fibromodulin	   -­‐29	  
1437218_at	   Fn1	   fibronectin	  1	   3	  
1455280_at	   Frem1	   Fras1	  related	  extracellular	  matrix	  protein	  1	   -­‐8	  
1416658_at	   Frzb	   frizzled-­‐related	  protein	   9	  
1421365_at	   Fst	   follistatin	   4	  
1418949_at	   Gdf15	   growth	  differentiation	  factor	  15	   3	  
1419080_at	   Gdnf	   glial	  cell	  line	  derived	  neurotrophic	  factor	   3	  
1424927_at	   Glipr1	   GLI	  pathogenesis-­‐related	  1	  (glioma)	   17	  
1457429_s_at	   Gm106	   gene	  model	  106,	  (NCBI)	   -­‐31	  
1429293_at	   Gpc2	   glypican	  2	  (cerebroglycan)	   -­‐7	  
1417836_at	   Gpx7	   glutathione	  peroxidase	  7	   -­‐4	  
1418492_at	   Grem2	   gremlin	  2	  homolog,	  cysteine	  knot	  superfamily	  (Xenopus	  laevis)	   -­‐3	  
1433930_at	   Hpse	   heparanase	   -­‐8	  
1416749_at	   Htra1	   HtrA	  serine	  peptidase	  1	   4	  
1419292_at	   Htra3	   HtrA	  serine	  peptidase	  3	   -­‐23	  
1440169_x_at	   Ifnar2	   interferon	  (alpha	  and	  beta)	  receptor	  2	   -­‐3	  
1454159_a_at	   Igfbp2	   insulin-­‐like	  growth	  factor	  binding	  protein	  2	   9	  
1458268_s_at	   Igfbp3	   insulin-­‐like	  growth	  factor	  binding	  protein	  3	   5	  
1421991_a_at	   Igfbp4	   insulin-­‐like	  growth	  factor	  binding	  protein	  4	   -­‐39	  
1452114_s_at	   Igfbp5	   	  insulin-­‐like	  growth	  factor	  binding	  protein	  5	   -­‐56	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1427351_s_at	   Igh-­‐6	   immunoglobulin	  heavy	  chain	  6	  (heavy	  chain	  of	  IgM)	   21	  
1426566_s_at	   Il17re	   interleukin	  17	  receptor	  E	   14	  
1417932_at	   Il18	   interleukin	  18	   3	  
1425145_at	   Il1rl1	   interleukin	  1	  receptor-­‐like	  1	   -­‐19	  
1416200_at	   Il33	   interleukin	  33	   4	  
1421034_a_at	   Il4ra	   interleukin	  4	  receptor,	  alpha	   5	  
1422053_at	   Inhba	   inhibin	  beta-­‐A	   9	  
1426858_at	  
Inhbb	  ///	  
LOC1000468
02	  
inhibin	  beta-­‐B	  ///	  similar	  to	  Inhbb	  protein	   16	  
1431591_s_at	   Isg15	   ISG15	  ubiquitin-­‐like	  modifier	   -­‐8	  
1418450_at	   Islr	   immunoglobulin	  superfamily	  containing	  leucine-­‐rich	  repeat	   -­‐4	  
1429159_at	   Itih5	   inter-­‐alpha	  (globulin)	  inhibitor	  H5	   -­‐6	  
1440955_at	   Kcp	   kielin/chordin-­‐like	  protein	   -­‐3	  
1426152_a_at	   Kitl	   kit	  ligand	   14	  
1419722_at	   Klk8	   kallikrein	  related-­‐peptidase	  8	   31	  
1418153_at	   Lama1	   laminin,	  alpha	  1	   7	  
1426285_at	   Lama2	   laminin,	  alpha	  2	   5	  
1427512_a_at	   Lama3	   laminin,	  alpha	  3	   -­‐8	  
1427747_a_at	   Lcn2	   lipocalin	  2	   -­‐26	  
1448380_at	   Lgals3bp	   lectin,	  galactoside-­‐binding,	  soluble,	  3	  binding	  protein	   -­‐3	  
1440147_at	   Lgi2	   leucine-­‐rich	  repeat	  LGI	  family,	  member	  2	   -­‐19	  
1421207_at	   Lif	   leukemia	  inhibitory	  factor	   17	  
1454984_at	   Lifr	   leukemia	  inhibitory	  factor	  receptor	   -­‐4	  
1450188_s_at	   Lipg	   lipase,	  endothelial	   7	  
1448228_at	   Lox	   lysyl	  oxidase	   4	  
1452436_at	   Loxl2	   lysyl	  oxidase-­‐like	  2	   6	  
1415904_at	   Lpl	   lipoprotein	  lipase	   -­‐13	  
1423607_at	   Lum	   lumican	   -­‐7	  
1454969_at	   Lypd6	   LY6/PLAUR	  domain	  containing	  6	   -­‐5	  
1455978_a_at	   Matn2	   matrilin	  2	   -­‐6	  
1416006_at	   Mdk	   midkine	   -­‐30	  
1417359_at	   Mfap2	   microfibrillar-­‐associated	  protein	  2	   -­‐15	  
1449082_at	   Mfap5	   microfibrillar	  associated	  protein	  5	   20	  
1417234_at	   Mmp11	   matrix	  metallopeptidase	  11	   -­‐4	  
1437568_at	   Mmp16	   matrix	  metallopeptidase	  16	   -­‐5	  
1417282_at	   Mmp23	   matrix	  metallopeptidase	  23	   -­‐5	  
1416298_at	   Mmp9	   matrix	  metallopeptidase	  9	   -­‐11	  
1460238_at	   Msln	   mesothelin	   71	  
1450468_at	   Myoc	   myocilin	   -­‐14	  
1426851_a_at	   Nov	   nephroblastoma	  overexpressed	  gene	   -­‐7	  
1440240_at	   Npb	   neuropeptide	  B	   -­‐15	  
1452107_s_at	   Npnt	   nephronectin	   -­‐18	  
1434802_s_at	   Ntf3	   neurotrophin	  3	   14	  
1450512_at	   Ntn4	   netrin	  4	   48	  
1436718_at	   Nxph1	   neurexophilin	  1	   58	  
1448475_at	   Olfml3	   olfactomedin-­‐like	  3	   -­‐7	  
	  	   258	  
1419534_at	   Olr1	   oxidized	  low	  density	  lipoprotein	  (lectin-­‐like)	  receptor	  1	   28	  
1418745_at	   Omd	   osteomodulin	   -­‐4	  
1432591_at	   Pappa	   pregnancy-­‐associated	  plasma	  protein	  A	   17	  
1448433_a_at	   Pcolce	   procollagen	  C-­‐endopeptidase	  enhancer	  protein	   -­‐4	  
1448995_at	   Pf4	   platelet	  factor	  4	   -­‐35	  
1429019_s_at	   Pon2	   paraoxonase	  2	   3	  
1449824_at	   Prg4	   proteoglycan	  4	  (megakaryocyte	  stimulating	  factor,	  articular	  superficial	  zone	  protein)	   -­‐5	  
1417905_at	   Prl7a2	   prolactin	  family	  7,	  subfamily	  a,	  member	  2	   34	  
1448608_at	   Prl8a2	   prolactin	  family	  8,	  subfamily	  a,	  member	  2	   4	  
1439549_at	   Prrg3	   proline	  rich	  Gla	  (G-­‐carboxyglutamic	  acid)	  3	  (transmembrane)	   7	  
1446560_at	   Prss23	   protease,	  serine,	  23	   10	  
1416211_a_at	   Ptn	   pleiotrophin	   -­‐3667	  
1417346_at	   Pycard	   PYD	  and	  CARD	  domain	  containing	   3	  
1426225_at	   Rbp4	   retinol	  binding	  protein	  4,	  plasma	   -­‐3	  
1453215_at	   Rnase10	   ribonuclease,	  RNase	  A	  family,	  10	  (non-­‐active)	   -­‐4	  
1449319_at	   Rspo1	   R-­‐spondin	  homolog	  (Xenopus	  laevis)	   156	  
1455893_at	   Rspo2	   R-­‐spondin	  2	  homolog	  (Xenopus	  laevis)	   -­‐164	  
1419383_at	   S100b	   S100	  protein,	  beta	  polypeptide,	  neural	   -­‐3	  
1450708_at	   Scg2	   secretogranin	  II	   -­‐688	  
1423150_at	   Scg5	   secretogranin	  V	   -­‐4	  
1420417_at	   Sema3a	  
sema	  domain,	  immunoglobulin	  domain	  (Ig),	  
short	  basic	  domain,	  secreted,	  (semaphorin)	  
3A	  
5	  
1427673_a_at	   Sema3e	  
sema	  domain,	  immunoglobulin	  domain	  (Ig),	  
short	  basic	  domain,	  secreted,	  (semaphorin)	  
3E	  
21	  
1460187_at	   Sfrp1	   secreted	  frizzled-­‐related	  protein	  1	   -­‐5	  
1448201_at	   Sfrp2	   secreted	  frizzled-­‐related	  protein	  2	   -­‐66	  
1448377_at	   Slpi	   secretory	  leukocyte	  peptidase	  inhibitor	   23	  
1415935_at	   Smoc2	   SPARC	  related	  modular	  calcium	  binding	  2	   -­‐13	  
1454710_at	   Spink2	   serine	  peptidase	  inhibitor,	  Kazal	  type	  2	   -­‐8	  
1416627_at	   Spint1	   serine	  protease	  inhibitor,	  Kunitz	  type	  1	   11	  
1451935_a_at	   Spint2	   serine	  protease	  inhibitor,	  Kunitz	  type	  2	   14	  
1418076_at	   St14	   suppression	  of	  tumorigenicity	  14	  (colon	  carcinoma)	   17	  
1420928_at	   St6gal1	   beta	  galactoside	  alpha	  2,6	  sialyltransferase	  1	   4	  
1436319_at	   Sulf1	   sulfatase	  1	   6	  
1430388_a_at	   Sulf2	   sulfatase	  2	   6	  
1418547_at	   Tfpi2	   tissue	  factor	  pathway	  inhibitor	  2	   9	  
1438303_at	   Tgfb2	   transforming	  growth	  factor,	  beta	  2	   4	  
1417455_at	   Tgfb3	   transforming	  growth	  factor,	  beta	  3	   3	  
1456250_x_at	   Tgfbi	   transforming	  growth	  factor,	  beta	  induced	   -­‐32	  
1433795_at	   Tgfbr3	   transforming	  growth	  factor,	  beta	  receptor	  III	   -­‐3	  
1450377_at	   Thbs1	   thrombospondin	  1	   3	  
1447862_x_at	   Thbs2	   thrombospondin	  2	   -­‐71	  
1416623_at	   Thbs3	   thrombospondin	  3	   -­‐8	  
1455262_at	   Thsd4	   thrombospondin,	  type	  I,	  domain	  containing	  4	   -­‐4	  
	  	   259	  
1450040_at	   Timp2	   tissue	  inhibitor	  of	  metalloproteinase	  2	   4	  
1419088_at	   Timp3	   tissue	  inhibitor	  of	  metalloproteinase	  3	   7	  
1423405_at	   Timp4	   tissue	  inhibitor	  of	  metalloproteinase	  4	   -­‐4	  
1417109_at	   Tinagl1	   tubulointerstitial	  nephritis	  antigen-­‐like	  1	   21	  
1420753_at	   Tll1	   tolloid-­‐like	   6	  
1436644_x_at	   Tmem25	   transmembrane	  protein	  25	   -­‐16	  
1456344_at	   Tnc	   Tenascin	  C	  (Tnc),	  mRNA	   22	  
1449033_at	   Tnfrsf11b	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  11b	  (osteoprotegerin)	   25	  
1448147_at	   Tnfrsf19	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  19	   -­‐82	  
1442590_at	   Tnfrsf22	  ///	  Tnfrsf23	  
tumor	  necrosis	  factor	  receptor	  superfamily,	  
member	  22	  ///	  tumor	  necrosis	  factor	  
receptor	  superfamily,	  member	  23	  
3	  
1419083_at	   Tnfsf11	   tumor	  necrosis	  factor	  (ligand)	  superfamily,	  member	  11	   -­‐136	  
1425546_a_at	   Trf	   transferrin	   626	  
1416689_at	   Tuft1	   tuftelin	  1	   7	  
1427256_at	   Vcan	   versican	   -­‐4	  
1439766_x_at	   Vegfc	   vascular	  endothelial	  growth	  factor	  C	   -­‐4	  
1452065_at	   Vstm2a	   V-­‐set	  and	  transmembrane	  domain	  containing	  2A	   126	  
1428811_at	   Wfikkn2	   WAP,	  follistatin/kazal,	  immunoglobulin,	  kunitz	  and	  netrin	  domain	  containing	  2	   -­‐6	  
1448593_at	   Wisp1	   WNT1	  inducible	  signaling	  pathway	  protein	  1	   4	  
1419015_at	   Wisp2	   WNT1	  inducible	  signaling	  pathway	  protein	  2	   11	  
1422941_at	   Wnt16	   wingless-­‐related	  MMTV	  integration	  site	  16	   -­‐47	  
1436978_at	   Wnt9a	   wingless-­‐type	  MMTV	  integration	  site	  9A	   10	  
 
 
Table A.1 All transcripts encoding extracellular proteins differentially 
expressed by cultured PAI-1-/- antral myofibroblasts compared to cultured wild 
type antral myofibroblasts. There were a total of 223 genes, classified as 
‘extracellular’ by gene product ontology, that were significantly differentially 
expressed by PAI-1-/- antral myofibroblasts compared to wild type (unpaired t-test, 
Benjamini-Hochberg correction, P < 0.05, fold-change ≥ 3 or ≤ -3).  
